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Abstract 
A ‘state of emergency’ was declared by the World Health Organization three years ago to combat the 
increasing rate of resistance arising in bacteria to all currently available antibiotics on the market. 
Antimicrobial resistance is now a worldwide concern, and renewed efforts are needed in the search 
for new replacement drugs for obsolete antibiotics. Antimicrobial peptides (AMPs) have been 
discovered and studied over decades; importantly very limited bacterial resistance has been reported 
to date. The work here aims to better characterize and understand the structure-function relationships 
of select β-hairpin AMPs, leading to the design of novel, optimized and potentially therapeutically 
valuable peptides. 
Chapter 1 reviews the field of β-hairpin AMPs and provides a background for the specific AMPs 
studied in this thesis. Chapter 2 consists of an original data set that strengthens the current knowledge 
of β-hairpin AMPs by comparing their activity profile under similar conditions. This work analysed 
the contribution of amphipathicity and hydrophobicity to antimicrobial activity and cytotoxicity of β-
hairpin peptides, concluding that a very fine balance between charge, hydrophobicity, amphipathicity, 
secondary and tertiary structure and mode of action is needed for a peptide to be therapeutically 
valuable. From this study, two distinct but linked areas of further investigation were identified (i) a 
structure activity and function relationship study and (ii) a determination of the mode of action of 
select β-hairpin AMPs. 
Chapter 2 identified that tachyplesin-1, a 17 amino acids β-hairpin AMP originating from the 
hemocyte debris of a horseshoe crab, Tachypleus tridentatus, was an ideal β-hairpin AMP candidate 
to study structure-activity and -toxicity relationships, as it possessed an 8-fold higher therapeutic 
index than other β-hairpin AMPs studied. Thus, chapter 3 contains an evaluation of the role of each 
amino acid of tachyplesin-1 through an alanine scan. New analog peptides were designed as a 
systematic approach to develop more therapeutically valuable peptides as replacements for antibiotics 
that have become ineffective. Measurements of activity and toxicity, combined with preliminary 
ADME data, led to the identification of two tachyplesin-1 analogs with great potential for future drug 
development. 
Chapters 4 and 5 consist of studies of the mode of action of arenicin-3, a 21 amino acid β-hairpin 
AMP originating from the coelomocytes of marine polychaeta lugworm, Arenicola marina, and its 
synthetic analog AA139. AA139 is a lead drug candidate of Adenium Biotech Ltd. currently in 
preclinical development for MDR urinary tract infection and MDR Gram-negative pneumonial 
diseases. Their 3D NMR solution structures revealed right handed twisted β-hairpin structures of 21 
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amino acids rigidified by two disulfide bridges (Cys3-Cys20 and Cys7-Cys16). The mode of action 
of arenicin peptides and their selectivity toward bacteria cells, and more specifically their interaction 
toward different lipid membrane systems, were examined. Chapter 4 focused on label free mode of 
action investigations, leading to a proposed model of arenicin mode of action involving three steps: 
(1) binding to the outer membrane through electrostatic interactions, (2) insertion into the 
hydrophobic core of the outer membrane creating partial permeabilization due to the ability of the 
peptide to modify its secondary structure allowing it to enter into the lipid bilayer without pore 
formation, (3) accessing and partially permeabilizing the cytoplasmic membrane. To provide further 
evidence of the arenicin peptides mode of action, chapter 5 contains a comprehensive structural 
investigation employing NMR experiments with 15N labelled AA139 in the presence of lipid bilayer 
model membranes, nanodiscs or vesicles, using solution and solid-state NMR, respectively. This 
work suggested that the C- and N-terminal of AA139 are the first point of interaction with lipid bilayer 
membranes. Following that first interaction, AA139 possibly undergoes a loss of its well-defined 3D 
solution structure, becoming dynamic and without a distinct fold whilst embedded in the membrane 
and causing the permeabilization of both outer and inner membranes. This study allowed us to gain 
a deeper understanding of AA139 mode of action, and of the differences between the successful lead 
drug candidate, AA139 and its therapeutically less valuable progenitor, arenicin-3. This study 
provides an example of potential approaches to employ when designing other improvements to 
antimicrobial peptides. More importantly, this study allowed us to confirm the great potential of 
nanodiscs, not only to study membrane proteins, but also to evaluate the mode of action of membrane-
active peptides. 
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Chapter 1    -  Introduction 
1.1 Antibiotic development  
Antibiotics, or antibacterial drugs, are chemicals used for the treatment of bacterial infections. 
Bacteria are all around us, being one of the first life forms to appear on earth and still constituting the 
biggest biomass present on the planet. We encounter bacteria on and inside us, from our fingerprints 
to the nooks and crannies of our intestines, with the human body consisting of about 10 bacterial cells 
for every human cell. Bacteria are part of our lives and to stay healthy we need to maintain a healthy 
ecosystem of bacterial flora that can fight against harmful, pathogenic or opportunistic species that 
can cause infection. Even though the body’s immune system is powerful enough to regulate its own 
bacterial flora, external help is sometimes required from antibiotics, to fight against the more 
persistent pathogenic bacteria. However, antibiotics can cause unintended side effects by causing 
dysbiosis via collateral damage to the beneficial microbiome. 
Antibiotics first appeared during the 1930’s with Alexander Fleming in 19281-3 discovering 
Penicillin, the first member of the β-lactam family. It was the first drug to show activity against 
bacterial infections caused by staphylococci and streptococci. Infections that were a common cause 
of death before, became curable. The mass production of penicillin expanded in the 1940’s followed 
by numerous other antibiotic families (Figure 1-1). 
 
 
Figure 1-1 - Chronological discovery of antibiotics. Antibiotic class in brackets. 
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The so-called “Golden-Age of Discovery” was the period between 1945 and 1960, which showed a 
rapid expansion in the number of new antibiotics discovered and developed, almost all derived from 
natural products (Figure 1-1). The discovery of antibiotics, able to prevent and cure deadly infections, 
facilitated the development of revolutionary medical interventions possible such as organ transplants, 
chemotherapy and invasive surgery.   This period was followed closely by the “Golden Age of 
Medicinal Chemistry”, from 1970 to 2000, where antibiotics were synthesized or semi-synthesized 
from naturally existing ones, improving their pharmacokinetic profiles and antibacterial potency (for 
example, from erythromycin to clarithromycin and later to roxithromycin and finally to 
solithromycin).4-8 
Unfortunately, the end of the 20th century marked the end of antibiotic discovery as no new families 
of drugs have been developed into clinically used antibiotics for the last 20 years. Almost all 
antibacterial classes, such as β-lactams, tetracyclines, chloramphenicol, aminoglycosides, 
macrolides, glycopeptides, streptogramines and quinolones, each with different mechanisms of 
action, were initially introduced into clinical practice during this Golden-Age of antibiotics. After this 
prolific period, very few antibiotic class have entered into the clinic. Despite the numerous efforts to 
find and develop new antibiotics and improve existing ones, bacteria continue to evolve, responding 
to exposure to antibiotics.  
Antibiotics are classified according to their chemical structure, their mode of action and their 
spectrum of activity. Two main classes of antibiotics can be distinguished (i) bacteriostatic agents, 
restricting the growth and reproduction of the bacteria, such as chloramphenicol, oxazolidinones, 
sulfonamides, tetracyclines and macrolides and (ii) bactericidal agents, causing bacterial cell death, 
like β-lactams, aminoglycosides, glycopeptides, quinolones, ansamycines, streptogramins and 
lipopeptides. Their modes of action to act against bacteria are diverse and can be classified into five 
main categories (Figure 1-2): cell wall synthesis, protein synthesis, bacterial cell membrane, nucleic 
acid synthesis and antimetabolite activity.  
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Figure 1-2 - Classes of antibiotics/antibacterial agents and their modes of action on bacteria.9  
 
1.2 Bacterial resistance 
The lack of new discoveries and decrease of pharmaceutical companies being involved in 
antimicrobial research and development, coupled with the increasing development of antimicrobial 
resistance, has triggered a serious threat to human health. The appearance of antibiotic resistant 
bacteria, where the bacteria are no longer controlled or killed by the antibiotic, is often observed only 
a few years after the antibiotic was first introduced into clinical use. Antibiotic resistant bacteria either 
spontaneously mutate to be able to counteract the efficacy of the antibiotics or transfer antibiotic 
resistance genes from one bacterium to another. Antibiotic resistant bacteria are able to survive and 
even multiply in the presence of antibiotics. Bacteria can be resistant to one or more antibiotics, with 
multi-drug resistant (MDR) bacteria known as ‘superbugs’. Figure 1-3 illustrates the correlation 
between the introduction of antibiotic use in the clinic versus the evolution of resistance that has 
arisen to those clinical antibiotics.10-18 On average, antibiotic resistance develops only 8 years 
following introduction of the drug’s use in the clinic. In earlier years, 1950s to 1960s, the time for 
resistance development was much longer than during the 21st century due to the high number of 
antibiotics available. 
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Figure 1-3 - Discovery to consequent development of antibiotic resistance timeline. The bars mark the time from the 
introduction of an antibiotic to the clinic until the first clinical case of resistance to that antibiotic was reported. 
 
Antimicrobial resistance occurs naturally over time, however, the rapid expansion of antimicrobial 
resistance is facilitated by the misuse and over prescription of antibiotics. Bacteria acquire several 
mechanisms to become resistant to antibiotics. It can be through the inactivation of the drug by 
enzymes, the alteration of the drug target, or by prevention of the drug reaching its target via 
modification of cell wall or the activation of a drug efflux pump (Figure 1-4). This is the case for 
Vancomycin Resistant Enterococci (VRE) for example, where the first case of resistance was reported 
in 1987.19 VRE became resistant to vancomycin via biochemical changes to its target, Lipid II. By 
changing an Lipid II alanine to a lactate or a serine, a hydrogen bond normally formed with 
vancomycin is eliminated, decreasing the in vitro binding affinity by 1000-fold.20 Methicillin 
Resistant Staphylococcus aureus (MRSA) is resistant to most β-lactam antibiotics with the first case 
reported in 1968. The mechanism of this resistance is mediated through the production of an enzyme 
known as beta-lactamase which is capable of deactivating penicillin via lactam hydrolysis, thus 
rendering it ineffective.21 
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Figure 1-4 - Mechanisms of antibiotic resistance. 
 
Current antibiotics generally target pathways susceptible to generate drug resistance via protein 
mutation, like folic acid synthesis, protein synthesis, RNA and DNA synthesis. Bacterial membrane 
is still a domain showing the least resistance mechanisms, making it a valuable target for new 
antibiotics. The only membrane-targeting antibiotic currently available to treat MDR Gram-negative 
(G-ve) bacterial infections is the lipopeptide colistin (polymyxin E). Unfortunately, colistin is poorly 
membrane-selective, highly nephrotoxic and imparts severe adverse effects in humans. Therefore, 
there is a definite need for safer drugs that can target G-ve bacterial membranes with high selectivity 
over mammalian membranes. 
 
1.3 New antibiotics, approaches to development 
In 2014, the World Health Organization (WHO) declared a ‘state of emergency’ to combat the 
increasing rate of resistance arising in bacteria to all current antibiotics on the market.22 More 
recently, in November 2015, WHO launched a multiyear campaign themed “Antibiotics: Handle with 
care” tackling antimicrobial resistance. Considering the urgency needed to find new antibacterial 
compounds, it begs the question; which techniques could be applied for their discovery? Historically, 
two main approaches of research have been fruitful (i) finding a new molecule from a natural source 
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and (ii) synthetic modification of existing antibacterial drugs.23 Mining the world for new 
antibacterial molecules is a big challenge. Molecules could be found in microorganisms, prokaryotes 
and eukaryotes. This work requires high sampling volumes and sensitive scanning techniques in order 
to identify bioactive molecules unknown to date. Most of the currently used antibiotics come from 
bacteria in the soil which produce them naturally in order to compete in their environment. However, 
to date, still 99% of the known microbial species are yet uncultured.24 Therefore, the potential for 
new antibacterial compounds from natural sources is promising, if they can be grown. The other way 
to find new antibacterial agents, is to synthetically modify existing ones. The most common and 
successful synthetic modifications are the ones which have been performed on existing successful 
drug classes. However, modifications could also be made to potent antibacterial molecules that have 
not been pushed for clinical trials due to their high degree of toxicity against mammalian cells, 
converting them into therapeutically valuable derivatives. Several pathways could be followed (i) 
study the mode of action of a successful antibacterial agent in order to replicate the mechanism on a 
different molecule (ii) characterize each amino acid of a potent antimicrobial peptide (AMP), by 
alanine scan for instance, to identify modifiable regions of the peptide in order to create a new peptide 
maintaining potency while reducing mammalian toxicity, (iii) modulate the structure by 
combinatorial chemistry. In this thesis, the latter two pathways are investigated with the aim of 
discovering a replacement for obsolete antibiotics and will be further discussed in chapters 2 to 5. 
Additional alternative pathways of finding new antibacterial agents could also be investigated. The 
reexamination of discarded antibiotics is an option. This was the case for daptomycin first discovered 
by Eli Lilly in 1980s, discarded due to toxicity concerns but brought back to market by the Cubist 
group in 2003 using a different dosage composition.25 The combination of several antibiotics together 
or hybrid antibiotics with non-antibiotics is another successful pathway, as shown by the very 
successful antibiotic Augmentin, a combination of ampicillin with the β-lactamase inhibitor 
clavulanic acid.   
 
1.4 Antimicrobial peptides (AMPs) 
The initial work requirement for synthetic modifications of an existing compound resides on the 
choice of the template molecule candidate for drug design. In general, microbes are considered to 
have developed little or no resistance to AMPs, in contrast to antibiotics, which have developed 
marked resistance. AMPs could thereby be a valuable starting point for synthetic modifications. 
AMPs are oligopeptides, ranging from five to a hundred amino acids, ubiquitous in nature. AMPs are 
produced by the innate immune defense system of multicellular organisms, microorganisms, plants 
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and animals to help them fight against external invading pathogens. Being mobilized shortly after 
microbial invasion, AMPs are expressed to act broadly and quickly. AMPs have the common 
characteristics of being amphipathic, cationic and membranolytic, properties which make them 
suitable for development as a drug candidate if selectivity for bacterial cells over mammalian cells 
can be established. AMPs were first discovered in 1939 by Dubos,26 who identified an AMP from the 
soil and named it gramicidin, which later became a topical therapeutic agent for wounds and ulcers.27 
Since then, thousands of antimicrobial molecules have been reported, with more than 2300 AMPs 
reported from eukaryotes (http://aps.unmc.edu/AP/about.php). AMPs are classified according to their 
source, their secondary structure and their mode of action.28-30 From all the AMPs reported only about 
40% of them have had their structure characterized. Approximately 90% of them have been 
determined to adopt α-helical secondary structure, Figure 1-5. This α-helical AMP category has been 
extensively examined.31-33 However, less known are the AMPs which adopt a β-sheet structure; these 
include peptides with a β-sheet structure consisting of three strands (most vertebrate defensins), two 
strands with a β-hairpin structure, or a mixed structure that includes both β-sheets and α-helices.34 
The α-helical AMPs are abundant in the extracellular fluids of insects and frogs and mostly exist as 
extended or unstructured conformers in solution. Many of these peptides only become helical when 
interacting with the cell membrane. However, β-sheet peptides adopt more ordered structures. Despite 
such differences, all AMPs share common features, including amphipathic composition, with distinct 
hydrophilic and hydrophobic surfaces. 
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Figure 1-5 - Clustering of antimicrobial peptides according to backbone torsion angles and antimicrobial activity.35 
Helixes are represented in cyan and β-sheet in magenta.  
 
1.5 β-hairpin AMPs 
The subcategory, β-hairpin AMPs, have the common characteristic of two anti-parallel β-sheets 
linked by a small turn of 3 to 7 amino acids, forming a hairpin shape. Twelve families of β-hairpin 
AMPs have been discovered and reported so far, from mammals and invertebrates. For most β-hairpin 
classes, representative members have been analyzed for their 3D solution structures by nuclear 
magnetic resonance (NMR) spectroscopy. Their structures vary from one disulfide bond to four and 
from linear to cyclic (head-to-tail) backbones, Table 1-1. Although the 3D NMR structures have never 
been assessed for either tigerinin-1 or bactenecin, computer modelling propose that their peptide 
chains also adopt β-hairpin secondary structure.36  
The β-hairpin AMPs share close sequence homology, with conserved disulfide bridges to stabilize 
the β−sheets, a β−turn motif, cationic Arg or Lys residues adjacent to the turn and distal C- and N-
termini flanked by hydrophobic, membrane-insertive Val, Leu, Ile, Tyr or Trp residues.  Together 
these motifs describe an amphipathic structure with one hydrophobic face and a basic face, which 
creates a hydrophobic moment in the structure. Amphipathicity is one of the key characteristics of 
AMPs and Fernandes-Vidal et al.37 showed that amphipathicity is more important than 
hydrophobicity for binding to microbial membranes. This makes AMPs an attractive candidate class 
to develop as new antibiotics. 
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Table 1-1 - β-hairpin AMPs origin, sequence and cartoon representation using Pymol 1.7.2.3. Disulfide bridges are 
shown as thin lines in the sequences and are yellow stick in the 3D structures. The bold line denotes the peptide bond that 
forms a θ-defensin cycle. (*) – C-terminal amidation, Z – N-terminal pyroglutamic acid. 
Name Source Amino acid sequence Cartoon representation PDB/Ref. 
tigerinin-1 
Rana tigerina 
(frog skin 
secretion)  
- 36 
bactenecin Bos taurus (bovine neutrophils)  
- 38 
tachyplesin-1 
Tachypleus 
tridentatus 
(horseshoe crab 
hemocytes) 
 
 
1WO0/39 
polyphemusin-
1 
Limulus 
polyphemus 
(horseshoe crab 
hemocytes) 
 
 
1RKK/40 
protegrin-1 Sus scrofa (porcine leukocytes)  
 1PG1/41 
gomesin 
Acanthoscurria 
gomesiana (spider 
hemocytes)  
 1KFP/42 
retrocyclin-2 
Macaca mulattav 
(rhesus monkey 
leukocytes)   
2LRI/43 
arenicin-1 
Arenicola marina 
(lugworm 
coelomocytes)   
2JSB/44 
thanatin 
Podisus 
maculiventris 
(spined soldier bug 
hemolymph) 
 
 8TFV/45 
alvinellacin 
Alvinella 
pompejana 
(Pompeii worm)   
2LLR/46 
androctonin 
Androctonus 
australis (scorpion 
hemolymph)  
 1CZ6/47 
lactoferricin B Bos taurus taurus (bovine milk)  
 
 
1LFC/48 
hepcidin 25 
Homo sapiens 
(human 
hepatocytes)  
 
2KEF/49 
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1.6 Cell membrane  
The cell membrane has been extensively studied over the past 100 years. This protecting barrier was 
first proposed by Gorter et al.50 in 1925 as a lipid bilayer membrane with the polar group orientated 
toward the inside of the cell. Their proposed theory of the cell membrane consisting of a lipid bilayer 
contained several experimental issues that were later corrected. Several modifications of the Gorter 
et al. lipid bilayer theory were discussed up until 1972, where Singer et al.51, proposed the “fluid 
mosaic model”, a model still in use to date. The model describes the cell membrane as a liquid matrix 
comprising lipids and proteins that restricts the lateral diffusion of membrane components. The liquid 
matrix was then found to be inhomogeneous and prone to forming lipid rafts, caused by stabilizing 
lipid-lipid and lipid-protein interactions.52 
The composition of the cell membranes is very complex and cell type dependent. Mostly constituted 
of lipids of various kinds, membrane proteins and a small amount of carbohydrates, the lipid matrix 
of biological membranes is formed asymmetrically in order to ensure the unique functionality of the 
cell type (Figure 1-6). This bilayer is composed of two leaflets of amphipathic lipid molecules, whose 
polar head groups are in contact with the intra- or extracellular aqueous phases, whereas their non-
polar tails face each other, constituting the hydrophobic interior of the membrane. 
 
Figure 1-6 - Fluid mosaic model. 
 
Whilst the cell membrane of human cells can be represented using the fluid mosaic model presented 
above, bacteria cell walls differ considerably. 
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Bacteria were first classified into two main categories by the Danish bacteriologist Hans Christian 
Gram who developed the Gram stain test that identified bacteria as belonging to one of two main 
categories, Gram positive (G+ve) and G-ve bacteria. The Gram test differentiates the bacteria 
according to the chemical and physical properties of their cell wall, detecting in particular the 
properties of the peptidoglycan. In this test, the G+ve bacteria appear a purple color, as the stain is 
retained in the larger and denser peptidoglycan structure, while G-ve bacteria appear pink, as their 
thin and light peptidoglycan is not able to retain the stain. Even though G-ve bacteria possess a 
second, outer membrane which acts as an additional barrier, the Gram staining process disrupts the 
membrane with alcohol, making the Gram staining a marker for the structure of the peptidoglycan 
rather than the presence or absence of a second membrane (Figure 1-7). 
The bacterial cytoplasmic cell content is surrounded by a plasma membrane followed by the inner 
peptidoglycan cell wall, and for G-ve bacteria an outer lipid bilayer. In G-ve bacteria, the 
peptidoglycan layer contains about 10% of the cell wall dry weight while in G+ve bacteria the 
peptidoglycan layer is thicker (about 40 layers) and constitutes about 20% of the cell wall dry weight.  
The structure of peptidoglycan contains a carbohydrate backbone of alternating units of N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid, with the N-acetylmuramic acid residues 
cross-linked to peptides. This is the peptidoglycan layer that confers the rigidity and strength to the 
bacterial cell. 
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Figure 1-7 - Schematic views of Gram-negative (top) and Gram-positive (bottom) bacteria cell walls, showing the 
complex assembly of high molecular weight compounds. 
 
However, the bacteria cell membrane constitutes many other components. For both types of bacteria, 
the cytoplasmic membrane (or inner bacterial membrane for G-ve bacteria) is constituted of a 
symmetric double layer of phospholipid molecules, the hydrophilic (polar) heads of which face the 
peptidoglycan and the cytoplasm while their hydrophobic (apolar) tails are hidden in the middle of 
the cell membrane.   Embedded in the lipid bilayer are proteins and glycoproteins (proteins with 
carbohydrates attached) serving different functions. For G-ve bacteria only, the distinctive outer 
membrane is even more complex featuring an asymmetric membrane, an inner phospholipid and an 
outer glycolipid leaflet. The glycolipid leaflet is a lipopolysaccharide (LPS) layer composed of O-
specific polysaccharide, core polysaccharide and lipid A attached to the surface. Traversing this 
membrane are outer membrane proteins such as porins that allow the diffusion of essential molecules 
across the otherwise impermeable barrier.   
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1.7 Lipid model membranes 
In this thesis, the cell membranes of human cell and bacteria cells are modelled in order to study the 
interaction and mode of action of peptides against the different types of cell membrane. Lipids 
constituting the lipid bilayer are mostly dominated by different types of phospholipids followed by a 
very small proportion of glycolipids and sterols.53 Phospholipids are amphipathic, containing a 
hydrophilic head comprised of a phosphate group functionalized with two hydrophobic fatty acid tail 
chains varying in length and saturation level. Phospholipids are often classified by their head group 
composition; predominantly phosphatidylcholine (PC), phosphatidylglycerol (PG) or 
phosphatidylethanolamine (PE). Bacteria cell membranes are overall very negatively charged and 
therefore contain a significant proportion of negatively charged PG, negatively charged 
phospholipids, whereas mammalian cells are more positively charged, thus composed of zwitterionic 
phospholipids such as PC or PE.  
Phospholipids, being amphipathic, aggregate in solution, naturally forming vesicles in solution. 
Vesicles are a very important tool used in many different areas of research. They serve as models for 
cell membranes, as delivery vehicles for drugs into living cells and through other hydrophobic 
barriers, and as useful components of other specialized applications, such as a support for 
semiconductor particles for the photoconversion of solar energy.54 In this thesis, lipid vesicles help 
us to model cell membranes to investigate the mode of action of AMPs. However, in order to 
understand the mechanisms of action, the models need to replicate as closely as possible the real cell 
membrane environment. Different lipid formations can be taken as a membrane mimicking 
environment. Micelles are the oldest mimic commonly used, however they do not reflect the true 
complexity of the bacteria and/or mammalian cell membranes due to their monolayer feature. 
Phospholipids tend to form liposomes, or lipid vesicles, made of bilayers, able to more accurately 
mimic the complexity and charge of different type of cell membrane. Vesicles vary in size and the 
number of bilayers present, from multilamellar vesicles (MLV) bigger than 500 nm to lipid bilayers 
as small as 8 nm, such as nanodiscs (ND). The latter are relatively recent innovations that incorporate 
a membrane scaffold protein (MSP) that considerably reduces the size of the lipid bilayer, allowing 
for a new way of membrane analysis and characterization via NMR.55 Figure 1-8, represents the basic 
structure of lipid vesicles and nanodisc models, used in this thesis (Chapters 3, 4 and 5).  
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Figure 1-8 - Lipid formation. (A) Multilamellar vesicle (MLV), (B) Large unilamellar vesicle (LUV), (C) Small 
unilamellar vesicle (SUV), (D) Micelle and (E) Nanodisc (ND).  
 
Whilst lipid vesicle formation occurs naturally once the lipid concentration meets a certain threshold, 
the formation of nanodiscs require additional membrane constraint. The MSP surrounding the lipid 
bilayer of nanodiscs comes from the truncation of the human apolipoprotein A1 (ApoA1). ApoA1 is 
the major protein constituent of reverse cholesterol transport in the human body. ApoA1 is a 30 kDa 
protein consisting of 267 amino acids produced and excreted from the liver, and its structure consists 
of 10 helixes forming a half circle, Figure 1-9. 
 
Figure 1-9 - Crystal structure of apolipoprotein A-1. PDB entry 3R2P. 
  
Sligar et al., when investigating the structure of reconstituted HDL from ApoA1 and synthetic 
phospholipids, discovered that ApoA1 could be used as a self-assembling phospholipid bilayer 
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support.56 In order to optimize the particle for nanodisc use, they produced a truncated version of 
ApoA1 that lacked the globular N-terminal domain. This modified protein, MSP, is also able to self-
assemble into discoidal monodisperse particles in the presence of synthetic phospholipids.57 The 
diameter of the nanodiscs will thus vary according to the length of MSP, forming discs of 8 to 12 nm. 
In this thesis, the MSP proteins used for the formation of nanodiscs are the MSP1D1ΔH5 and cNW9. 
MSP1D1 refers to the ApoA1 signal and globular motif that has been replaced by a histidine-TEV-
tag and the helix 1 truncated to helix 0.5. ΔH5 refers to the deletion of helix 5, Table 1-2. TEV is a 
protease recognition site used for removal of the affinity tag during purification. cNW9 is the same 
construct as MSP1D1ΔH5 but able to covalently circularize via linkage by sortase.58   
 
Table 1-2 - MSP protein motifs and sequence construct. 
Protein Motifs 
ApoA1 SIGNAL-GLOBULAR-H1-H2-H3-H4-H5-H6-H7-H8-H9-H10 
MSP1D1 HisTEV-H0.5 -H2-H3-H4-H5-H6-H7-H8-H9-H10 
MSP1D1ΔH5 HisTEV-H0.5 -H2-H3-H4-H6-H7-H8-H9-H10 
cNW9 HisTEV-H0.5 -H2-H3-H4-H6-H7-H8-H9-H10-LinkerHis 
    
Protein Sequence 
ApoA1 
MKAAVLTLAVLFLTGSQARHFWQQDEPPQSPWDRVKDLATVYVDVLKDSGRDYVS
QFEGSALGKQLNLKLLDNWDSVTSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMS
KDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSP
LGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATE
HLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ 
MSP1D1 
MGHHHHHHHDYDIPTTENLYFQGSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMS
KDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLRAELQEGARQKLHELQEKLSP
LGEEMRDRARAHVDALRTHLAPYSDELRQRLAARLEALKENGGARLAEYHAKATE
HLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ 
MSP1D1ΔH5 
MGHHHHHHHDYDIPTTENLYFQGSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMS
KDLEEVKAKVQPYLDDFQKKWQEEMELYRQKVEPLGEEMRDRARAHVDALRTHLA
PYSDELRQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPV
LESFKVSFLSALEEYTKKLNTQ 
cNW9 
MGSSHHHHHHENLYFQGSTFSKLREQLGPVTQEFWDNLEKETEGLRQEMSKDLEEV
KAKVQPYLDDFQKKWQEEMELYRQKVEPLGEEMRDRARAHVDALRTHLAPYSDEL
RQRLAARLEALKENGGARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKV
SFLSALEEYTKKLNTQLPGTGAAALEHHHHHH 
 
Nanodiscs are able to self-assemble in only a few steps via addition of an adequate ratio of 
phospholipids to the MSP, stored in detergent, followed by the addition of non-polar polystyrene 
beads, biobeads, which trigger the formation of nanodiscs by removing the detergent, Figure 1-10. 
Subsequently, homogeneous nanodiscs are purified from the reconstitution mixture by gel filtration.59 
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Each nanodisc is constituted of two MSPs wrapped around the phospholipid bilayer. The composition 
of phospholipids can be varied in order to mimic different types of cell membranes.   
 
Figure 1-10 - Nanodiscs formation process. 
 
1.8 Mode of action 
The capacity of AMPs to kill microorganisms relies on their ability to disrupt and/or permeate the 
organisms’ cell membrane. The AMPs, generally being cationic, are well designed to bind and 
interact with the negatively charged lipophilic outer membrane of the bacteria cell.  The mode of 
action of AMPs, especially α-helical AMPs, have been well studied, demonstrating very diverse and 
complex mechanisms. For cell destruction, the cell membrane can be disrupted or not. Most of the 
AMPs studied disrupt the cell membrane either via pore formation, with either barrel stave 
(Alamethicin60) or toroidal (Magainin-260) pore structures, or by non-pore mechanisms, such as a 
carpet-like mechanism (Cecropin61), Figure 1-11.  In all cases, the peptides initially accumulate at the 
membrane surface. Then, above a certain concentration threshold, toroidal or barrel stave pores are 
formed by peptides aligned perpendicular to the membrane plane together with phospholipid 
molecules. Alternatively, the peptides cover the membrane surface like a carpet and ultimately disrupt 
the bilayer. Some AMPs polarize the membrane to form anionic lipid clusters.62 A minority of AMPs, 
however, do not cause membrane disruption, but instead act on intracellular targets such as nucleic 
acids and functional proteins to activate cell death, after crossing the bacterial cell wall and the 
cytoplasmic membrane.63,64 
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Figure 1-11 - Mechanisms of action for cell destruction.  
 
 
A summary of the modes of action of the β-hairpin AMPs are presented in Table 1-3. Like any other 
AMPs, the β-hairpin AMPs act via diverse and complex mechanisms of action, where one or more 
mechanisms are combined to yield the unique activity of the peptide. Pore formation has been 
suggested for arenicin-1, bactenecin, androctonin, gomesin and protegrin-1.65-71 The initial binding 
of the AMP to the bacteria is driven by electrostatic interactions with the negatively charged cell 
surface. The peptide then adopts a parallel orientation to the lipid bilayer. From this point, the AMPs 
adopt one of two mechanisms (i) they stay parallel to the lipid bilayer forming clusters similar to a 
carpet-like model and, as the concentration increases, the membrane weakens and the peptide 
eventually intercalates into the cell causing the membrane to disrupt, or (ii) they are positioned 
parallel to the surface of the membrane, but then insert perpendicularly into it and cause deformation, 
creating a toroidal pore mechanism. Additionally, a lipid flip-flop mechanism has been observed for 
tachyplesin-1 and polyphemusin-1.72-74 The peptide first binds to the outer leaflet of the lipid bilayer 
then translocates to the other side of the membrane using surrounding lipids to internalize into the 
intracellular compartment of the cell. A translocation mechanism has been suggested with 
spontaneous internalization or nonspecifically, for lactoferricin B and thanatin, respectively.75-78 To 
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date, tigerinin-1 is the only AMP reported to create membrane depolarization to finally open and 
disrupt the membrane.36 Hepcidin 25 is an interesting AMP, as the activity as well as the mode of 
action is dependent on the environmental pH, and therefore this AMP will act differently in the body 
according to the location (e.g. the gut intestinal track has a different pH to other tissues).64  Each AMP 
finds its own unique way to kill its target by combining one or more of the models discussed above, 
and potentially with mechanisms that have yet to be identified. 
To assess these mechanisms of action, a variety of techniques are utilized, such as fluorescence assays 
and NMR, relying on membrane models mimicking the bacterial cell. Although, the membrane 
models are established to mimic bacteria as closely as possible, the models are far from perfect and 
must be applied carefully, in the context of a good understanding of the differences between the 
models and true cell membrane architecture and dynamics. Every model has its benefits, matching 
one or more characteristics to the real membrane, but at the same time they displays imperfections 
which could lead to an incorrect interpretation of the true mode of action. Therefore, much research 
is still ongoing to establish new ways of modelling cell membranes that could replicate the cell 
membrane far better than the models currently in use. 
 
Table 1-3 - Mode of action of the β-hairpin AMPs. 
Peptide Mode of action Ref. 
tigerinin-1 disruption membrane depolarization model 36 
bactenecin disruption carpet/toroidal pore model 65 
tachyplesin-1 translocation and 
disruption 
lipid flip-flop with vesicle leakage of outer membrane 
followed by toroidal pore formation of cytoplasmic 
membrane and intracelular target 
72,73  
polyphemusin-1 translocation lipid flip-flop model 73,74 
protegrin-1 disruption disordered toroidal pore model 66, 67 
gomesin disruption carpet-like model 68,69 
rectrocyclin-2 disruption mechanism not elucidated yet 79 
arenicin-1 disruption carpet/toroidal pore model 70,71 
thanatin translocation nonspecific mechanism 75 
alvinellacin not studied yet   
androctonin disruption carpet-like model 80 
lactoferricin B translocation spontaneous internalization, pore formation model 77,76,78 
hepcidin 25 translocation pore formation with pH dependant model 64 
 
1.9 Bacterial resistance to AMPs 
Although very limited, bacterial resistance to AMPs has been reported, and is mainly focused on cell 
membrane modifications. For instance, the bacterial membrane can remodel to inhibit the first 
electrostatic binding between negatively charge membrane and positively charged AMPs. This could 
be seen as modification of the teichoic acid in G+ve bacteria or modification of the lipid A in G-ve 
bacteria to neutralize the cell membrane surface charge.81,82 Bacterial protease and peptidases can 
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degrade and inactivate AMPs, for example in the cases of cathelicidin LL-37 or C18G.83,84 
Additionally, bacteria can also sequester AMPs and inhibit their antimicrobial activity.85  
 
1.10 Significance and aims 
Antibiotic resistant bacteria are a major public health concern today, highlighted by the World Health 
Organization in its 2014 report: “Antibiotic resistance is no longer a prediction for the future as it is 
happening right now, across the world, and is putting at risk the ability to treat common infections in 
the community and hospitals. Without urgent, coordinated action, the world is heading towards a 
post-antibiotic era, in which common infections and minor injuries, which have been treatable for 
decades, can once again kill.”22 Treatment failure reports for gonorrhea usually treated by third 
generation cephalosprins, urinary tract infections caused by Escherichia coli normally solved by 
fluoroquinolones, and intestinal bacteria medically treated by carbapenem antibiotics are now 
widespread across the world. Multi-drug resistant (MDR) G-ve infections normally cured by last 
resort antibiotics, colistin (polymyxin E), has seen rapid resistance developing around the world, 
aided by plasmid-mediated transmission of mcr-1. Therefore, there is a definite need for safer 
membranolytic drugs with higher selectivity for G-ve bacteria cells over mammalian cells.  
AMPs are one of the only classes of compounds thus far against which bacteria have developed little 
resistance. Even though having been discovered and studied for over 80-years, commercialization of 
AMPs is mainly limited by their inherently low stability in human serum and potential storage 
degradation, their immunogenicity and the need to establish selectivity over mammalian cell toxicity.  
My thesis focuses on the subclass of β-hairpin AMPs which have not yet been extensively explored. 
Whilst limited in number, β-hairpin AMPs are very attractive molecules due to their very potent and 
broad spectrum of antibacterial and antifungal activities as well as their very limited bacterial 
resistance reported to date. Thus, β-hairpin AMPs provide an attractive starting point for the design 
of new antimicrobial drugs to replace obsolete ones. 
Given that β-hairpin AMPs are not naturally safe for clinical development due to their toxicity against 
mammalian cells, the overall aim of this thesis is to understand the relationship and correlation 
between antimicrobial activity and toxicity, membrane activity and microbial activity, of β-hairpin 
AMPs. These findings will be used to create a safe and effective alternative to colistin for the 
treatment of infections caused by MDR G-ve bacteria. 
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1.11 Thesis outline 
The thesis comprises four research chapters. The first two chapters cover the characterization of β-
hairpin AMPs and more specifically tachyplesin-1. The last two investigate the mode of action of 
arenicin-3 and its synthetic analog, AA139. 
Chapter 2 focuses on a comparative study between the physicochemical properties (amphipathicity 
and hydrophobicity) and the antimicrobial activity and toxicity of six β-hairpin AMPs (arenicin-3, 
tachyplesin-1, polyphemusin-1, gomesin, protegrin-1 and thanatin). The outcome of this study shows 
that β-hairpin AMPs display a complex and fine balance between charge, hydrophobicity, 
amphipathicity, secondary and tertiary structure, and mode of action. This study also identified 
tachyplesin-1 as a leading candidate for further optimisation, with 7-fold higher therapeutic index 
than any of the other β-hairpin AMPs investigated here. This work was published in April 2016 in 
ACS Infectious Diseases. 
Chapter 3 investigates the β-hairpin AMP tachyplesin-1 (TP1). TP1 exhibits potent antimicrobial 
activity against a broad range of G+ve and G-ve bacteria, as well as fungi. However, it also displays 
high toxicity towards mammalian cells, making it unsuitable to be developed as a therapeutic in its 
own right. This study evaluates structure-function and structure-toxicity relationships using an 
alanine scan to assess the impact of each amino acid of TP1, to assist in the design of novel 
therapeutically valuable peptides. This template-based approach focused not only on an alanine scan 
of TP1, but also modified the overall hydrophobicity / amphipathicity by amino acid replacement at 
select positions. My findings revealed three newly designed peptides TP1[F4A], TP1[I11A] and 
TP1[C3A,C16A] with 26- to 64-fold improved antimicrobial activity / toxicity index, rendering them 
very attractive as potential drug candidates. Structural studies of TP1[F4A] and TP1[I11A] identified 
a conserved β-hairpin secondary structure motif correlating with their very high stability in mouse 
and human plasma. This study was published in September 2017 in ACS Infectious Diseases.  
Chapter 4 evaluates the mode of action of AA139, a synthetic analog of arenicin-3 discovered by 
Adenium Pty Ltd, and under advanced preclinical development by this company. The aim of this 
chapter is to understand the structural and functional changes between the two analogs, arenicin-3 
and AA139 that leads to different activity. In this study, I have characterized arenicin-3 and its 
synthetic analog, AA139, with elucidation of their 3D structures in aqueous solution confirming 
disulfide-bridged β-hairpin peptide structures. The mode of action of both arenicin peptides was 
investigated using lipid model membranes and Escherichia coli bacterial cells. This work suggested 
that arenicin peptides bind, insert and partially permeabilize both negatively charged lipid vesicles 
and the cell membranes of G-ve bacteria. Interestingly, the mode of action of arenicin peptides seems 
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to not only depend on electrostatic interaction and membrane permeabilization, but also rely on 
additional mode(s) of action.      
Chapter 5 investigates the mode of action of AA139 from a structurally focused point of view. In this 
study, three approaches were explored: (i) a computational modelling study to provide an 
experimental speculation of the orientation of the peptide at the interface with the cell membrane, (ii) 
a solution NMR study using lipid bilayer nanodiscs, and (iii) a solid-state NMR study using lipid 
bilayer vesicles. This study allowed the refinement of the mode of action studied in chapter 4. The 
solution NMR results identified the N- and C- terminal ends of the peptide as the first point of contact 
with the cell membrane. The preliminary work performed using solid-state NMR suggests that the 
peptide loses its well-defined 3D structure upon insertion in the hydrophobic core of the membrane.    
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Chapter 2    - β-hairpin 
antimicrobial peptides 
This chapter includes the manuscript published in ACS Infectious Diseases journal (2016). The 
manuscript discussed the relationship between physicochemical properties and antimicrobial 
properties of six β-hairpin AMPs. This study concluded in a complex balance between charge, 
amphipathicity, structure, and mode of action for a peptide to be therapeutical valuable. See Appendix 
II, page 7-122 for supporting information.  
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2.1 Abstract 
Bacteria have acquired extensive resistance mechanisms to protect themselves against antibiotic 
action.  Today the bacterial membrane has become one of the ‘final frontiers’ in the search for new 
compounds acting on novel targets to address the threat of MDR and XDR bacterial pathogens. β-
hairpin antimicrobial peptides are amphipathic, membrane-binding antibiotics that exhibit a broad 
range of activities against Gram-positive, Gram-negative and fungal pathogens. However, most 
members of the class also possess adverse cytotoxicity and hemolytic activity that precludes their 
development as candidate antimicrobials. We examined peptide hydrophobicity, amphipathicity and 
structure to better dissect and understand the correlation between antimicrobial activity and toxicity, 
membrane binding and membrane permeability. The hydrophobicity, pI, net charge at physiological 
pH, and amphipathic moment for the β-hairpin antimicrobial peptides tachyplesin-1, polyphemusin-
1, protegrin-1, gomesin, arenicin-3 and thanatin were determined, and correlated with key 
antimicrobial activity and toxicity data. These included antimicrobial activity against five key 
bacterial pathogens and two fungi, cytotoxicity against human cell lines and hemolytic activity in 
human erythrocytes. Observed antimicrobial activity trends correlated with compound 
amphipathicity, and to a lesser extent with overall hydrophobicity. Antimicrobial activity increased 
with amphipathicity, but unfortunately so did toxicity. Of note, tachyplesin-1 was found to be 8-fold 
more amphipathic than gomesin. These analyses identify tachyplesin-1 as promising scaffold for 
rational design and synthetic optimisation towards an antibiotic candidate. 
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2.2 Introduction  
Antibiotic-resistant bacteria are a serious and growing threat to human health and national healthcare 
systems.1 These ‘superbugs’ kill 100,000s of people each year and are estimated to add >$20bn in 
healthcare costs in the US alone.2 Multi-drug resistant Gram-negative (MDR G-ve) strains of 
Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii and Pseudomonas aeruginosa 
that possess extended spectrum beta lactamase (ESBL) and metallo-beta-lactamases (MBL) are of 
grave concern.3 There are now extensive and widely dispersed pools of resistance elements that cover 
all of the classical pathways targeted by current antibiotics: cell wall, folic acid, protein, RNA and 
DNA synthesis.4 Most antibiotics target specific receptors, enzymes or proteins that are susceptible 
to single point mutations that can lead to resistance.  However, compounds that target the bacterial 
membrane (such as antimicrobial peptides, AMPs) or its biosynthesis (such as moenomycin and the 
recently reported teixobactin5), are much less likely to select for spontaneous, single step resistant 
mutants. Today the only membrane-targeting antibiotics suitable for MDR G-ve infections are the 
closely related lipopeptides colistin (polymyxin E) and polymyxin B.  Unfortunately, resistance to 
these key ‘last resort’ antibiotics has appeared, with a recent study6 demonstrating a plasmid mediated 
mcr-1 gene conferring colistin resistance found in China and Europe.  Colistin and polymyxin B are 
both highly nephrotoxic with a low therapeutic index, often imparting severe adverse effects in 
humans at doses required for efficacy. Therefore there is an urgent unmet medical need for safer 
antibiotics to treat highly drug-resistant G-ve infections, and this can potentially be achieved by 
developing drugs that target G-ve bacterial membranes with high selectivity over mammalian 
membranes. 
AMPs are ubiquitous in nature. All multicellular organisms, microorganisms, plants and animals have 
an innate immune defence system that secretes AMPs. Endogenous AMPs are produced when 
infections occur, and can also be stored in exposed tissues of animals and plants, constituting a first 
line of defence that is fast and efficient. These peptides have broad spectrum antimicrobial activity 
and are also able to host repair and adaptive immune responses in a concerted response to multi-drug 
resistant bacteria.7 AMPs are generally small (< 10kDa), characterized by their charge and structural 
rigidity. They are grouped according to their secondary structure, (α-helical, β-sheet or extended 
peptides)8,9 which confer distinct physicochemical properties and biological mechanisms of action. 
About 2,000 AMPs have been reported (http://aps.unmc.edu/AP/main.php) from eukaryota having 
antibacterial activity. Approximately 90% of them have been determined to adopt α-helical structure. 
This category has been extensively explored and reviewed elsewhere.10  
Less known are the antimicrobial peptides which adopt a β-sheet structure; these include β-hairpin 
and cyclic α-, β- and θ-defensins.11 This paper focuses on the β-hairpin AMPs, which have undergone 
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few studies and limited characterisation. A recent compilation of β-hairpin compounds was reported 
by Panteleev in 2015.12 Here we focus on the physiochemical properties of this AMP class, and their 
contribution to the AMP antimicrobial activity and toxicity. β-Hairpin AMPs are usually small (< 30 
amino acid residues), cationic and adopt amphipathic structures that confer excellent binding to the 
lipid bilayer of bacterial membranes. Fernandez-Vidal et al.13 demonstrated that amphipathicity is 
more important than hydrophobicity for binding to microbial membranes. Most of the β-sheet AMPs 
cause membrane disruption due to electrostatic interactions with the cell membrane.14,15 However, 
other modes of action have been suggested.16,17 Unfortunately, most AMPs are not directly suitable 
as antibiotic leads for clinical development as they often cause hemolysis and/or mammalian cell 
cytotoxicity. Modification is required to generate therapeutically valuable molecules.18 For example, 
a synthetic cyclic peptide derived from the β-hairpin AMP protegrin-1 has been developed by 
Polyphor Ltd (Basel, Switzerland)19, demonstrating the potential for this class of compounds. 
POL7080 (RG7929) completed a Phase 2 trial for non-cystic fibrosis bronchiectasis in Nov 2015 
(clinical trial identifier NTC02096315), and is currently undergoing Phase 2 testing in patients with 
P. aeruginosa ventilator-acquired pneumonia (VAP) co-administered with standard of care 
(NCT02096328). POL7080 is proposed to act against G-ve bacteria by targeting the β-barrel protein 
LptD (Imp/OstA), which is involved in the outer-membrane biogenesis of lipopolysaccharide 
(LPS)19. Another β-hairpin AMP is being developed by Adenium Biotech (Denmark), which has been 
working with variants of arenicin-3, leading to one analog (NZ17074) undergoing preclinical 
studies.20, 21 
 
2.3 Results and discussion 
Structure analysis. Some β-hairpin AMPs are intrinsically disordered and require contact with their 
lipophilic membrane target to adopt an ordered conformation. Others adopt a preferred structural 
organization, but may change conformation between being in solution and in contact with the surface 
of a cell membrane. AMPs, often cationic at physiological pH, form amphipathic structures that 
mirrors that of the phospholipids, allowing the AMPs to interact with bacterial lipid membranes.7 
Previous studies on β-hairpin AMPs have been conducted using different strains of bacteria and assay 
methods, which does not allow for robust comparison of antimicrobial activity and toxicity. We have 
now examined representatives of the β-hairpin class under a standard set of conditions in order to 
directly correlate the therapeutic parameters of the peptides in relation to their origin, length, number 
of disulfide bridges and turn type.  
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The β-hairpins originate from diverse sources, including both invertebrates and mammals. They adopt 
the common characteristic of anti-parallel β-sheets linked by a small turn of 3 to 7 amino acids, 
forming a hairpin shape that is maintained by interstrand disulfide bridges in both aqueous and lipid-
mimicking environments.22-26 Table 2-1 summarizes the six β-hairpin AMPs chosen for our analysis. 
The peptides vary from 17 to 21 residues in length, with most containing two disulfide bonds that 
adopt a common linkage pattern, Cys1-Cys4 and Cys2-Cys3. The exception is thanatin, which has 
only one disulfide bridge. NMR solution structures indicate that the length of the β-sheet differs 
between β-hairpins, with the arenicin-3 β-sheet pair rigidifying almost the whole structure, but a less 
dominant β-sheet conformation in polyphemusin-1 resulting in greater flexibility.   
 
Table 2-1 - β-hairpin AMP origin, turn type, PDB ID and cartoon representation. 
Compound Origin Type of turn 
PDB 
ID Cartoon representation Ref. 
arenicin-3 
coelomocytes of 
marine polychaeta 
lugworm Arenicola 
marina 
I’ β-turn - 
 
27 
tachyplesin-1 
hemocyte debris of 
Tachypleus 
tridentatus 
II four-
residue β-
turn 
1WO0 
 
28 
polyphemusin-1 hemocyte debris of Limulus Polyphemus 
I’ four-
residue β-
turn 
1RKK 
 
29 
gomesin 
hemocytes of the 
spider Acanthoscurria 
gomesiana 
noncanonical 
four-residue 
β-turn 
1KFP 
 
30 
protegrin-1 porcine neutrophils 
distorted 
four-residue 
β-turn 
1PG1 
 
31 
thanatin spined soldier bug, Podisus maculiventris 
standard β-
turn 8TFV 
 
32 
The cartoon representation was generated using PyMOL (Schrödinger). Disulfide bridges are shown as sticks. 
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Table 2-2 - β-hairpin AMPs sequence alignment.   
 
(*) = C-terminal amidation and Z = N-terminal pyroglutamic acid. The grey sections are the 
conserved region. The cystines are marked in bold. The cationic residues are marked in red and the 
hydrophobic in green.  The boxes indicate the turn region.  
 
The amino acid sequence alignment, presented in Table 2-2, demonstrates the sequence homology 
and importance of particular amino acids shared between β-hairpin AMPs. Two areas are defined as 
conserved: i) tyrosine placed adjacent to a disulfide bond and either included in the turn 
(tachyplesin-1, polyphemusin-1 and gomesin) or forming part of a β-sheet (arenicin-3, protegrin-1 
and thanatin), and ii) the conserved C-terminal cysteine forming the external disulfide bridges of all 
six compounds. The arrangement of the cationic Arg and Lys residues included in the turn and the 
distal C- and N-termini regions, flanked by hydrophobic, membrane-insertive Val, Leu, Ile, Tyr or 
Trp residues, results in an amphipathic structure with one hydrophobic and one basic face, which 
creates a hydrophobic moment in the structure and allows the molecules to disrupt the bacterial lipid 
membrane. 
The high representation of Tyr and Arg, as displayed by an amino acid frequency graph of all β-
hairpin peptide sequences (Appendix II, Figure S7.2-1), consistently confers the elements of 
hydrophobicity and overall positive charge, respectively to this class of antibiotics.  
 
Physicochemical analysis. Many AMPs, including all of the β-hairpin class, act on the membrane of 
microorganisms by utilizing physicochemical peptide-lipid interactions to bind to, and disrupt the 
lipid bilayer of the bacterial membrane. The most important physicochemical property widely 
reported is amphipathicity, which allows the peptides to attack the membrane by interacting with the 
hydrophobic-hydrophilic character of the lipids. The physicochemical properties of the β-hairpin 
AMPs are reported in Table 2-3. The peptide isoelectric point (pI) was calculated using PepCalc.com 
online tool. Hydrophobicity was calculated based on the normalized consensus scale of Eisenberg.33  
 
arenicin-3 - G F C W Y V C V Y R N G V R V C Y R R C N - - -
tachyplesin-1 - K W C F R V C - Y R G I - - - C Y R R C R * - -
polyphemusin-1 R R W C F R V C - Y R G F - - - C Y R K C R * - -
gomesin - - Z C R R L C - Y K Q R - - - C V T Y C R G R *
protegrin-1 - - R G G R L C - Y C R R - R F C V - - C V G R *
thanatin G S K K P V P I I Y C N R R T G - - - K C Q R M *
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Table 2-3 - Physicochemical properties of β-hairpin AMPs. 
Peptide pI 
Net 
charge 
Hydrophobicity 
Amphipathic 
moment* 
arenicin-3 11.17 +4 -0.11 0.44 
tachyplesin-1 12.58 +6 -0.43 -0.11 
polyphemusin-1 12.41 +7 -0.56 0.48 
gomesin 12.58 +6 -0.61 0.83 
protegrin-1 13.10 +6 -0.42 0.36 
thanatin 12.71 +6 -0.34 -0.69 
* see Figure 2-1 
 
The pI is directly correlated with solubility, and proteins are soluble, avoiding aggregation, at greater 
than one or two pH units on either side of the pI. Since AMPs need to access lipid membranes from 
an aqueous phase they need to be soluble in both environments. If AMPs aggregate in solution, they 
will lose their ability to interact with the cell membrane. All of the molecules presented in Table 2-3 
have a calculated pI between 11 and 13, which avoids self-association driven by a loss of side chain 
charges at physiological pH. 
Being highly cationic is a key feature of β-hairpin AMPs with net charge varying only slightly, 
ranging from +4 to +7. It has been demonstrated that the AMP net charge has a direct correlation to 
their attraction/interaction to negatively charged bacterial membranes, with a lower net charge 
reducing attraction.34,35   
The hydrophobicity is relatively similar for all six β-hairpin AMPs with an average value of -0.41. 
Gomesin has the lowest hydrophobicity at -0.61. Hydrophobic residues facilitate interactions with the 
fatty acyl chains. The relatively low hydrophobicity prevents binding to the zwitterionic membranes 
found in mammalian cells, resulting in low toxicity.36,37 Hydrophobicity is also required for bacterial 
membrane permeabilisation, but some studies have demonstrated that above an optimum level or 
threshold (as determined by Glukhov et al.38) of hydrophobicity, further increase leads to a loss in 
antimicrobial activity and increase in toxicity.39 
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Figure 2-1 - Lipophilicity/amphipathic moment calculation of β-hairpin AMPs. All residues pointing down, toward 
the membrane, are classified as hydrophobic phase (orange) and those pointing up, away from the membrane, polar phase 
(green). 
 
Figure 2-1 summarises the lipophilicity, or amphipathic moment, of the β-hairpin AMPs based on 
analysis of the NMR solution structures, taking the direction of the Cβ-atom of each residue (the rest 
of the side chain being too flexible for accurate calculation). The amphipathic moment (Table 2-3) 
was calculated using our own model, specific for β-hairpin compounds. Our model considers the most 
probable orientation of the protein-membrane complex, where the AMPs make contact with the 
membrane with a perpendicular interaction between the surface of the bacterial or mammalian 
membrane and the β-sheets, taking into account the twisting of the molecule. This approach agrees 
with the reported findings of Matsuzaki et al40, i.e. that the mean axis of the β-sheet of tachyplesin-1 
is parallel to the surface of lipid film when binding to the bacteria membrane. For each molecule the 
amphipathic moment was calculated as the difference between the average value of hydrophobic 
phase residues and the average value of polar phase residues using the Eisenberg_M scale. The 
resulting amphipathic moment allowed the classification of the selected hairpin peptides into three 
groups. The first group constitutes the more amphipathic compounds which have an amphipathic 
moment <abs|0.4|, including tachyplesin-1 and protegrin-1. The second group consists of those with 
a medium amphipathic moment between abs|0.4| and abs|0.5| (arenicin-3 and polyphemusin-1), with 
the third group comprising those which are least amphipathic, including gomesin and thanatin with 
values > abs|0.5|.  
NMR conformational analysis showed that the two-stranded β-sheet in all six β-hairpin AMP 
structures studied here possess a significant twist. This distortion allows shielding of the hydrophobic 
side of the β-sheet from contact with the polar solvent. Surface representations that display the 
electrostatic and molecular hydrophobicity (Figure 2-2) of the six β-hairpin AMPs illustrate the 
absence or presence of amphipathicity in aqueous solution. Although amphipathic in nature, the 
charged and hydrophobic residues are scattered throughout the peptide sequences, rather than 
grouped. Therefore, the structures possess a more distributed amphipathicity compared to the two 
Hydrophobic phase Lipophilicity [ave(Eisenberg_M)]
Polar phase Diff
arenicin-3 - G F C W Y V C V Y R N G V R V C Y R R C N - - -0.12 -0.55 0.44
tachyplesin-1 - K W C F R V C - Y R G I - - - C Y R R C R - - -0.86 -0.75 -0.11
polyphemusin-1 R R W C F R V C - Y R G F - - - C Y R K C R - - -0.64 -1.12 0.48
gomesin - - Z C R R L C - Y K Q R - - - C V T Y C R G R -0.73 -1.56 0.83
protegrin-1 - - R G G R L C - Y C R R - - - R F C V C V G R -0.70 -1.06 0.36
thanatin G S K K P V P I I Y C N R R T G - - - K C Q R M -1.00 -0.31 -0.69
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clear and distinct faces of opposing properties often seen by other amphipathic molecules, such as the 
helical AMPs. 
 
Peptide 
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Figure 2-2 - Two-sided view of electrostatic and molecular hydrophobicity. a - The electrostatic views are based on 
the continuum model of the Poisson-Boltzmann equation. b - The molecular hydrophobicity views are based on the 
normalized consensus scale value of Eisenberg.41 
 
Antimicrobial activity. To determine correlations between the physicochemical properties of the β-
hairpin AMPs and their antimicrobial activity and/or toxicity, the selected peptides were tested 
against a panel of bacteria and fungi, with toxicity determined based on hemolytic activity and 
cytotoxicity assays against mammalian cells. 
Potent and broad-spectrum antimicrobial activity was seen for tachyplesin-1, polyphemusin-1, 
protegrin-1 and arenicin-3 (Table 2-4). Gomesin showed less potency yet retained broad-spectrum 
180° 180° 
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antimicrobial activity, with the exception of K. pneumoniae (ATCC 700603, MDR) and S. aureus 
(ATCC 43300, MRSA) for which the activity was reduced 4-8 fold. Thanatin showed a much 
narrower spectrum of antimicrobial activity; showing inhibitory preference for Enterobacteriaceae 
(E. coli ATCC 25922 and K. pneumoniae ATCC 13883), with activity against other species or 
resistant strains 8-32 fold less active. 
The mechanism of action of β-hairpin AMPs has been suggested to involve disruption of the integrity 
of the bacterial lipid bilayer.24,26,42-44 We carried out a fluorescent probe study (SYTOX green dye; 
data included in the supplementary information) to assess the inner (cytoplasmic) bacteria membrane 
permeability. The results show that all compounds except thanatin permeabilised the inner bacteria 
membrane, suggesting that they act via disruption of the membranes of G-ve and G+ve bacteria. The 
ability of each β-hairpin peptide to permeabilise the E. coli cytoplasmic membrane was in agreement 
with previous studies31,33,49-51 To further investigate this mechanism, we compared the antimicrobial 
activity of the peptides against three strains of E. coli: (i) a control E. coli strain (ATCC 25922) that 
possessed a ‘smooth’ lipopolysaccharide (LPS) outer layer, (ii) a membrane mutant, E. coli K12 
(ATCC 700926), a ‘rough’ strain deficient in the O-antigen chain of the LPS, and (iii) a membrane 
mutant,  E. coli MB 4902, ∆lpxC mutant, where LpxC is a key enzyme involved in the biosynthesis 
of lipid A, a phosphorylated glycolipid that anchors the lipopolysaccharide to the outer membrane of 
the cell.  All peptides were slightly more active (2- to 16-fold) against the ‘rough’ K12 mutant than 
the ‘smooth’ strain, except for thanatin, for which activity remained the same. With the ∆lpxC mutant, 
there was a significant increase in potency for all compounds (4- to 128-fold decrease in MICs), with 
protegin-1 and polyphemusin-1 showing the greatest potency at 0.015 and 0.03 μg/mL, respectively. 
Taken together, these data imply the peptides are able to more readily penetrate the lipid bilayer 
resulting in cell death with decreased lipid A in the outer membrane (OM). The potency of protegin-1 
and polyphemusin-1 against the ∆lpxC E. coli mutant suggests that their mode of action may differ 
subtly from the other peptides. 
Interestingly, out of the six β-hairpin AMPs tested, one group (arenicin-3, tachyplesin-1 and thanatin) 
were most active against G-ve bacteria, and in particular E. coli, whereas, the second group 
(polyphemusin-1, protegrin-1 and gomesin) were all more potent (2 to 10 fold) against B. subtilis 
(G+ve bacteria) and C. neoformans (fungi) than any other strains of bacteria and fungi.  It is likely 
that this second group of compounds has a different mode of action to the other AMPs studied, an 
observation supported by the inner bacteria membrane permeabilisation study (data in supplementary 
information), where all three peptides (polyphemusin-1, protegrin-1 and gomesin) showed 
permeabilisation at a lower concentration than their MIC for the same E.coli ATCC 25922 strain.  
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Table 2-4 – Antimicrobial activity of β-hairpin AMPs. 
Compound 
name 
MIC (μg/mL) 
Bacteria 
G-ve 
Bacteria 
G+ve 
Fungi  
Yeast 
E.
 c
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2 
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A
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C 
70
09
26
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12
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M
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49
02
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lp
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) 
A
TC
C 
13
88
3 
A
TC
C 
70
06
03
 
(M
D
R)
 
BA
A
 2
14
6 
(N
D
M
-1
 p
os
) 
A
TC
C 
19
60
6 
A
TC
C 
27
85
3 
A
TC
C 
60
51
 
A
TC
C 
43
30
0 
(M
RS
A
) 
A
TC
C 
90
02
8 
A
TC
C 
20
88
21
 
colistin 0.03 0.03 0.009 0.5 0.125 0.03 0.03 0.25     
vancomycin         0.25 1   
amphotericin B           0.06 0.015 
arenicin-3 0.5 0.25 0.125 1 4 4 0.5 1 8 64 64 8 
tachyplesin-1 0.06 0.03 0.016 0.125 0.25 0.25 0.125 0.25 0.125 1 4 0.125 
polyphemusin-1 0.5 0.06 0.03 0.5 1 2 0.06 2 0.25 2 1 0.06 
gomesin 16 8 4 16 64 32 16 16 2 128 16 2 
protegrin-1 2 0.25 0.015 0.5 4 4 0.25 4 0.03 4 2 0.06 
thanatin 8 8 2 8 64 256 >256 256 128 256 64 64 
colistin, vancomycin and amphotericin B were used as positive inhibitor controls for G-ve, G+ve and fungi, 
respectively. Data: n = 4. 
 
Toxicity. For a peptide to be considered for therapeutic development it not only needs to possess 
potent antimicrobial activity, it also needs to have low toxicity to human cells. Here we evaluated the 
hemolytic activity of the profiled peptides, reported in Table 2-5 as a percentage value of hemolysis 
(compared to 100 % hemolysis induced by 1 % Triton –X100) when tested at 300 μg/mL (Appendix 
II, Figure S7.2-2). Protegrin-1 showed the highest hemolytic activity with 65 % disruption at the 
concentration tested. Tachyplesin-1 and polyphemusin-1 both possessed hemolytic activity of 
approximately 30 %, while arenicin-3 and gomesin were much less hemolytic (4 %). Thanatin was 
the only compound deemed to be non-hemolytic. Cytotoxicity was assessed using two different 
human cell lines (kidney and liver) in combination with two serum concentrations, 1 % and 10 %. 
With reduced serum in the assay, the cells are more susceptible to damage as their growth is not as 
robust. The compounds were far less toxic when 10 % FBS was present (Table 2-5), but these 
conditions can potentially lead to false negatives as there is likely to be less unbound active compound 
available (due to plasma protein binding) to interfere with the cells. Both cell lines were affected to a 
similar degree and in the same order of magnitude for all compounds except for gomesin, which 
showed approximately 2-fold more toxicity toward the kidney cells (HEK293) than the liver cells 
(HepG2). In terms of cytotoxicity, only thanatin remained non-toxic at the highest concentration (300 
uM) tested. Plasma Protein Binding (PPB), as measured by ultrafiltration in 100 % human plasma, 
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ranged from 63 % for polyphemusin-1 to 92 % for thanatin (Table 2-5). The lack of toxicity observed 
with thanatin may be partly due to its high protein binding, but protegrin-1 (89 %) was similarly 
highly bound, yet showed the greatest toxicity. The therapeutic potential of β-hairpin AMPs is valued 
on the basis of their selectivity toward microbial cells as compared to normal mammalian cells. This 
cell selectivity is expressed as the therapeutic index (TI) of the peptides, which in this study is 
calculated as the ratio of the average toxicity (the sum of % value of hemolysis plus CC50 values of 
both cytotoxicity using media with minimal serum; 1 % FBS, divided by three) to the median of the 
MIC determined toward all tested bacteria and fungi strains. A larger therapeutic index value indicates 
better bacterial / mammalian cell selectivity.   
 
Table 2-5 - Hemolytic activity, cytotoxicity, Therapeutical Index (TI) and Plasma Protein Binding (PPB) of β-
hairpin AMPs.   
Compound 
Hemolysis 
(%) at 
300 μg/mL  
Cytotoxicity (CC50) (μg/mL) 
TI* 
 
HepG2 HEK293 
PPB 
(%)  
1 % FBS 10 % FBS 1 % FBS 10 % FBS  
arenicin-3 4.4 ± 1.1 95.2 ± 4.1 >300 104.6 ± 1.8 >300 17 68 
tachyplesin-1 27.8 ± 3.9 65.7 ± 1.5 >300 94.7 ± 1.1 >300 335 76 
polyphemusin-1 29.6 ± 2.4 36.5 ± 8.6 254.3 ± 14.2 36.6 ± 1.4 188.5 ± 1.1 46 63 
gomesin 4.4 ± 0.1 162.4 ± 1.1 219.7 ± 73.3 102.3 ± 1.1 116.1 ± 25.1 6 87 
protegrin-1 64.8 ± 3.5 31.4 ± 2.0 96.1 ± 1.1 19.6 ± 1.2 93.9 ± 1.1 19 89 
thanatin 1.3 ± 0.4 >300 >300 >300 >300 3 92 
*TI is the therapeutic index calculated as the ratio of the average toxicity (hemolytic and cytotoxic at 1 % 
FBS) to the median of the MIC determined toward all tested bacteria and fungi strains. 
 
Based on the activity profiles obtained, the six peptides can be ranked by order of antimicrobial 
activity and toxicity from the most active/toxic to the least active/toxic, Figure 2-3. 
 
(A)  
(B)  
Figure 2-3 - (A) Antimicrobial activity and (B) Toxicity ranking. From left (most) to right (least) comparing the 
antimicrobial activity across the whole panel of bacterial and fungal strains and the toxicity as a combination of hemolytic 
activity and cytotoxicity. 
 
From this ranking, two distinct groups form. The first group includes tachyplesin-1, polyphemusin-1 
and protegrin-1, constituting the most active but also most toxic (MAMT) compounds. The second 
group, represented by arenicin-3, gomesin and thanatin, are the least active and least toxic (LALT) 
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compounds. This correlates with the therapeutic indices calculated for the peptides, where the 
peptides with best TI values correspond to the MAMT group and the peptides with lower TI values 
fit into the LALT group.  
A comparison of the physicochemical properties (Table 2-3) with antimicrobial activity and toxicity 
(Figure 2-3) shows that the peptides that are the most amphipathic and the least hydrophobic are those 
belonging to the MAMT group, like tachyplesin-1, polyphemusin-1 and protegrin-1. Arenicin-3 is 
moderately amphipathic and quite hydrophobic, which explains it belonging to the LALT group. 
Gomesin however has poor amphipathicity but the lowest overall hydrophobicity, dis-allowing 
interaction with either mammalian or bacterial cells, which explain its belonging to the LALT group. 
The structure-function relationship study from Mattei et al45 concluded that more hydrophobic 
analogs of gomesin have higher antimicrobial activity, whereas peptides more hydrophilic abolish 
antimicrobial activity. It was concluded that the interaction of gomesin with bacterial membranes 
depends on interplay between surface electrostatic interactions, which drives anchoring to the 
membrane surface and vesicle aggregation, and insertion of the hydrophobic portion into the 
membrane core, responsible for causing membrane rupture/permeabilization. Thanatin, unlike 
gomesin, has good hydrophobicity but is not overly amphipathic, leading to the same behaviour and 
explains the classification of this compound in the LALT group. 
The correlation between antimicrobial activity and toxicity resides in cell selectivity. The cationic 
property of AMPs contributes to cell selectivity because the surface of bacterial membranes is more 
negatively charged than that of mammalian cells. However, the hydrophobicity and the 
amphipathicity, of the peptide are key components of the interaction of AMPs with mammalian cell 
membranes. Many studies have demonstrated that hemolytic peptides exhibit strong interaction with 
the zwitterionic phospholipid, phosphatidylcholine, whereas non-hemolytic peptides do not.46, 47 Our 
data correlates with these rules, with the most amphipathic compounds being the most hemolytic. For 
all AMPs, the maintenance of the peptide hydrophobic–hydrophilic balance may be the critical 
parameter to producing a highly bacterial selective peptide therapeutic.48  
The key features required for efficient bactericidal or hemolytic activities rise from understanding the 
secondary and tertiary structures of AMPs. The knowledge of key structure-function relationships 
may assist in the rational design toward improved analogs for clinical use. As a common supportive 
structural feature of proteins and peptides, it is highly likely that the disulfide bridges play an 
important role in β-hairpin AMP antimicrobial activity. The role of disulfide bridges in AMPs has 
been studied for numerous cases, with their importance appearing to be compound dependent. There 
are two main categories of compounds; (i) AMPs whose antimicrobial activity is independent of the 
presence or absence of disulfide bridges, for example human β-defensin-322 and bovine β-defensin-2, 
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(ii) AMPs that display decreased antimicrobial activity in the absence of disulfide bonds, for example 
human β-defensin-2 and α-defensin HNP-122 or bactenecin22. The β-hairpin AMPs fall into both 
categories, but their activity appears dependent on the ability of the peptides to retain their 
amphipathic structure upon membrane contact.14,49-52 Therefore, to design new analogs, the secondary 
structure and amphipathic modifications have to be the key parameters to take into account for 
developing good structure-activity relationships. Cys could potentially be replaced by aromatic 
residues like Tyr or Phe which would allow the secondary structure of the peptide to be maintained 
and increase the hydrophobicity of the peptide which should allow better cell selectivity.48 
  
2.4 Materials and methods 
Compounds tested. Tachyplesin-1, polyphemusin-1, gomesin, protegrin-1 and thanatin were 
synthesized by Mimotopes Pty Ltd (Clayton, Australia) using Fmoc-based solid phase peptide 
synthesis and orthogonal Cys protection (Fmoc Cys(Acm)-OH for C3, C16, and Fmoc Cys(Trt)-OH 
for C7, C12); the first disulfide bond was formed by air oxidation following cleavage from the resin, 
with iodine treatment generating the fully cyclized peptide that was purified by RP-HPLC to >95 % 
purity. Identity and purity were confirmed by LC-MS and HRMS. Arenicin-3 was supplied by 
Adenium Biotech.   
Antimicrobial assay (Minimum Inhibitory Concentration [MIC]). Both antibacterial and 
antifungal MIC assays were performed by a broth microdilution plate based method as per CLSI 
guidelines for antimicrobial susceptibility testing.53, 54 The assay was performed in Mueller Hinton 
Broth (MHB, Bacto laboratories, 211443) for bacteria and Yeast Extract-Peptone Dextrose (YPD, 
Sigma-Aldrich, Y1500) for fungi and the MIC was determined as the lowest concentration of 
compound that prevented microorganism growth after 18-24 h. Full assay details are included in the 
Appendix II with a full list of strains tested in Table S7.2-1. 
Cytotoxicity assay. Cytotoxicity to HEK293 and HepG2 cells was determined using the Alamar Blue 
(resazurin) assay,55, 56 with 24h incubation and either 1 % or 10 % serum concentration. Full assay 
details are included in the supplementary information. 
Hemolysis assay. Hemolytic activity was performed as previously descripted in the literature with 
slight modifications.57 Full assay details are included in the supplementary information.  
Plasma protein binding assay. Plasma protein binding was performed using an Ultrafiltration 
method.58 
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2.5 Conclusion 
Despite the small number of β-hairpin AMPs found in nature, we can start to discern trends to 
determine key features required for optimal compound design. The AMPs have diverse structural 
arrangements and physicochemical properties, allowing them to act selectively against bacteria 
compared to mammalian cell types. However, some key elements are required to remain constant in 
order to maximize antimicrobial activity and minimize toxicity. The strategy for a good β-hairpin 
AMP does not involve only one factor but rather requires a good balance between charge, 
hydrophobicity, amphipathicity, secondary and tertiary structure, and mode of action. β-hairpin 
AMPs offer a wide spectrum of antimicrobial activity with very limited bacterial resistance observed 
to date, likely due to the significant change in membrane properties that this would require. β-hairpin 
AMPs therefore present many advantages over antibiotics already available in the clinic and are 
worthy of further investigation to develop as replacements for antibiotics that have become 
ineffective. 
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Chapter 3    - Therapeutical 
enhancement of tachyplesin-1 
The chapter includes the manuscript published in ACS Infectious Diseases journal (2017). The 
manuscript investigated the structure activity relationship of tachyplesin-1 to design therapeutically 
valuable peptides. This study concluded in two new tachyplesin-1 analogs with great potential. See 
Appendix III, page 7-143 for supporting information.  
 
The research findings have been published in the manuscript Edwards, Ingrid A., et al. "Structure–
Activity and −Toxicity Relationships of the Antimicrobial Peptide Tachyplesin-1." ACS Infectious 
Diseases 2017, 3 (12), pp 917–926., DOI: 10.1021/acsinfecdis.7b00123. The publication can be 
obtained, along with supplementary material associated with the article, from 
http://pubs.acs.org/doi/abs/10.1021/acsinfecdis.7b00123. 
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3.1 Abstract 
Tachyplesin-1 (1) is a cationic β-hairpin antimicrobial peptide with a membranolytic mechanism of 
action. Whilst it possesses broad-spectrum, potent antimicrobial activity, 1 is highly hemolytic 
against mammalian erythrocytes, which precludes it from further development. In this study we report 
a template-based approach to investigate the structure-function and structure-toxicity relationships of 
each amino acid of 1. We modulated charge and hydrophobicity by residue modification and 
truncation of the peptide. Antimicrobial activity was then assessed against six key bacterial pathogens 
and two fungi, with toxicity profiled against mammalian cells. The internal disulfide bridge Cys7-
Cys12 of 1 was shown to play an important role in broad-spectrum antimicrobial activity against all 
pathogenic strains tested. Novel peptides based on the progenitor were then designed, including 5 
(TP1[F4A]), 12 (TP1[I11A]) and 19 (TP1[C3A,C16A]).  These had 26- to 64-fold improved 
activity/toxicity indices, and show promise for further development. Structural studies of 5 
(TP1[F4A]) and 12 (TP1[I11A]) identified a conserved β-hairpin secondary structure motif 
correlating with their very high stability in mouse and human plasma. Membrane binding affinity 
determined by surface plasmon resonance confirmed their selectivity toward bacterial membranes, 
but the degree of membrane binding did not correlate with the degree of hemolysis, suggesting that 
other factors may drive toxicity.  
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3.2 Introduction  
Increasing rates of bacterial resistance to antibiotics has fueled a dire need for the discovery of new 
replacement drugs for obsolete antibiotics.1 Antimicrobial peptides (AMPs) are common in nature, 
being essential components of the innate immune system in the majority of multicellular organisms. 
AMPs have been well studied over three decades with more than 2000 AMPs reported from 
eukaryotes (http://aps.unmc.edu/AP/main.php). AMPs, being short, cationic and amphipathic, are 
characterized with broad range antimicrobial activity resulting from a membranolytic mechanism of 
action, which consequently offers a low rate of resistance development. Tachyplesin-1 (TP1) 1 is a 
member of the closely related tachyplesin and polyphemusin families, both originating from the 
horseshoe crab.2,3  1 is a 17 amino acid AMP (KWCFRVCYRGICYRRCR) extracted from the 
hemocytes of the horseshoe crab, Tachypleus tridentatus. 1, constrained by two disulfide bridges 
(Cys3-Cys16, Cys7-Cys12), forms a β-hairpin structure (Figure 3-1), both in aqueous solution and in 
lipid-mimicking environments.4,5 1 exhibits potent activity against Gram-positive (G+ve) and Gram-
negative (G-ve) bacteria, as well as fungi. 1 did not induce resistance in short term studies6, but caused 
decreased susceptibility under long-term continuous selection conditions7. 1 has been shown to 
compromise the integrity of both the outer and cytoplasmic cell membranes of Escherichia coli.8 In 
addition to its high antimicrobial activity, 1 unfortunately also displays high toxicity towards 
mammalian cells, a common detrimental characteristic of many AMPs that renders them unsuitable 
for therapeutic development. Analogs of 1 have been reported in the past, with amino acid 
substitutions around the disulfide bridge regions.9-13 However, no systematic study has been reported 
to ascertain a clear structure-function relationship for each amino acid in the sequence. In this report, 
we have conducted an alanine scan of 1 followed by modifications of the overall hydrophobicity by 
replacement at select positions that the Ala scan indicated were amenable to change. We assessed the 
effects of amino acid replacements on antimicrobial activity, cytotoxicity, and hemolytic activity. 
Furthermore, we evaluated the membrane binding affinity of the most interesting peptides by surface 
plasmon resonance (SPR). We then assessed the stability of the most promising peptides in plasma, 
and conducted solution phase NMR structrural studies.  
 
 
3.3 Results and discussion 
Peptide design. In this study, we systematically determined the importance of each amino acid in 1 
in a search for therapeutically valuable analogs of 1. A schematic representation of 1 (Figure 3-1) 
illustrates the structural amphipathicity of the peptide.  There are two distinct faces; one β-sheet (top) 
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composed mainly of hydrophobic residues and the other one (bottom) being more hydrophilic and 
charged. Thus, 1 has been identified as one of the most amphipathic β-hairpin AMPs.14 
 
Figure 3-1 - Schematic representation of 1 
(TP1). Hydrophobic residues in green and 
charged residues in blue. 
 
To modulate the properties of a peptide several methodologies are commonly exploited (i) alteration 
of the hydrophobicity/amphipathicity by replacing hydrophobic residues with less hydrophobic (e.g. 
Ala, Gly) or more hydrophilic (e.g. Ser) residues, (ii) modification of the charge by replacing basic 
or acidic residues, (iii) truncation of the peptide, (iv) combination of (i) to (iii).15,16 Here we have 
chosen a panel of peptide modifications that encompass all these methods. An alanine scan is 
commonly employed to ascertain the importance of individual residues within a peptide.  Alanine is 
the most commonly used amino acid to study the amino acid function in a peptide because it 
eliminates side-chain interactions without altering the main-chain conformation. It has the ability to 
form α-helices and/or β-sheets, is flexible and has low hydrophobicity.   
We studied the physicochemical properties of all 1 analogs (Table 3-1). The peptides ranged from 
2009 Da (29, 16 residues) to 2293 Da (23, 17 residues). The ExPASy ProtParam tool17 was used to 
calculate the physicochemical properties of the peptide analogs. The charge of the analogs varied 
from +4 (29 and 33) to +6 (1), while their pI varied from 9.25 (29 and 33) to 12.71 (9 and 14). 
GRAVY score (grand average of hydropathicity index) is a method used to calculate the 
hydrophobicity/solubility of a peptide. A negative GRAVY score indicates hydrophilicity and a 
positive GRAVY score indicates hydrophobicity. All peptides were hydrophilic except for two, 31 
with GRAVY = 0.000, and 33 with a positive hydrophobic GRAVY = 0.224. 
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Table 3-1 - Amino acid sequences and physicochemical properties of tachyplesin-1 and its analogs. 
Number Peptide H-Sequence-NH2 MW (Da) Charge pI GRAVY 
1 TP1 KWCFRVCYRGICYRRCR 2263.7 +6 12.29 -0.518 
2 TP1[K1A] AWCFRVCYRGICYRRCR 2206.7 +5 12.28 -0.182 
3 TP1[W2A] KACFRVCYRGICYRRCR 2148.6 +6 12.29 -0.359 
4 TP1[C3A,C16S] KWAFRVCYRGICYRRSR 2217.6 +6 12.29 -0.753 
5 TP1[F4A] KWCARVCYRGICYRRCR 2187.7 +6 12.29 -0.576 
6 TP1[R5A] KWCFAVCYRGICYRRCR 2178.6 +5 12.12 -0.147 
7 TP1[V6A] KWCFRACYRGICYRRCR 2235.7 +6 12.29 -0.659 
8 TP1[C7A,C12S] KWCFRVAYRGISYRRCR 2217.7 +6 12.29 -0.753 
9 TP1[Y8A] KWCFRVCARGICYRRCR 2170.0 +6 12.71 -0.335 
10 TP1[R9A] KWCFRVCYAGICYRRCR 2178.6 +5 12.12 -0.147 
11 TP1[G10A] KWCFRVCYRAICYRRCR 2277.8 +6 12.29 -0.388 
12 TP1[I11A] KWCFRVCYRGACYRRCR 2221.7 +6 12.29 -0.676 
13 TP1[C7S,C12A] KWCFRVSYRGIAYRRCR 2217.7 +6 12.29 -0.753 
14 TP1[Y13A] KWCFRVCYRGICARRCR 2171.7 +6 12.71 -0.335 
15 TP1[R14A] KWCFRVCYRGICYARCR 2178.7 +5 12.12 -0.147 
16 TP1[R15A] KWCFRVCYRGICYRACR 2178.7 +5 12.12 -0.147 
17 TP1[C3S,C16A] KWSFRVCYRGICYRRAR 2217.7 +6 12.29 -0.753 
18 TP1[R17A] KWCFRVCYRGICYRRCA 2178.7 +5 12.12 -0.147 
19 TP1[C3A,C16A] KWAFRVCYRGICYRRAR 2203.7 +6 12.29 -0.600 
20 TP1[C7A,C12A] KWCFRVAYRGIAYRRCR 2203.7 +6 12.29 -0.600 
21 TP1[C3A,C7A,C12A,C16A] KWAFRVAYRGIAYRRAR 2140.5 +6 11.84 -0.682 
22 TP1[V6R,R9A] KWCFRRCYAGICYRRCR 2239.8 +6 12.29 -0.659 
23 TP1[K1R] RWCFRVCYRGICYRRCR 2292.7 +6 10.16 -0.553 
24 TP1[F4G] KWCGRVCYRGICYRRCR 2174.6 +6 9.93 -0.706 
25 TP1[F4S] KWCSRVCYRGICYRRCR 2204.6 +6 9.93 -0.729 
26 TP1[Y8G] KWCFRVCGRGICYRRCR 2158.6 +6 10.16 -0.465 
27 TP1[I11G] KWCFRVCYRGGCYRRCR 2208.6 +6 9.93 -0.806 
28 TP1[F4A,Y8A,I11A] KWCARVCARGACYRRCR 2054.4 +6 10.16 -0.553 
29 TP1[-R5,R17G] KWC - FVCYRGICYRRCG 2009.4 +4 9.25 -0.013 
30 TP1[K1A,F4A] AWCARVCYRGICYRRCR 2131.5 +5 9.69 -0.241 
31 TP1[K1A,Y8A] AWCFRVCARGICYRRCR 2115.5 +5 9.88 0.000 
32 TP1[K1A,I11A] AWCFRVCYRGACYRRCR 2165.5 +5 9.69 -0.341 
33 TP1[R9A,R17A] KWCFRVCYAGICYRRCA 2094.5 +4 9.25 0.224 
 
Antimicrobial activity, toxicity and cell selectivity. 1 was determined previously to possess potent 
and broad-spectrum antimicrobial activity.14 Here we assessed the antimicrobial activity of 32 analogs 
of 1 against a broad range of bacteria, both G-ve and G+ve, as well as fungi. Table 3-2 reports the 
results of testing against a panel of ATCC reference strains and drug resistant clinical isolates of 
Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa (strain details in 
Appendix III, Table S7.3-1). The majority of the analogs tested retained potent activity across the 
range of microbes, even the most resistant ones, as compared to 1, though no analog displaying 
increased antimicrobial activity. All peptides, including 1, showed a marked reduction in activity 
against Candida albicans as compared to other microbes, with at least 8-fold reduction in antifungal 
activity as compared to Cryptococcus neoformans. Similarly, for G+ve bacteria the peptides had 
lower potency against Staphylococcus aureus compared to Bacillus subtilis, with antibacterial activity 
consistently at least 4-fold lower. For K. pneumoniae, all peptides demonstrated a reduction in activity 
between the reference strain, and the multidrug-resistant (MDR) strains of 2- to 8-fold, with no 
difference between the various MDR strains. Another 4- to 32-fold reduction in activity was noted 
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when tested against an extensively drug-resistant (XDR) strain across all peptides. This difference in 
activity was not demonstrated in the case of A. baumannii or P. aeruginosa with the MIC activity 
remaining within a tight range (~2-fold, i.e. within accepted assay fluctuation range), between 
reference strains and resistant strains, including XDR and polymyxin resistant isolates. 
The alanine scan showed that single Ala replacements of amino acids at positions 1, 2, 4, 5, 6, 8, 9, 
10, 11, 13, 14, 15 or 17 (producing peptides 2, 3, 5, 6, 7, 9, 10, 11, 12, 14, 15, 16 or 18, respectively) 
gave analogs that retained the broad-spectrum potent antimicrobial activity of 1; therefore these 
positions are presumably not key for the antimicrobial activity of the peptide. An NMR and 
tryptophan fluorescence study performed by Kushibiki et al5 concluded that Trp2 inserted into the 
hydrophobic acyl chains of LPS and suggested that the residues located at the N- and C-termini of 1 
are involved in the binding to LPS, indicating their importance in the mode of action of 1. Our results 
do not correlate well with those findings as 3 (TP1[W2A]) showed only 3-fold reduction in 
antimicrobial activity across all tested strains, with 2 and 18 also showing good activity. Positions 3, 
7, 12 and 16 of 1 correspond to Cys residues, forming two disulfide bridges (3-16 and 7-12) that 
create the disulfide bridge constrained β-hairpin structure as characterized by several earlier studies.4,5 
Removal of the disulfide bridge was achieved via two different approaches: (i) by Ala replacement 
of one Cys while the partnering Cys residue was replaced by Ser, therefore retaining the same 
hydrophilic properties of Cys-SH without potential misfolding of the peptide through mismatched 
disulfide bond formation18 and (ii) by complete abolition of the disulfide bridge properties by Ala 
replacement of both Cys residues. The deletion of the internal disulfide bridge (7-12) in 8, 13 or 20 
reduced the antimicrobial activity of 1 by 3- to 12-fold. However, the deletion of the external disulfide 
bridge (3-16) in 4, 17 or 19 more significantly reduced the antimicrobial activity of 1, by 4- to 128-
fold. Deletion of both disulfide bridges, 21, dramatically reduced the overall antimicrobial activity 
by 64-fold across all tested strains, in accordance with the work performed by Tamamura et al.9 This 
reduction in antimicrobial activity is presumably due to the subsequent loss of β-sheet stacking, as a 
direct result of the removal of the disulfide bridges.7,8,15 In our study, there were several unexpected 
results. Of the three analogs that removed the external disulfide bond, 19 (TP1[C3A,C16A]) and 17 
(TP1[C3S,C16A]) had similar antimicrobial activities across all strains tested, losing only 2 to 16-
fold activity as compared to 1. However, 4 (TP1[C3A,C16S]) showed around 100-fold reduction in 
antimicrobial activity for most strains tested, except for B. subtilis and C. neoformans where the 
reduction was only 10-fold. Cys3 is flanked by hydrophobic residues, Trp2 and Phe4, and Cys16 is 
flanked by polar residues, Arg15 and Arg17. By inserting the hydrophobic residue Ala into position 
3 and hydrophilic residue Ser into position 16, the amphipathicity of the peptide was increased 
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considerably, potentially creating a repulsive effect between the β-sheets that led to an unfolded 
structure (1H NMR in Appendix III, Figure S7.3-13). 
Several positions were selected for further modifications. The modulation of 
hydrophobicity/amphipathicity at position 4 was studied by mutating Phe with Ala (F4A) 5, Gly 
(F4G) 24 or Ser (F4S) 25, resulting in reduced antimicrobial activity, around 2-fold at each mutation, 
as hydrophobicity decreased. A selection of five peptides (4 (TP1[C3A,C16S]), 19 
(TP1[C3A,C7A,C12A,C16A]), 22 (TP1[V6R,R9A]), 28 (TP1[F4A,Y8A,I11A]) and 29 (TP1[-
R5,R17G])) showed a considerable loss, at least 100-fold, in antimicrobial activity across the full 
panel of bacteria and fungi. These five peptides were designed with a range of modifications that 
comprise physicochemical properties from all regions of the spectrum of MW, charge, pI and 
hydrophobicity. No trend was identified that correlated physicochemical properties with 
antimicrobial activity, and it is therefore more likely that the overall peptide structure and sites 
specific to mode of action are the key elements to increasing and decreasing antimicrobial potential 
of the 1 peptide scaffold.  
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Table 3-2 - Antimicrobial activity of tachyplesin-1 and its analogs 
Compound name 
MIC (μg/mL) 
Bacteria G-ve Bacteria G+ve Fungi Yeast 
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colistin 0.015 0.125 0.03 0.125 >32 0.06 >32 0.125 >32     
meropenem ≤0.03 0.03 0.06 >32 >64 1 >64 0.5 >32     
vancomycin          0.125 1   
fluconazole            0.5 8 
amphotericin B            0.25 0.15 
1 0.06 0.06 0.25 0.25 2 0.06 0.125 0.125 0.25 0.06 0.25 2 0.125 
2 0.03 0.06 0.125 0.125 2 0.125 0.125 0.25 0.5 0.03 0.5 8 0.25 
3 0.25 0.5 1 1 >16 0.5 0.5 0.5 4 0.5 8 8 0.5 
4 4 16 16 >16 >16 >16 >16 >16 >16 0.5 >16 >16 4 
5 0.125 0.5 0.5 0.5 16 0.5 0.5 0.5 2 0.25 4 8 0.5 
6 0.125 0.125 0.5 0.5 8 0.06 0.125 0.25 0.5 0.03 0.5 4 0.25 
7 0.25 0.25 1 1 16 0.25 0.5 1 2 0.25 4 8 1 
8 0.5 0.5 4 2 16 0.25 0.25 2 4 0.25 2 8 0.5 
9 0.06 0.125 0.25 0.5 8 0.125 0.5 1 2 0.25 4 8 0.5 
10 0.125 0.03 0.25 0.125 2 0.06 0.125 0.25 1 0.125 1 2 0.25 
11 0.06 0.03 0.25 0.25 4 0.06 0.06 0.25 0.5 0.03 0.5 2 0.06 
12 0.125 0.25 0.5 0.25 8 0.25 0.25 0.25 1 0.125 2 2 0.5 
13 1 4 16 8 16 0.5 1 8 16 0.125 16 2 0.5 
14 0.25 0.25 0.5 0.5 8 0.125 0.25 0.5 2 0.06 4 4 0.5 
15 0.125 0.06 0.5 0.25 1 0.125 0.125 0.125 0.25 0.125 0.5 8 0.25 
16 0.25 0.25 2 1 16 0.25 0.25 4 4 0.03 4 2 0.25 
17 0.25 1 2 1 16 0.25 0.25 1 4 0.125 4 4 0.25 
18 0.015 0.125 0.25 0.25 4 0.125 0.125 0.25 0.5 0.015 0.5 4 0.25 
19 0.25 1 1 1 >16 0.25 0.5 2 8 0.125 8 8 1 
20 0.125 0.25 2 1 16 0.25 0.25 1 2 0.125 2 8 1 
21 8 16 16 16 >16 4 4 >16 >16 1 16 >16 1 
22 0.5 >16 16 >16 >16 16 >16 >16 >16 0.25 >16 >16 4 
23 0.125 0.125 0.5 0.25 4 0.125 0.25 0.25 0.5 0.125 1 4 0.25 
24 0.25 2 1 2 >16 0.5 2 1 16 0.5 16 8 2 
25 0.5 2 4 4 >16 0.5 2 4 >16 0.5 16 >16 4 
26 0.5 2 8 8 >16 1 2 8 16 0.5 16 >16 4 
27 0.25 0.25 0.5 2 8 0.5 0.5 1 4 0.25 4 8 1 
28 8 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 >16 
29 8 >16 >16 >16 >16 16 >16 >16 >16 1 >16 >16 4 
30 2 4 4 4 >16 2 16 8 >16 16 >16 >16 >16 
31  0.125 0.25 0.5 1 8 0.25 0.5 1 4 0.5 8 >16 2 
32 0.125 0.125 0.25 0.5 4 0.25 0.25 0.5 2 0.125 4 >16 1 
33 0.03 0.06 0.5 0.5 4 0.25 0.5 0.5 2 0.06 2 8 0.5 
colistin, meropenem, vancomycin, fluconazole and amphotericin B were used as positive inhibitor controls for G-ve, G+ve and fungi, 
respectively. Data: n = 4, XDR (extensively drug resistant), PmxR (polymyxin resistant). 
 
The toxicity of the analogs of 1 was tested against Human Embryonic Kidney cells (HEK293) and 
human red blood cells (RBC). None of the peptides showed cytotoxicity against HEK293 cells at the 
highest tested concentration, 100 μg/mL. Hemolytic activity (MHC) is reported in Table 3-3 as the 
minimum hemolytic concentration that caused 10% hemolysis of fresh RBCs. 1 possessed reasonably 
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potent hemolytic activity (MHC = 0.25 μg/mL) and most of the peptide analogs did not improve this 
quality by decreasing hemolytic potency. However, nine of the analogs (3 (TP1[W2A]), 4 
(TP1[C3A,C16S]), 5 (TP1[F4A]), 9 (TP1[Y8A]), 12 (TP1[I11A]), 19 (TP1[C3A,C16A]), 20 
(TP1[C7A,C12A]), 22 (TP1[V6R,R9A]) and 30 (TP1[K1A,F4A])) did show promising 32 to 160-
fold reductions in MHC. Similarly to antimicrobial activity, this did not correlate with the 
physicochemical properties of the peptides and no trend or correlation could be discerned. 
Additionally, for some analogs the reduction in hemolytic activity correlated to the loss of 
antimicrobial activity, meaning these peptide sequences essentially lost all biological activity. This is 
the case for 22, a peptide designed to reduce the hydrophobicity of 1 without change of charge, 
reducing the overall amphipathicity of 1. This change was not beneficial, emphasizing again the 
importance of peptide amphipathicity to its activity. 
Commonly, the overall therapeutic potential of a peptide is assessed via a cell selectivity or 
antimicrobial activity/toxicity index (ATI). The ATI, Table 3-3, can be improved in one of the 
following ways (i) increase in antimicrobial activity, (ii) decrease in hemolytic activity, or (iii) a 
combination of both, increasing antimicrobial activity while decreasing hemolytic activity. Here we 
calculated the ATI from the ratio of the minimum hemolytic concentration (MHC) to the median of 
the minimum inhibitory concentrations (MIC) determined towards all tested bacteria and fungi (MM). 
Therefore, a larger ATI value indicates greater desirable cell selectivity. From these ATI calculations, 
three peptides (5 (TP1[F4A]), 19 (TP1[C3A,C16A]) and 12 (TP1[I11A])) stood out. These analogs 
had ATI values that were 26-, 40- and 64-fold improved, respectively, retaining relatively high 
antimicrobial activity while dramatically decreasing hemolytic activity. 
  
Chapter 3 – Therapeutical enhancement of TP1 
 
 3-55 
Table 3-3 - Biological activity and 
activity/toxicity indices of tachyplesin-1 and its 
analogs 
Peptide MM
a 
(μg/mL) 
MHCb 
(μg/mL) ATI
c 
1 0.125 0.25 2.0 
2 0.125 2.1 16.8 
3 0.4 8 20.0 
4 16 8 0.5 
5 0.5 40 80.0 
6 0.125 2 16.0 
7 0.25 1.2 4.8 
8 0.5 1 2.0 
9 0.25 8 32.0 
10 0.125 2 16.0 
11 0.125 0.5 4.0 
12 0.25 32 128.0 
13 1.5 0.6 0.4 
14 0.25 1 4.0 
15 0.163 0.5 3.1 
16 0.25 0.45 1.8 
17 0.5 3 6.0 
18 0.125 0.45 3.6 
19 0.75 40 53.3 
20 0.375 8 21.3 
21 8 0.24 0.0 
22 16 11 0.7 
23 0.163 1 6.2 
24 1 0.47 0.5 
25 2 0.23 0.1 
26 3 0.4 0.1 
27 0.5 0.2 0.4 
28 16 0.9 0.1 
29 16 0.3 0.0 
30 6.4 32 5.0 
31 0.75 0.4 0.5 
32 0.5 0.2 0.4 
33 0.375 0.2 0.5 
aThe median of the peptide Minimum Inhibitory 
Concentrations (MICs) against all bacteria and 
fungi tested (MM). 
bThe MHC was determined as the minimum 
hemolytic concentration that caused ≤10% 
hemolysis of fresh red blood cells.  
cThe activity/toxicity index (ATI) is the ratio of 
the MHC to the MM. Larger values indicate a 
greater selectivity of the peptides for microbe 
cells.  
 
The Ala scan peptides that showed an improved ATI, 5 (TP1[F4A]), 9 (TP1[Y8A]) and 12 
(TP1[I11A)], were subsequently substituted with Gly instead of Ala, to see if further reduction in side 
chain hydrophobicity was beneficial.  The F4G substitution 24 had similar antimicrobial activity to 
F4A 5 but almost 100-fold increase in hemolytic activity. Similarly, while Tyr8 and Ile11 substituted 
by Ala (9 and 12) retained 1’s antimicrobial activity and reduced its hemolytic activity; the analogs 
with Gly (26 and 27) had reduced antimicrobial activity while retaining similar levels of hemolytic 
activity. In a study by Panteleev et al19, Tyr8 and Ile11 of 1 were substituted by Arg or Ser, in both 
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cases dramatically reducing the hemolytic activity without detriment to the antimicrobial activity, 
hence making the compounds very promising for development as antibiotic candidates. In our study, 
the replacement of the Tyr8 or Ile11 by a less hydrophobic amino acid was also shown to be highly 
beneficial for the cell selectivity of the peptide. However a fine balance needs to be found, as if the 
amino acid composition of the peptide becomes too hydrophilic the toxicity increases significantly. 
This may be influenced by the overall conformation of the peptide as well as the specific conformation 
of the peptide turn. Residues Tyr8 and Ile11 both form part of the β-turn and the replacement of either 
residue to a Gly would change the type of structural turn.   
The beneficial mutations seen in analogs 5, 9 and 12 were then combined to see if the effects were 
additive. Unfortunately, none of 28, 30, 31, 32 and 33 showed the desired improvements; while they 
kept relatively potent antimicrobial activity (except for 28 and 30), they also concomitantly retained 
high hemolytic activity (except for 30).  
Another method to increase the activity/toxicity index of 1 was reported by Saravanan et al,12 who 
deleted the four Cys residues of 1 without replacement (peptide named CDT). In this case, the β-
hairpin structure was less rigid but conserved in solution and in the presence of LPS, due to hydrogen 
bonding and packing interactions across the sheets, allowing the peptide to maintain potent 
antimicrobial activity while reducing its hemolytic activity. Wood et al,20 studied the SAR of CDT, 
finding that two analogs [des-Arg12,13] CDT and [Ile2,3,6,10] CDT increased the selectivity index.  
 
Peptide membrane binding followed by Surface Plasmon Resonance. To investigate the cell 
selectivity, we determined the peptide membrane binding affinity of select peptides by SPR. We 
selected two model membranes, one mimicking the outer leaflet of the G-ve bacteria E. coli (taken 
as representative of the AMP antimicrobial activity) and the other one mimicking the outer leaflet of 
the human red blood cell (taken as representative of the AMP hemolytic activity). Bacterial 
membranes are more negatively charged than mammalian cells due to their lipid composition. 
Moreover, the cell composition of the outer leaflet of bacterial membranes differs between classes. 
E. coli is predominantly composed of palmitoyloleoyl-phosphatidylethanolamine (POPE), 
palmitoyloleoyl-phosphatidylglycerol (POPG) and cardiolipin, and was therefore modelled as 
POPE/POPG/cardiolipin (15:4:1) in our study.21 In contrast, about half of the mass of the RBC 
membrane is comprised of protein and the other half is lipids, predominantly phospholipids with the 
addition of cholesterol.22 Palmitoyloleoyl-phosphatidylcholine (POPC), a zwitterionic phospholipid 
forming a fluid bilayer at room temperature, is the major component of eukaryotic cells. However, 
cholesterol also plays a key role in the membrane composition of RBCs. Therefore, POPC/cholesterol 
Chapter 3 – Therapeutical enhancement of TP1 
 
 3-57 
(4:1) was used here as a simplistic model to reflect the charge and fluidity of the outer leaflet of RBCs. 
Matsuzaki et al.23 stated that hemolytic peptides exhibited strong interactions with zwitterionic 
phospholipids, whereas non-hemolytic peptides did not. We thus investigated the relative membrane 
binding affinities of the three peptides possessing the highest ATI values (5, 12 and 19), as well as 
less active 1 and 27, to assess this hypothesis.  In our study (Figure 3-1), all five peptides exhibited a 
stronger interaction to POPE/POPG/cardiolipin, modelling the outer leaflet of E. coli, as opposed to 
POPC/cholesterol, modelling the outer leaflet of RBCs. The cell selectivity was relatively similar 
amongst the five peptides. These data do not correlate with the findings of Matsuzaki et al.23 and did 
not correspond with our observed antimicrobial and hemolytic activity and hemolytic activity testing, 
which showed that all five peptides had similar antimicrobial potency but differed by their hemolytic 
activity. 1 and 27 exhibited high hemolytic activity compared to the other three peptides. We would 
therefore have expected to see an increase in binding affinity to RBC with 1 and 27. This lack of 
correlation between the model membrane binding affinities and the biological data could be due to 
several hypotheses (i) our RBC model is too simplistic and does not reflect the full complexity of 
what occurs in vitro with live cells, as the RBC membrane is a very complex ensemble of two 
asymmetric layers,24,25 composed mainly of phosphatidylcholine (PC), sphingomyelin (SM) and 
cholesterol, or (ii) the affinity for the peptide to bind to the membrane is only the first step in the 
mode of action for activity. It is likely that the peptide not only needs to bind to the membrane but 
must also act to disrupt the cell to exhibit activity and cause cell death. This is in accordance with the 
findings of Imura et al,26 suggesting a lipid flip-flop with toroidal pore formation mechanism of 
action.  
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Figure 3-2 - Membrane binding affinity of tachyplesin-1 and its analogs as monitored by surface plasmon 
resonance. The response to the total amount of lipid deposited on the chip surface was normalized by calculating the 
peptide-to-lipid ratio (P/L mol/mol) (1RU = 1 pg.mm-2). Sensorgrams obtained upon injection of 64 μg/mL of peptide 
over (A) POPC/Cholesterol (4:1) [RBC] or (B) POPE/POPG/cardiolipin (15:4:1) [E. coli] bilayers. (C) Comparison of 
the P/L obtained for the five peptides at the reported point at the end of the association phase over both model bilayers. 
Error bars represent standard error of the mean of three replicates. 
 
Plasma stability. Plasma stability is an important parameter for potential peptidic drug candidates. 
Compounds with certain functional groups are more susceptible to hydrolysis by plasma enzymes 
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than others. These include esters, amides, lactones, lactams, carbamides, sulfonamides and peptide 
mimetics. The plasma stability assay is designed to focus on these classes of compounds. To evaluate 
the stability of the three peptides possessing the highest ATI values (5, 12 and 19), we performed a 
plasma stability assay against mouse and human plasma over 2 hours. The percentage of peptide 
remaining in plasma was followed by LC-MS, as shown in Figure 3-3. Interestingly, 1, 5 and 12 
remained fully stable in both mouse and human plasma, however, 19 was rapidly degraded to leave 
only 13% or 52% after two hours, in mouse and human plasma, respectively. Loss of the disulfide 
bridge in 19 TP1[C3A,C16A] improved the activity/toxicity relationship but made 19 
TP1[C3A,C16A], more susceptible to hydrolysis in the plasma environment.  
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Figure 3-3 – Plasma stability of tachyplesin-1 and its analogs as monitored by LC-MS. Stability of 1 TP1(black), 5 
TP1[F4A] (red), 12 TP1[I11A] (blue) and 19 TP1[C3A,C16A] (green) in mouse (dotted line) and human (full line) plasma 
over 120 min. Points represent the average of two replicates.   
 
 
Structural characterization. To better understand the observed variation of peptide stability in 
plasma, the structural characterization of the four peptides was investigated. NMR spectroscopy was 
used to confirm the folding of the TP1 analogs and to compare their structures. The NMR assignment 
of 1 was comparable to the chemical shift assignment reported previously, BMRB 5486.27 A 
comparison of the Hα chemical shifts of the four TP1 analogs (Figure 3-4A) illustrates that the 
structures are conserved for 1, 5 and 12. However, 19 shows very different Hα chemical shifts as 
compared to the other three analogs, demonstrating that its secondary structure is not conserved. In 
Figure 3-4B, secondary chemical shifts were calculated by comparing the experimentally observed 
Hα chemical shifts (HA) for each residue with the chemical shifts observed for the corresponding 
residues in random coil (RC) peptides28, to compare 1 and its analogs in relation to sheet formation. 
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1, 5 and 12 show a similar pattern, with defined β-hairpin structure as compared to 19, where the β-
hairpin motif is lost due to the reduction of the length of the first β-sheet region, from Trp2-Cys7 to 
Arg5-Cys7. It is logical to attribute this to the loss of the disulfide bridge Cys3-Cys16, rendering the 
N- and C-terminal more flexible and reducing the size of the N-terminal β-sheet, changing the overall 
β-hairpin secondary structure motif.  
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Figure 3-4 – TP1 and analogs chemical shifts. (A) Hα chemical shifts and (B) Hα secondary chemical shifts of TP1 1 
(black) and analogs 5 (red), 12 (blue) and 19 (green). Secondary chemical shifts were calculated by comparing the 
experimentally observed Hα chemical shifts (HA) for each residue with the chemical shifts observed for the corresponding 
residues in random coil (RC) peptides.28 The sequence mutations are annotated. 
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3.4 Materials and methods 
Materials. Tachyplesin-1 and tachyplesin-1 analogs were synthesized by Mimotopes Pty Ltd 
(Clayton, Australia) and WuXi AppTech (Shanghai, China) using Fmoc-based solid phase peptide 
synthesis and orthogonal Cys protection (Fmoc Cys(Acm)-OH for Cys3, Cys16, and Fmoc Cys(Trt)-
OH for Cys7, Cys12); the first disulfide bridge was formed by air oxidation following cleavage from 
the resin, with iodine treatment generating the fully cyclized peptide that was purified by RP-HPLC 
to > 90% purity. Identity and purity were confirmed by LC-MS, HRMS and 1H and 2D TOCSY 
NMR (Figures S7.3-1 to S7.3-103). Proton chemical shifts of 1 (TP1) were comparable of previously 
reported tachyplesin-1 (PDB ID 1ma2 and BMRB 5486) and taken as reference for the identity 
confirmation of 1 analogs.27  Synthetic lipids palmitoyloleoyl-phosphatidylcholine (POPC), 
palmitoyloleoyl-phosphatidylglycerol (POPG), palmitoyloleoyl-phosphatidylethanolamine (POPE) 
and cardiolipin were purchased from Avanti Polar Lipids (Alabaster, AL). All chemicals were used 
without further purification. The tachyplesin analogs used in this study do not contain any structures 
with potential PAINS (Pan Assay Interference Compounds) liabilities. 
Antimicrobial activity. Both antibacterial and antifungal assays were performed by a broth micro-
dilution plate based method as per CLSI guidelines for antimicrobial susceptibility testing.29, 30 The 
assay was performed in Mueller Hinton Broth (MHB, Bacto laboratories, 211443) for antibacterial 
testing and Yeast Extract-Peptone Dextrose (YPD, Sigma-Aldrich, Y1500) for antifungal testing, and 
the Minimum Inhibitory Concentration (MIC) was determined as the lowest concentration of 
compound that prevented all visible microorganism growth after 18-24 h. Compounds were prepared 
at 0.64 mg/mL solution in water:DMSO (4:1). 
For antimicrobial assays, the tested strains, Table S7.3-1, were cultured either in Luria broth (LB) (In 
Vitro Technologies, USB75852), Nutrient Broth (NB) (Becton Dickson, 234000) or MHB at 37 °C 
overnight. A sample of culture was then diluted 40-fold in fresh MHB and incubated at 37 °C for 1.5-
2 h. The compounds were serially diluted two-fold across the wells of 96-well plates (Corning 3641, 
Non-binding Surface [NBS]), with compound concentrations ranging from 0.015 μg/mL to 64 μg/mL, 
plated in duplicate. The resultant mid-log phase cultures were diluted to the final concentration of 
1×106 CFU/mL, then 50 µL was added to each well of the compound-containing plates giving a final 
compound concentration range of 0.008 μg/mL to 32 μg/mL and a cell density of 5x105 CFU/mL. All 
plates were then covered and incubated at 37 °C for 18 h. Resazurin was added at 0.001% final 
concentration to each well and incubated for 2 h before MICs were read by eye. Resazurin was added 
to assist MIC determination as small spindle tissue or precipitate was present in otherwise clear wells. 
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For the antifungal assay, fungi strains, Table S7.3-1, were cultured for 3 days on YPD agar at 30 °C. 
A yeast suspension of 1x106 to 5x106 CFU/mL was prepared from five colonies. These stock 
suspensions were diluted with Yeast Nitrogen Base (YNB) (Becton Dickinson, 233520) broth to a 
final concentration of 2.5×103 CFU/mL. The compounds were serially diluted two-fold across the 
wells of 96-well plates (Corning 3641, Non-binding Surface [NBS]), with compound concentrations 
ranging from 0.015 μg/mL to 64 μg/mL and final volumes of 50 μL, plated in duplicate. Then, 50 μL 
of the fungi suspension that was previously prepared in YNB broth to the final concentration of 
2.5×103 CFU/mL, was added to each well of the compound-containing plates, giving a final 
compound concentration range of 0.008 μg/mL to 32 μg/mL. Plates were covered and incubated at 
35 °C for 24 h. C. albicans MICs were determined by measuring the absorbance at OD530. For C. 
neoformans resazurin was added at 0.006% final concentration to each well and incubated for a 
further 3 h before MICs were determined by measuring the absorbance at OD570-600. 
Hemolytic assay. The ability of the peptides to hemolyze human red blood cells was determined by 
a previously reported method.31 Human red blood cells were separated from serum and washed in 
phosphate-buffered saline (PBS, pH 7.4) with 4–5 times centrifugation at 4000 rpm. Erythrocytes 
were then resuspended in phosphate-buffered saline as a 0.25% (v/v) solution. Stock solutions (300 
μM) of compounds were prepared. Two-fold serial dilutions were prepared yielding eight solutions 
in total, which were aliquoted (20 μL) into a 96-well plate (NUNC 96 wells polypropylene plates 
round bottom, Sigma Aldrich P6866). The erythrocyte solution (100 μL) was dispensed into each 
well and incubated with diluted peptide solution at 37 °C for 1 h. Triton X-100 solution (1%, v/v, 20 
μL) was used as a positive control to represent 100% cell lysis, and PBS solution (20 μL) was used 
as a negative control (spontaneous lysis after 1 h incubation). The 96-well plate was centrifuged to 
pellet intact red blood cells, and the supernatant of each well was collected in a fresh plate (NUNC 
96 wells polypropylene plates flat bottom, Sigma Aldrich P7366) and measured by visual absorption 
spectroscopy at 415 nm. The percentage of hemolysis was calculated according to the following 
equation: 
𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻 (%) = � 𝑂𝑂𝑂𝑂415(𝐻𝐻𝑠𝑠𝐻𝐻𝑠𝑠𝐻𝐻𝐻𝐻) − 𝑂𝑂𝑂𝑂415(𝑧𝑧𝐻𝐻𝑧𝑧𝐻𝐻 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻)
𝑂𝑂𝑂𝑂415(100% 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻) − 𝑂𝑂𝑂𝑂415(𝑧𝑧𝐻𝐻𝑧𝑧𝐻𝐻 𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻𝐻)� 𝑥𝑥100% 
All peptide solutions were assayed in triplicate. 
Cytotoxicity. Cytotoxicity to HEK293 cells was determined using the resazurin assay.32,33 In brief, 
HEK293 cells were seeded as 4000 cells/well in black-wall, clear-bottom 384-well plates (Corning, 
Australia) and incubated for 24 h at 37 °C, 5% CO2. Compounds were then added into each well. 
After 24 h incubation, 5 µM resazurin was added per well and incubated at 37 °C for 2 h. Fluorescence 
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intensity was then read using a Polarstar Omega with excitation/emission 560/590. The data were 
then analyzed using GraphPad Prism 6 software. CC50 values were calculated using the following 
equation: Percentage Viability = (FITEST – FINegative/FIUNTREATED –FINegative)*100. 
Surface Plasmon Resonance. The binding affinity of 1 and its analogs for model membranes 
composed of POPC/Cholesterol (4:1) and POPE/POPG/cardiolipin (15:4:1) were compared using 
SPR. Solutions were freshly prepared and filtered (0.22 µM pore size). L1 sensor chip and BIAcore 
3000 system (Biacore, GE Healthcare) were used. Small unilamellar vesicles (diameter, 50 nm) were 
prepared by freeze-thaw fracturing and sized by extrusion. Vesicle suspensions were deposited on an 
L1 chip over 40 min at a flow rate of 2 µL/min to allow the vesicles to bind, fuse and form a stable 
lipid bilayer. The association of the peptide sample to the lipid bilayer was evaluated by injection for 
240 s at flow rate of 5 µL/min and the dissociation was followed for 600 s at the same flow rate. The 
L1 chip was regenerated after each injection cycle, by injection of 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) (5 µL/min, 60 s), followed by an 
injection of 10 mM sodium hydroxide in 20 % methanol (w/w) (50 µL/min, 60 s) and to finish an 
injection of 10 mM sodium hydroxide (50 µL/min, 36 s) buffer. All measurements were conducted 
at 25 °C. 10 mM HEPES buffer pH7.4 containing 150 mM NaCl (to mimic the physiological 
conditions) was used as running buffer and to prepare samples and lipid vesicles.34,35 The peptide 
samples were prepared at 7 different concentrations, starting from 64 to 1 µg/mL following 2-fold 
dilution steps. The lipid deposited onto the chip surface is dependent on the lipid mixture, therefore, 
the response units were converted into peptide to lipid ratio (mol/mol).  
Plasma stability. Test compound (final concentration 2 μM) was combined with pre-warmed CD-1 
mouse or human plasma at 37 °C (100 μL volume). At each time point (t = 0, 15, 30, 60 and 120 
min), 100 μL of 4% H3PO4/H2O was added and the reaction was quenched with 600 μL of cold stop 
solution (200 ng/mL tolbutamide plus 20 ng/mL buspirone in 50% ACN/MeOH). Upon 
centrifugation at 4,000 g for 10 min, the clear supernatants (100 μL) were transferred to a 96-well 
plate and mixed with 100 μL of ultra-pure water. The samples were shaken at 800 rpm for 10 min 
before being analysed by LC-MS-MS. The percentage of remaining parent compound at each time 
interval relative to the t = 0 min sample is calculated from peak area ratios in relation to the internal 
standard. All samples were run in duplicate with propantheline bromide as a positive control and 
tolbutamide as internal standard. 
NMR characterization. 1H and 2D TOCSY NMR were acquired on a Bruker Avance III 
spectrometer equipped with a cryogenically cooled triple resonance probed operating system at a 
normal 1H frequency of 600 MHz at 298 K. Water suppression was performed via excitation 
sculpting. Secondary chemical shifts were calculated by comparing the experimentally observed Hα 
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chemical shifts (HA) for each residue with the chemical shifts observed for the corresponding 
residues in random coil (RC) peptides.28 The NMR assignment of 1 TP1 was compared to the 
chemical shifts reported previously, BMRB 5486.27   
 
3.5 Conclusion 
This work presents a structure-function relationship study of tachyplesin-1 by a systematic amino 
acid replacement strategy with characterization of the resultant antimicrobial, cytotoxicity and 
hemolytic activity. We identified three modified peptides: 5 (TP1[F4A]), 12 (TP1[I11A]) and 19 
(TP1[C3A,C16A]), that possessed substantially improved therapeutic indexes (26- to 64-fold) over 
the progenitor. With high potency against broad-spectrum microbes and considerably less hemolytic 
toxicity, these compounds may be considered as promising hit compounds for further development 
towards new treatments for infections caused by Gram-negative and Gram-positive bacterial 
pathogens, as well as potential fungal infections. Structural studies and preliminary ADME testing 
support further investigations of two of the three promising novel antimicrobial peptides, as 5 and 12 
not only conserve the β-hairpin secondary structure motif but are highly stable in mouse and human 
plasma. Additional studies examining bioavailability, pharmacokinetics, toxicity, mutagenicity and 
in vivo efficacy of 5 and 12 are required to further validate these interesting novel antibiotics. 
 
3.6 Ancillary information 
Supporting Information. Bacterial strain descriptions and QC data of each compound by HRMS, LC–MS 
and, 1H and 2D NMR. This information is available free of charge via the Internet at http://pubs.acs.org/. 
Abbreviations Used: TP1, tachyplesin-1; ADME, Adsorption Distribution Metabolism Elimination; AMP, 
Antimicrobial peptide; GRAVY, grand average of hydropathicity index; MIC, Minimum inhibitory 
concentration; MM, Median of the peptide MICs against all bacteria and fungi tested; MHC, Minimum 
hemolytic concentration; ATI, activity/toxicity index; ATCC, American Type Culture Collection; G-ve, 
Gram-negative; G+ve, Gram-positive; HEK293, human embryonic kidney 293; RBC, Red Blood Cell; RC, 
Random Coil. 
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Chapter 4    - The antimicrobial 
activity of AA139 reveals dual 
mode of action 
 
4.1 Introduction 
The overuse and misuse of antibiotics over decades has led to a dramatic increase in the rate of 
bacterial resistance to current antibiotics. We have, in the last few years, reached a worldwide state 
of emergency, where simple infections can cause death. The World Health Organization launched a 
multi-year campaign with the theme “Antibiotics: Handle with care” in November 2015 to tackle the 
concern of antibiotic resistance. The discovery of new drugs is thus vital for the replacement of 
obsolete antibiotics.1  
Antimicrobial peptides (AMPs) are ubiquitous in nature, being part of the innate immune defense 
system of microorganisms, plants and animals. AMPs are generally small, cationic and amphipathic, 
ideally adapted for the protection of their host against pathogenic microorganisms. To date over 2,000 
AMPs have been reported from eukaryotes (http://aps.unmc.edu/AP/main.php), however their broad 
range antimicrobial activity is not enough for entry into the clinical pipeline as they often also exhibit 
mammalian cell toxicity.2  
Arenicin peptides, originated from a lugworm, Arenicola marina, were discovered about a decade 
ago by Ovchinnikova et al3. Arenicin-1 and arenicin-2, both β-hairpin AMPs with one disulfide bond 
have been the focus of attention of many researches.4,5 The antimicrobial mode of action of arenicin-
1 and -2 is considered to involve binding to and permeabilization of the bacterial membrane.6 More 
recently, Adenium Biotech Ltd discovered a third member of the arenicin family, arenicin-3 
(GFCWYVCVYRNGVRVCYRRCN), a 21 amino acid β-hairpin AMP constrained by two disulfide 
bonds.7 Arenicin-3 was found to be very potent against a broad range of microbial pathogens however 
the drawback for further clinical study was its toxicity towards mammalian cells.2 AA139, an 
arenicin-3 analog (GFCWYVCARRNGARVCYRRCN) retains broad range antimicrobial activity 
and concomitantly displays reduced mammalian cell toxicity, rendering it the current lead candidate 
under advanced preclinical development by Adenium Biotech Ltd.   
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This study focuses on the comparison between arenicin-3 and its synthetic analog, AA139, 
investigating their mode of action and aiming to understand how simple amino acid mutations 
reformed arenicin-3 into a suitable candidate for clinical development. To do so, we divided our 
investigation into three parts. First, we characterized both arenicin peptides, evaluating their 
physicochemical properties and elucidating their 3D solution structures in solution using NMR. We 
then focused on their mode of action using lipid bilayer model membranes, investigating their 
membrane binding affinity, their ability to cause vesicle leakage and aggregation and their secondary 
structure modification using circular dichroism spectroscopy. We then evaluated the potential of 
arenicin peptides to permeabilize the cytoplasmic membrane upon interaction with E. coli 
ATCC25922 cells using fluorescence emission assay followed by FACS cytometry. 
 
4.2 Results and discussion  
Physicochemical parameters. Arenicin peptides are β-hairpin AMPs, cationic and amphipathic, 
allowing them to interact with the cell membrane. Their hydrophobic side is formed by the residue 
predominantly situated toward the N-terminal part of the molecule and the lipophilic side toward the 
C-terminal end. The AA139 mutations of two valine residues to less hydrophobic alanine, and 
tyrosine to less hydrophobic arginine lowers the overall hydrophobicity of AA139 as compared to 
arenicin-3. Moreover, the charge of the entire molecule has been increased by one positive charge 
from the additional Arginine (Arg9) in AA139. Thus the combination of the increase in the overall 
charge and decrease of hydrophobicity leads to an increase in the amphipathic moment of AA139 
(Table 4-1).2 
 
Table 4-1 – Sequence, molecular weight (MW), number of charges, mean hydrophobicity and amphipathic 
moment of arenicin-3 and AA139 based on the normalized consensus scale value of Eisenberg_M. 
Peptide Sequence MW (g/mol) Charge Hydrophobicity 
Amphipathic 
moment 
arenicin-3 GFCWYVCVYRNGVRVCYRRCN 2611.1 +4 -0.11 +0.44 
AA139 GFCWYVCARRNGARVCYRRCN 2548.1 +5 -0.28 -0.10 
 
Mapping of the electrostatic and molecular hydrophobicity surface of arenicin-3 and AA139 
produced representations that did not show distinct faces, with charges and hydrophobic residues 
being evenly distributed along the peptide backbone. Therefore, these results are not shown. 
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The antimicrobial activity of AA139 has high selectivity for bacterial cells. The arenicin peptides 
were tested for their antimicrobial activity against G-ve and G+ve bacteria, Table 4-2. Across all 
pathogenic strains tested, AA139 displayed a 2- to 4-fold increase in antimicrobial activity as 
compared to arenicin-3. The toxicity of arenicin peptides against HEK293 cells and their hemolytic 
activity were also tested, Table 4-2. The hemolytic activity, shown as HC20, reflects the concentration 
to induce 20% hemolysis. AA139 required 15-fold higher concentration to induce 20% hemolysis 
than arenicin-3. The cytotoxicity was assessed against HEK293 (kidney) cells at 1% serum 
concentration. Arenicin-3 displayed at least 3-fold more toxicity than AA139. These results highlight 
the increased therapeutic potential for AA139 as compared to arenicin-3 due to its improved 
antimicrobial activity and concomitantly reduced mammalian cell interactions.  
Table 4-2 - Antimicrobial activity and toxicity of arenicin peptides. 
Peptide 
MIC (μg/mL)a HC20 
(μg/mL) 
 
RBC 
CC50 
(μg/mL) 
 
HEK293 
E. coli 
ATCC 
25922 
K. 
pneumoniae 
ATCC 
13883 
A. 
baumannii 
ATCC 
19606 
P. 
aeruginosa 
ATCC 
27853 
B. 
subtilis 
ATCC 
6051 
S. aureus 
ATCC 
43300 
arenicin-3 0.5 1 0.5 1 8 >32 1.2 ± 1 104.6 ± 1.8 
AA139 0.125 0.25 0.125 0.5 4 16 18.8 ± 1.5 >300 
a. Assay performed as n = 4.  
 
NMR. We determined the NMR solution structures of arenicin-3 and AA139, PDB 5V0Y - BMRB 
30259 and PDB 5V11 – BMRB 30260, respectively (Figure 4-1 and Table 4-3). Chemical shifts of 
the protons in both arenicin peptides were measured from 2D 1H–1H TOCSY and NOESY NMR 
spectra. Secondary Hα shifts (Figure 4-2) are reported as the difference between the observed 
chemical shift of each α-proton and its respective random coil shift, this provides information about 
the secondary structure of the peptide.8 Residues with secondary Hα shifts larger than ± 0.1 ppm are 
generally considered to correspond to structured regions of a peptide, with positive Hα shifts 
indicating β-sheet secondary structure and negative Hα shifts indicating turns or helices. As shown 
by the secondary Hα shifts in Figure 4-2, arenicin peptides are composed of two β-strands and a turn 
forming a β-hairpin structure. A summary of the NMR data obtained for arenicin-3 and AA139 in 
aqueous solution is shown in Figure S4-5 and Figure S4-6, respectively. The peptide structures are 
stabilized by two disulfide bridges Cys3-Cys20 and Cys7-Cys16. The two β-strands cover residues 
Cys3-Arg10 and Arg13-Cys20. The β-strands are intervened by a type I’ β-turn (Asn11/Gly12) forming 
slightly twisted anti-parallel β-strands in the β-hairpin structure. The distortion created by the right-
handed twist of the two-stranded β-sheet offers the possibility for the molecule to create an 
amphipathic environment where the hydrophobic side of the β-sheet is shielded from contact with the 
polar solvent. 
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Figure 4-1 – 3-Dimensional NMR solution structures of (A) arenicin-3 (green) and (B) AA139 (cyan). Structures are 
displayed in cartoon form showing the classic ß-hairpin assembly created by anti-parallel ß-sheets and two stabilizing 
disulfide bonds (yellow) across the sheets, key residues labelled for orientation and the N- and C-terminus. Images created 
using PyMol.  
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Figure 4-2 - Secondary Hα shifts (variation from random coil) for (A) arenicin-3 and (B) AA139.  
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Table 4-3 - Statistical analysis of the NMR structures of arenicin-3 and AA1391. All statistics are given as mean ± 
S.D. a. Only structurally relevant restraints, as defined by CYANA, are included. b. Only hydrogen-deuterium exchange 
were used to define the H-bond restraints. c. As reported by Molprobity (http://molprobity.biochem.duke.edu). d. Defined 
as number of steric overlaps >0.4 Å per thousand atoms. 
  arenicin-3 AA139 
Experimental restraintsa   
 Interproton distance restraints   
 Intraresidue 102 66 
 Sequential 125 114 
 Medium range (i–j < 5) 46 45 
 Long range (i–j > 53) 108 108 
 Dihedral-angle restraints (f, y, c1) 65 65 
 Number of H-bondb 7 4 
 Total number of restraints per residue 21.6 19.1 
R.m.s. deviation from mean coordinate structure (Å)   
 Backbone atoms (residues 1–21) 0.11 0.18 
 All heavy atoms (residues 1-21) 0.61 0.57 
Stereochemical qualityc   
 Residues in most favoured Ramachandran region (%) 100.0 ± 0.0 100.0 ± 0.0 
 Ramachandran outliers (%) 0 ± 0 0 ± 0 
 Unfavourable sidechain rotamers (%) 1.3 ± 2.4 16.2 ± 2.6 
 Clashscore, all atomsd 3.06 ± 0.6 0 ± 0 
 Overall MolProbity score 1.23 ± 0.24  (98th percentile) 
1.41 ± 0.06  
(96th percentile) 
 
The 3D solution structure supplemented by the H-bond experiments, hydrogen-deuterium exchange 
(Table S4-2) and amide temperature coefficient (Table S4-3), suggests AA139 to be a more flexible 
structure than arenicin-3, Figure 4-1.  
Despite the higher structural order of arenicin-3 compared to AA139, the activity and toxicity data 
demonstrate that AA139 is the better candidate for drug development. This data would suggest that 
the increased flexibility of AA139 may play a role in the improved bacterial toxicity and reduced 
mammalian cytotoxicity observed. A possible mechanism would be that the flexibility of AA139 
allows it to more easily rearrange its structure into an active conformation upon interaction with the 
bacterial cell membrane.   
 
Arenicin peptides bind to lipid model membranes. The membrane binding affinity of arenicin 
peptides was followed by SPR using model membranes deposited onto an L1 Chip (Figure 4-3). To 
mimic the anionic surface of bacterial cell membranes, negatively charged systems (POPC/POPG 
(1:1 molar ratio) or POPC/POPG (4:1)) were used, and to mimic the neutral surface of mammalian 
cell membranes, bilayers composed of POPC were used. Membrane-binding studies show that both 
peptides, have a preference (about 2- to 3-fold) for negatively-charged model membranes 
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(POPC/POPG), compared to zwitterionic membranes (POPC). This is consistent with the basic nature 
of these peptides. 
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Figure 4-3 - Arenicin-3 and AA139, 25 μM (~64 μg/mL), membrane binding affinity followed by SPR using model 
membranes composed of POPC/POPG (1:1) (green bar), POPC/POPG (4:1) (red) or POPC (blue). The error bars 
represent the standard deviation of triplicates. * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤0.0001. 
 
Both peptides are able to bind to different lipid vesicle compositions, with lower affinity towards the 
neutral POPC bilayers, compared to the negatively-charged membranes.  
 
Arenicin peptides permeabilize negatively charged lipid model membranes.  
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Figure 4-4 - Leakage from POPC and POPC/POPG (1:1) vesicles (lipid concentration at 5 µM) induced by 
arenicin-3 (black dots) and AA139 (grey squares). 0.1% Triton-X100 was used to establish 100% of leakage and buffer 
was used as blank to establish 0% leakage.   
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LUVs (POPC and POPC/POPG (1:1)) (diameter, 100 nm) loaded with carboxyfluorescein (CF) were 
incubated with a series of 2-fold dilution concentration of arenicin peptides. The vesicle leakage 
assay9 evaluated the content leakage from LUVs by CF fluorescence emission quenching induced by 
arenicin-3 and AA139, Figure 4-4. The results showed that both peptides did not induce leakage of 
POPC vesicles, over the concentration range tested. However, arenicin peptides induced leakage of 
POPC/POPG (1:1) vesicles. The maximum leakage was 48% and 35% for arenicin-3 and AA139, 
respectively, at 100 μg/mL (peptide/lipid ratio 2:1). This suggests that arenicin peptides were able to 
partly permeabilize the POPC/POPG (1:1) vesicles. The partial leakage induction could be explained 
by the electrostatic attraction of the cationic peptides to the negatively charged lipid bilayer 
membranes and therefore suggest that membrane permeabilization is not the only mode of action 
causing bacterial cell death. This type of weak leakage induced behaviour has previously been shown 
for Sub3, a cationic AMP, whose mode of action involved permeabilization of the outer membrane 
and internalisation without permeabilization of the inner cytoplasmic membrane.10  
 
Arenicin peptides aggregate negatively charged lipid model membranes. 
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Figure 4-5 - Vesicle aggregation studies. OD436 nm was monitored after addition of 25 μM (~ 64 μg/mL) of arenicin-
3 or AA139 to 500 μM of LUVs prepared in 10 mM HEPES pH 7.4, containing 150 mM NaCl. The OD values were 
normalized for the baseline. 
 
The ability of arenicin peptides to interact with lipid vesicles was further investigated by following 
vesicle aggregation. Vesicle integrity is generally kept by inter-vesicle forces such as electrostatics 
and hydration forces. The addition of a cationic peptide to the negatively charged vesicle environment 
could cancel repulsive electrostatic forces of negatively charged vesicles and induce dehydration of 
the lipid polar groups leading to aggregation of the vesicles.11,12 A solution becoming turbid, reflects 
aggregation has occurred and leads to an increase in OD436 absorbance measurement. In our study, 
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Figure 4-5, arenicin-3 and AA139 do not induce aggregation of vesicles composed of POPC only. 
However, they are able to induce aggregation of negatively charged vesicles POPC/POPG (4:1) and 
(1:1). Arenicin-3 induces more aggregation than AA139 and at a faster rate. These results support our 
SPR binding and leakage assay findings where arenicin peptides do not bind to or permeabilize the 
membrane of POPC vesicles but do bind and partially permeabilize the membrane of more negatively 
charged vesicles POPC/POPG. These results suggest that the antimicrobial mode of action of arenicin 
peptides might not necessarily be dependent on membrane permeabilization.  
 
Arenicin peptides alter their secondary structure upon interaction with lipid membranes. 
Circular dichroism spectroscopy is most commonly used to identify the presence of random coil and 
α-helix secondary structure, and to a lesser extent for determining β-sheet content. We have used this 
technique to interrogate information about changes in the overall 3D structure of the peptides when 
bound to lipid bilayers.13,14  The amide chromophore of the peptide bond dominates the CD spectra 
of the peptides below 250 nm. Their transitions n->π* and π0->π* give the signature of an α-helix or 
β-sheet structure. In the CD study, the lipid mixtures were prepared as LUVs rather than SUVs (as 
was used previously for SPR studies) due to the curvature effects present in SUVs.15 Arenicin peptide 
secondary structures were studied in the absence and presence of LUVs at physiological pH (7.4) as 
well as in 50% TFE, Figure 4-6. Arenicin-3 and AA139 demonstrate quite atypical CD signatures in 
solution containing one big positive band at 227 nm and two negative bands at 208 and 195 nm which 
is not what is expected for β-hairpin structural peptides. This atypical spectrum can be explained by 
the presence of the two disulfide bridges and the aromatic residues (Try or Trp) as well as the twist 
in the β-sheet which can affect the CD spectra in the far-UV region (190-250 nm).16 Both peptides, 
showed similar secondary structures in solution and in presence of POPC LUVs, further reflecting 
the weak binding of arenicin peptides with POPC vesicles. Similar secondary structure was observed 
in 50% TFE, which mimics the hydrophobic environment of microbial membranes. In the presence 
of POPG, both peptides demonstrated a change in molar ellipticity signature which could be due to 
two reasons; (i) a change in flexibility of the peptides upon interaction with the lipid model 
membranes and (ii) the peptides might have precipitated with the vesicles leading to being quenched 
from the solution which would explain the drop in the overall signal. Although retaining a molar 
ellipticity signature more typical of an antiparallel β-sheet, AA139 seems to undergo a more 
significant secondary structure modification. This suggests that the arenicin peptides might undergo 
a slight twist modification of their β-sheet or align to the lipid bilayer membrane in a particular 
orientation,17 but overall keep their β-hairpin structure.     
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Figure 4-6 - CD spectra of arenicin peptides in the absence or presence of lipid vesicles. CD spectra of 50 μM (~ 128 
μg/mL) of arenicin-3 (A) and AA139 (B) prepared in 10 mM PO4 pH 7.4, containing 150 mM NaF in absence or presence 
of LUVs at 500 μM (P/L molar ratio of 1/10).  
 
Arenicin peptides insert into lipid membranes. The fluorescence emission spectrum of tryptophan 
is influenced by the polarity of its local environment.18 Whilst, in a polar environment, the tryptophan 
fluorescence emission spectrum shifts toward longer wavelengths, in more hydrophobic 
environments, the tryptophan fluorescence shifts toward shorter wavelengths (blue shift). Arenicin-3 
and AA139 both possess only one Trp in their sequence located at the N-terminal region, in position 
4. Tryptophan fluorescence was monitored here to judge the polarity of its environment and thus 
determine the insertion of the Trp4 into lipid bilayer vesicles. In the absence of vesicles, the maximum 
of the fluorescence emission was 347 and 349 nm, for arenicin-3 and AA139, respectively. Upon 
titration with LUVs POPC/POPG (1:1), the fluorescence emission spectra showed a blue shift for 
both peptides, Figure 4-7 (A) and (B) and Table 4-4. At the saturation point of the LUVs 
concentration, the maximum wavelength of tryptophan fluorescence emission was 327 nm for both 
peptides. These remarkable blue shifts are representative of the tryptophan residue of arenicin 
peptides inserting into the hydrophobic environment of membranes composed of POPC/POPG (1:1). 
A comparative study of different LUV compositions was carried out to evaluate whether arenicin 
peptides have selectivity towards more negatively charged lipid bilayers. No change in the 
fluorescence emission was observed for both arenicin peptides, upon titration with POPC vesicles. 
However, when titrating with POPC/POPG (4:1) or POPC/POPG (1:1) vesicles, a typical blue shift 
in the Trp fluorescence emission spectrum was observed, with a concomitant increase in the 
fluorescence emission quantum yield, Figure 4-7 (C) and (D). This suggests that Trp4 of both arenicin 
A B 
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peptides inserts into the lipid bilayer of model membranes containing negatively-charged 
phospholipids in their composition.  
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Figure 4-7 – Partitioning of Trp residue of arenicin peptides into model membranes followed with 25 μM (~ 64 
μg/mL) of peptide in 10 mM HEPES, pH 7.4, containing 150 mM NaCl. (A) Arenicin-3 and (B) AA139 fluorescence 
emission spectra (λexcitation = 280 nm) upon titration with POPC/POPG (1:1) LUVs with pink trace highlighting the highest 
concentration of LUVs. (C) and (D) Fluorescence emission of arenicin-3 and AA139, respectively, normalised to [lipid] 
= 0 (I/Iw) upon titration with POPC (blue dots), POPC/POPG (4:1) (red squares) and POPC/POPG (1:1) (green triangles) 
LUVs. (E) Arenicin-3 and (F) AA139 emission fluorescence quenching by acrylamide in solution (black diamonds) or in 
presence of 2 mM LUVs POPC (blue dots) or POPC/POPG (1:1) (green triangles). 
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The affinity of a peptide for a lipid system can be assessed by the partition coefficient, Kp, ratio of 
the amount of peptide interacting with the membrane to the amount of peptide in solution. The 
partition coefficient was calculated as before19 and results are shown in Table 4-4. Arenicin-3 had the 
highest partition coefficient when interacting with POPC/POPG (1:1) (KP = (3.4 ± 1.7) x 104), about 
10-fold higher than with POPC/POPG (4:1) and about 4-fold higher than AA139 with POPC/POPG 
(1:1). None of the peptides had its Trp residue inserting into POPC vesicles under the conditions 
tested but the Trp partition increased with the increasing amount of POPG in the composition of the 
vesicles.     
Table 4-4 – Partition of arenicin-3 and AA139 into different lipid mixtures as followed by Trp fluorescence 
emission. The Kp and IL/IW parameters were obtained from fitting a non-linear equation. Emission fluorescence 
quenching of arenicin-3 and AA139 induced by acrylamide. 
Peptide Lipid mixture Kp (x103) Blue shift (nm)a IL/IW KSV, acrylamide (mM-1) 
arenicin-3 buffer - - - 7.0 ± 0.3 
 POPC - 0 - 2.8 ± 1.3 
 POPC/POPG (4:1) 3.73 ± 0.6 20 2.7 ± 0.8 - 
 POPC/POPG (1:1) 33.7 ± 17 20 2.5 ± 2.4 2.0 ± 0.3 
AA139 buffer - - - 10.1 ± 0.2 
 POPC - 0 - 8.3 ± 0.1 
 POPC/POPG (4:1) 0.19 ± 0.03 12.5 6.1 ± 1.5 - 
 POPC/POPG (1:1) 8.3 ± 3.3 22.5 3.2 ± 2.4 0.2 ± 0.5 
aFluorescence emission blue shift obtained upon addition of [lipid] = 2 mM.  
   
To assess the degree of solvent exposure of Trp4 of arenicin peptides, fluorescence quenching studies 
were carried out for arenicin-3, Figure 4-7 (E), and AA139, Figure 4-7 (F), in the presence and 
absence of POPC or POPC/POPG (1:1) LUVs using acrylamide, an aqueous fluorescence quencher 
unable to partition into lipid membranes. The peptides were excited at 290 nm to minimize the relative 
quencher/fluorophore light absorption ratio. The fluorescence emission intensity data were corrected 
for the simultaneous light absorption of fluorophore and quencher and analyzed using Stern-Volmer 
equation as before,20 Table 4-4. The Trp fluorescence quenching efficiency induced by acrylamide, 
as quantified with Ksv, calculated from the slope of the Stern-Volmer plots, Table 4-4, was high when 
both peptides were in buffer, 7.0 ± 0.3 (x103) and 10.1 ± 0.2 (x103) for arenicin-3 and AA139, 
respectively. This large quenching of the Trp fluorescence emission confirms exposure of Trp4 
residue to the aqueous solvent. However, in presence of LUVs, the quenching by acrylamide was less 
efficient. This lower quenching efficiency in the presence of vesicles suggested that the Trp4 residue 
in both arenicin peptides inserts into the hydrophobic core of the lipid bilayer and is thus less 
accessible to acrylamide. The insertion of the Trp4 residue in vesicles is different for the two arenicin 
peptides. For arenicin-3, the Trp seems to insert almost similarly in POPC or POPC/POPG (1:1) 
vesicles with only 1.4-fold reduction from POPC to POPC/POPG (1:1) type of vesicle. However, for 
AA139, the difference of Ksv between both types of vesicles is quite drastic going from 8.3 ± 0.1 
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(x103) to 0.2 ± 0.5 (x103), a 41.5-fold reduction. Overall, in presence of POPC/POPG (1:1) LUVs, 
the quenching was reduced by 3.5- to 50-fold for arenicin-3 and AA139, respectively, as compared 
to buffer alone. Taken together, these results show that the Trp4 residue of both arenicin peptides, and 
therefore the N-terminus of the peptides, can insert in the hydrophobic region of the phospholipid 
membrane and more so of the negatively charged ones. The AA139 N-terminus seems to insert even 
deeper than arenicin-3 does with a clear distinction between zwitterionic and negatively charged lipid 
bilayer vesicles.  
 
Surface charge of model membranes and E. coli cells induced by arenicin peptides. The surface 
charge of lipid vesicles or bacterial cells in aqueous solution can be measured by ζ- potential. 
Following zeta potential of vesicles or cells upon titration with arenicin peptides allows us to evaluate 
and determine changes in their surface charge density.21 
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Figure 4-8 – Surface charge of 200 μM POPC (blue dots), POPC/POPG (1:1) (green triangles) vesicles and E. coli 
ATCC 25922 (grey squares) in the presence of (A) arenicin-3 and (B) AA139 as followed by ζ-potential. Average ± 
SD of three replicates. 
 
Results in Figure 4-8, show that the surface charge of POPC vesicles does not change upon titration 
with both arenicin peptide (zeta potential values are constant and around neutralization point), 
suggesting that these two peptides do not interact with POPC vesicles. This correlates well with the 
low binding affinity or permeabilization shown for zwitterionic lipid bilayers. For POPC/POPG (1:1) 
LUVs, both arenicin peptides reduce the negative zeta potential of the LUVs. The initial value -29.1 
± 1.56 mV for POPC/POPG (1:1) LUVs steadily climb up to less negative values as the concentration 
of arenicin peptides increases. Arenicin-3 neutralizes the surface charge of POPC/POPG (1:1) LUVs 
at 100 μg/mL. AA139 does not neutralize the surface charge of POPC/POPG (1:1) LUVs as 
efficiently as arenicin-3 does, only reaching -16.7 ± 0.866 mV at 100 μg/mL. This is surprising, 
considering the overall charge of both peptides, +4 and +5 for arenicin-3 and AA139, respectively. 
A B
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We would have expected that the more positively charged the peptide is, the faster the neutralization 
of negatively charged LUVs occur. However, in our case, even though AA139 is more positively 
charged, it renders the surface charge of the LUVs less negative but does not neutralize the 
POPC/POPG (1:1) at the highest tested concentration, 100 μg/mL, as arenicin-3 does. For both 
arenicin peptides, the results suggest that arenicin-3 binds more strongly to the lipids and that the 
hydrophobicity of arenicin-3 is a stronger determinant of lipid binding than the added charge of 
AA139.   
To get a deeper insight of the mode of action of arenicin peptides and determine whether electrostatic 
interactions are necessary for their antibacterial activity, the membrane surface potential of E. coli 
was monitored by ζ-potential measurements, Figure 4-8. In the absence of peptides, the E. coli cell 
surface displayed a ζ-potential of -16.9 mV. This negative surface net charge of E. coli originates 
mostly from the lipopolysaccharides and the negatively charged phospholipids covering the outer 
leaflet of the cells. The titration of E. coli cells with arenicin peptides led to a reduction of the negative 
surface charge, with the values increasing from -16.9 to -3.5 mV or -8.0 mV, when titrating with 
arenicin-3 or AA139, respectively. The results suggest that both arenicin peptides bind to the E. coli 
cells and affect their surface charge.  
 
Arenicin peptides permeabilize the cytoplasmic bacterial membrane. The cytoplasmic 
permeabilization activity of arenicin peptides, arenicin-3 and AA139, against the membrane of E. coli 
ATCC 25922 cells were investigated by a fluorescence dye-based assay, using the DNA-binding 
probe SYTOX® Green. This assay assisted in investigating whether arenicin peptides permeabilize 
the inner membrane of E. coli ATCC 25922 cells. SYTOX® Green is a cell-impermeant nucleic acid 
stain, allowing the distinction between non-permeabilized from permeabilized cells by the increased 
fluorescent signal due to DNA-binding of SYTOX® Green. The fluorescence emission followed by 
flow cytometry was measured as a peptide titration of E. coli bacterial cells where SYTOX® Green 
was added following peptide-cell pre-incubation. For each sample, the fluorescence signals were 
expressed as a percentage of partial and full cell permeability as compared to intact (untreated) and 
damaged (treated with isopropanol) cell controls. Polymyxin B was included as a positive control 
compound, as it has the ability to disrupt the cytoplasmic membrane by pore formation. Meropenem 
was used as negative control compound, being an antimicrobial compound that enters cells without 
compromising the bacterial cell membrane. 
The results, Figure 4-9, suggest that arenicin peptides permeabilize the cytoplasmic membrane of E. 
coli cells at lethal concentrations (50% of the cells are permeabilized upon treatment with 0.7-1 
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μg/mL) and induced 100% of cell permeabilization at concentration ≥4 μg/mL for both arenicin 
peptides. Taking into account the number of cells used in this assay compared to the MIC assays 
(9x106 and 5x105 cells/mL respectively, 18-fold difference), arenicin peptides fully permeabilize the 
inner (cytoplasmic) membrane of E. coli cells at the same concentration as their MIC. The 
permeabilization profile is different for both arenicin peptides, arenicin-3 possess a significantly sharp 
point of permeabilization whereas AA139 shows a steady increase of permeabilization proportional 
to the concentration showing probably a different mode of action on the membrane of the cells.    
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Figure 4-9 – Cytoplasmic membrane permeabilization of E. coli ATCC 25922 using arenicin-3 (blue dots), AA139 
(red squares), polymyxin B (green down triangles) and meropenem (orange up triangles), evaluated from SYTOX 
Green fluorescence emission intensity. Average ± SD of three replicates.   
 
 
4.3 Materials and methods 
Materials. Arenicin-3 and AA139 were supplied to us by Adenium Biotech Pty Ltd. Peptides were 
synthesized using a yeast expression system by GenScript (Denmark) for small scale synthesis (~5 
mg), and PolyPeptide Laboratories (Sweden) for larger scale synthesis (>5 mg), on behalf of Adenium 
Biotech Pty Ltd. Synthetic lipids, palmitoyloleoyl-phosphatidylcholine (POPC) and palmitoyloleoyl-
phosphatidylglycerol (POPG) were purchased from Avanti Polar Lipids (Alabaster, AL). All 
chemicals were used without further purification. 
NMR spectroscopy 
3D solution structure 
Arenicin-3 and AA139 were analyzed at 3.5 and 2.5 mM concentration respectively, in phosphate 
buffer at pH 3.3 containing 10% D2O. All NMR experiments were performed on a Bruker Avance III 
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spectrometer equipped with a cryogenically cooled triple resonance probe operating at a nominal 1H 
frequency of 700 MHz. The excitation sculpting sequence was used to suppress the solvent (H2O) 
resonance. Two-dimensional TOCSY [tm (MLEV17 spin-lock mixing pulses) = 80 ms], NOESY [tm 
(mixing time) = 300 ms], 15N-HSQC and 13C-HSQC were recorded at 25 °C.  Chemical shifts were 
referenced relative to the 2,2-dimethylsilapentane-5-sulfonic acid (DSS) signal at 0 ppm. The 
assignment of proton resonances was carried out using TOCSY and NOESY data using the CCPNMR 
software.22 Torsion angles constraints were obtained using the Talos software.23 Structure 
calculations were performed using CYANA 3.0.24 Additional upper/lower restraints were applied to 
form disulfide bonds between Cys3- Cys20 and Cys7-Cys16. 
Hydrogen-deuterium exchange studies  
All NMR spectra for the hydrogen-deuterium exchange studies were recorded on the spectrometer 
described above at 25 °C. Spectra were referenced to DSS at 0 ppm. Lyophilized peptide was initially 
solubilized in phosphate buffer at pH 3.3. The peptide was then lyophilized. Lyophilized peptide was 
dissolved in 100% D2O and immediately placed in the spectrometer for measurement. 1D 1H and 
TOCSY spectra were recorded at specific time points over a 24 h period. Hydrogen-deuterium 
exchange rates were measured by integrating each exchangeable amide resonance separately.  
Amide temperature coefficient studies  
The temperature dependence of amide proton resonances was derived from 1D 1H and TOCSY 
spectra recorded on a Bruker ARX 500 MHz spectrometer. Spectra were measured between 15 °C to 
35 °C, in 5 °C increments, and referenced to DSS at 0 ppm. Assignment of the spectra was performed 
using the program CCPNMR.22  
Antimicrobial activity, Minimum Inhibitory Concentration (MIC). Antibacterial assays were 
performed by a broth micro-dilution plate based method as per CLSI guidelines for antimicrobial 
susceptibility testing.25, 26 The assay methodology was previously reported in chapter 3.  
Hemolytic assay. The ability of the peptides to hemolyse human red blood cells was determined by 
a previously reported method in chapter 3. 
Cytotoxicity. Cytotoxicity to HEK293 cells was determined using the resazurin assay.27,28 Cell 
culturing, cytotoxicity assays and calculation of percentage of cell death were performed as 
previously described in chapter 3.29 
Preparation of vesicles. Small unilamellar vesicles (SUVs) (50 nm diameter) for SPR and large 
unilamellar vesicles (LUVs) (100 nm diameter) for all other assays were used as membrane models 
and prepared by extrusion method as previously described.30,31 The synthetic lipids were used to 
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prepare model membrane composed of POPC, POPC/POPG (4:1 or 1:1molar ratio). All lipid 
suspensions were prepared in 10 mM HEPES pH 7.4, containing 150 mM NaCl unless otherwise 
stated.  
Surface plasmon resonance. The binding affinity of the peptides for model membranes composed 
of POPC or POPC/POPG (4:1 or 1:1) were compared using SPR. The methodology was already 
described in chapter 3.  
Vesicles leakage assay. Vesicle leakage was quantified by carboxyfluorescein (CF) dequenching as 
previously described.9 LUVs composed of POPC or POPC/POPG (1:1) were prepared containing 50 
mM CF and homogenized to a diameter of 100 nm by extrusion. CF-loaded LUVs and non-
encapsulated CF were separated by gel filtration on a Sephadex G50 column equilibrated with HEPES 
buffer. Several concentrations (2-fold dilution starting from 100 µg/mL) of arenicin peptides were 
incubated during 10 min with LUVs (5 µM final lipid concentration). The fluorescence emission 
intensity (FI; excitation/emission = 485 nm /520 nm) of the released CF was read using a PHERAstar 
plate reader (BMG Labtech). Controls with Triton X-100 0.1% (v/v) and with HEPES buffer were 
included to establish the FI with 100% and 0% of leakage, FITriton and FIbuffer, respectively. The 
percentage of leakage was calculated using the following equation: 
% Leakage= (FIsample- FIbuffer)/(FITriton- FIbuffer)x 100 
Vesicle aggregation. Aggregation of POPC or POPC/POPG (4:1 or 1:1) LUVs induced by arenicin 
peptides was evaluated by optical density at 436 nm (OD436). Arenicin peptides (25 μM) were added 
to LUVs (500 μM), and optical density was recorded as a function of time.11  
Circular dichroism (CD) spectroscopy. CD spectra were recorded on a Jasco J-810 Circular 
Dichroism Spectropolarimeter at ambient temperature using a 1 mm path length cuvette. Wavelengths 
from 260 to 185 nm were recorded with a 0.1 step and a 50 nm/min speed. Spectra were collected 
and averaged over 3 scans and corrected for background contributions. LUVs were prepared by 
extrusion method as mentioned earlier. Samples and lipid vesicles were prepared in 10 mM K2PO4 
pH 7.4 containing 150 mM NaF. Lipid vesicles were prepared at 0.5 mM and sample peptide at 50 
µM giving a peptide to lipid molar ratio (P/L) of 1/10. The lipid vesicles scatter light below 195 nm, 
therefore no data were recorded below this value. The peptides were also followed upon titration with 
trifluoroethanol (TFE), up to 50 %, mimicking hydrophobic environment. Signal was recorded in 
milli-degrees and the following equation was used to normalize the milli-degrees into mean-residue 
ellipticity, [𝜃𝜃]𝑀𝑀𝑀𝑀𝑀𝑀 =  𝜃𝜃 (𝑐𝑐 × 𝐻𝐻 × 𝑁𝑁𝑡𝑡)⁄ , where θ is the data in milli-degrees, c is the peptide 
concentration in molar, l is the cuvette path length in mm, and Nt is the number of residues. 
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Partition into lipid vesicles followed by Trp fluorescence emission. Arenicin peptides have 
intrinsic fluorescence due to a Trp residue in position 4. The involvement of the Trp residue in the 
interaction of arenicin peptides with POPC or POPC/POPG (4:1 or 1:1) LUVs was examined 
following the Trp fluorescence properties using a Perkin Elmer LS50 spectrometer with a quartz 
cuvette (pathlength = 0.5 cm). Tryptophan fluorescence emission spectra were scanned upon titration 
of a stock solution of LUVs (0-4 mM final lipid concentration) into peptide solution (25 μM). The 
excitation wavelength was set to 280 nm and emission was monitored from 300 to 450 nm at 25 °C. 
Partition curves were plotted, and the partition coefficient, Kp, was determined to compare the affinity 
for the three lipid mixtures.19  
Fluorescence quenching experiments were performed by stepwise addition of acrylamide from a 
stock solution (4 M) into peptide solution at room temperature.  The results were analyzed by fitting 
to the Stern-Volmer equation, I0/I = 1 + KSV[Q] and quenching efficiency quantified with KSV (Stern-
Volmer constant).32 I0 and I are the fluorescence intensities at appropriate emission wavelength in the 
absence and presence of quencher (acrylamide), respectively. [Q] is the molar concentration of 
acrylamide.20  
ζ potential measurements on model membranes and bacterial cells. Zeta potential measurements 
were conducted to evaluate changes in the surface charge of lipid bilayer model membranes and in 
E. coli cells in the presence of arenicin peptides at several concentrations. Studies were conducted in 
a Zetasizer Nano ZS90 (Malvern Instruments) equipped with a 633 nm HeNe laser and disposable 
DTS1070 ζ cells with gold electrodes. LUVs of POPC and POPC/POPG (1:1) at final concentration 
of 200 μM were incubated for 15 min at 25 °C with peptide from 0 to 100 μg/mL. Bacterial cells were 
pelleted, washed three times and resuspended in HEPES buffer at 2 x 107 CFU/mL. Peptides were 
added and samples were incubated for 30 mins at 37 °C. The ζ potential was calculated using the 
Smoluchowski equation. Ten measurements of 100 runs each were carried out for all the 
concentrations of peptide with the experiments run in duplicate.10   
Inner membrane permeability followed by SYTOX Green fluorescence emission. E. coli ATCC 
25922 cells were grown to exponential phase (OD~0.6), centrifuged at 2500 RCF for 10 min, the 
pellet washed with PBS buffer three times to remove any trace of nucleic acids and residual growth 
media, and cells were resuspended in buffer at 1 x 107 CFU/mL. Bacterial cell suspensions were 
incubated with peptides at different concentrations (five-fold dilutions starting from 20 μg/mL) for 1 
h at 37 °C, repeated in triplicate. SYTOXTM Green (Life Technologies S7020), a DNA-binding dye 
that becomes fluorescent when bound to nucleic acids and only enters cells with comprised plasma 
membranes,33 was added to the peptide–treated cells at a final concentration of 2 μM, and incubated 
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for 5 min at room temperature. The fluorescence emission intensity of the bacterial suspensions were 
then scanned using λex = 488 nm and λem = 530 nm with 30 nm band pass by flow cytometry 
performed with a BD FACS Canto II (BD biosciences). For each sample 100000 events were recorded 
and the fluorescence signals were expressed as a percentage of cell permeability as compared to intact 
(untreated) and damaged (treated with isopropanol) cell controls. Polymyxin B was included as a 
positive inner membrane permeating compound control and meropenem as negative inner membrane 
permeating compound control (antimicrobial compound that enters cells without compromising the 
bacterial cell membrane). 
Based on forward and side scattering measurements of the intact versus damaged cell controls, two 
distinct populations were identified; i) healthy or intact cells, ii) dead/unhealthy or 
completely/partially permeabilized cells. Healthy cells were deemed as 101 to 103 range of detection, 
at 530 nm, and dead or unhealthy cells were deemed as 103 to 105 range of detection at 530 nm. 
 
4.4 Conclusion 
Bacteria are developing resistance to current antibiotics rendering them ineffective even for the 
treatment of the simplest diseases. The development of new drugs to replace obsolete antibiotics is 
thus an emergency. AMPs have fascinated scientists for decades due to their large range of 
antimicrobial activity, however what is suitable for microorganisms, plants and animals is not 
necessary suitable for human as most AMPs display toxicity towards mammalian cells. To counteract 
mammalian cell toxicity, the method of choice, is to design analogs of natural AMPs, in order to 
retain its antimicrobial property and concomitantly reduce its mammalian toxicity. This is what has 
been achieved, in the case of AA139, a synthetic analog of arenicin-3, offering potent broad-spectrum 
antimicrobial activity and very low mammalian cell toxicity. In the attempt to develop drug 
candidates at a faster rate than bacteria develop resistance to antibiotics, the study of the mode of 
action of those molecules is required.  
In this study, we examined the 3D solution structures and mode of action of both arenicin-3 and 
AA139. The comparison between arenicin-3 and AA139, revealed the significant implications simple 
amino acid changes, could have on the properties of AMPs. The mutations of two valines for alanine 
as well as a tyrosine for an arginine, reduced the overall hydrophobicity of the molecule and 
consequently increased its amphipathicity. We confirmed that these arenicin peptides are β-hairpin 
right handed twisted peptides, constrained by two disulfides bridges Cys3-Cys20 and Cys7-Cys16. The 
mutations of three amino acids between arenicin-3 and AA139 did not affect the peptide backbone, 
which is almost perfectly superimposable. Although, almost identical, the NMR study revealed that 
Chapter 4 – Label free AA139 MoA 
 
 4-85 
arenicin-3 has a more rigid and stable structure than AA139 possessing almost 2-fold more H-bonds 
than AA139. Its more flexible structure offer AA139, the possibility to probably slightly rearrange 
its structure to maneuver through the lipid bilayer of the cell membranes.   
We investigated the mode of action of both peptides against bacterial and mammalian cells. To do 
so, we evaluated the effect of the peptides on the cell membrane, through assays using lipid bilayer 
model membranes and bacterial cells. Studies conducted with lipid vesicles using SPR and 
fluorescence methodologies suggested that arenicin peptides bind, permeabilize and insert into 
negatively charged lipid vesicles (POPC/POPG). Their β-hairpin secondary structures were not 
modified, but rather, might slightly twist upon interaction with negatively charged lipid model 
membrane or might align to the lipid bilayer membrane in a particular orientation. Arenicin-3 induces 
more aggregation of negatively charged lipid bilayer model membranes than AA139 and at a faster 
rate. The N-terminus of AA139 (Trp4) inserts deeper into the hydrophobic core of negatively charged 
phospholipid membranes than zwitterionic ones (41.5-fold difference of Ksv) rendering it more 
selective for negatively charged phospholipid membranes, as compared to arenicin-3 (1.4-fold 
difference of Ksv), which seems to have its N-terminus inserting quite similarly in both types of 
membranes. These results correlate well with the difference seen in toxicity of both arenicin peptides, 
with AA139 displaying a reduced hemolytic activity as compared to arenicin-3. The results obtained 
with bacterial cells, E. coli ATCC 25922, confirmed that arenicin peptides permeabilize the inner 
bacterial membrane.34 Our study suggests that arenicin peptides act on the membrane of E. coli cells 
and are most likely attracted to the cell surface due to electrostatic attraction. AA139 permeabilizes 
the inner (cytoplasmic) membrane of E. coli cells with a steady increase proportional to its 
concentration, thus it is possible to suggest that AA139 antimicrobial mode of action differs from 
arenicin-3 and AA139 can kill bacteria via an alternative means as opposed to pure membrane 
disruption.  
In summary, the use of lipid bilayer model membranes and bacterial cells, allowed us to propose a 
model for the mechanism of action of AA139, Figure 4-10, involving three steps: (1) binding the 
outer membrane through electrostatic interactions, (2) inserting into the hydrophobic core of the outer 
membrane creating partial permeabilization due to the ability of the peptide to modify its secondary 
structure allowing it to enter into the lipid bilayer without pore formation, (3) accessing and 
permeabilizing the cytoplasmic membrane.  
AA139 flexibility may be a clue to the difference between both arenicin peptides. Usually, β-hairpin 
AMPs are extremely rigid and a change in their structure would lead to a loss of antimicrobial activity. 
However, it was observed, for the case of LytA239–253, a peptide encompassing the β‐hairpin core 
of the third CBR of pneumococcal C‐LytA, that this peptide would undergo complete secondary 
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structure modification when interacting with detergent micelle and SUVs, changing from β-hairpin 
to α-helical secondary structure.35 Structural flexibility is also usually observed for most AMPs which 
adopt random coil secondary structure in solution and become α-helical upon binding to cell 
membranes. We could imagine that structural modification or rearrangement could lead to a more 
valuable therapeutic peptide in the case of AA139.       
 
Figure 4-10 - Model of the mechanism of action of AA139 against Gram-negative bacteria cell membrane. 1) 
AA139 binds to the negatively charged outer membrane of Gram-negative bacteria via electrostatic interactions; 2) 
AA139 inserts into the hydrophobic core of the outer membrane creating partial permeabilization; 3) AA139 accesses 
and permeabilizes the cytoplasmic membrane. 
 
We now have a deeper understanding of the mode of action of arenicin peptides and how the mutation 
of only three amino acids has made a significant increase in the therapeutic value of the peptide. Other 
β-hairpin AMPs have been reengineered to generate therapeutically valuable molecules. For example, 
Iseganan, a synthetic analog of protegrin-1 that was redesigned by reducing and redistributing the 
overall charge and hydrophobicity of the peptide by simple two amino acid deletion/mutations, was 
shown to be effective for the prevention of oral mucositis. However, this peptide failed phase III 
clinical trials for the prevention of ventilator-assisted pneumonia due to high toxicity.36 A 14 amino 
acid synthetic cyclic peptide derived from protegrin-1, Murepavadin (POL7080), an outer membrane 
protein targeting antibiotic, was engineered by Polyphor. Polyphor announced on 19th May 2017 the 
success of a phase II clinical trial and the recruitment of the first patient for a phase III clinical trial 
in Q1/2018 for the treatment of nosocomial pneumonia (ventilator-associated and hospital-acquired 
Chapter 4 – Label free AA139 MoA 
 
 4-87 
pneumonia; VAP/HAP) caused by infections of Pseudomonas aeruginosa, including its resistant 
strains. Natural AMPs offer great potential for the fight against resistant bacteria. The redesign of 
AMPs to produce better therapeutic candidates than the native prototype is now exemplified by 
AA139, which possesses promising therapeutic qualities for further drug development. AA139 
provides an example of successful improvements that should be considered when designing other 
potential antimicrobial peptides.  
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Chapter 5    - Structural AA139 
mode of action study 
5.1 Introduction 
The label free studies presented in chapter 4 allowed us to gain an insight into the mode of action of 
arenicin peptides toward bacterial and mammalian cells. To deepen our comprehension, a structural 
characterization study is beneficial to understand the mechanism on a 3D molecular level. To date, 
the most established techniques for determination of high-resolution structures are X-ray 
crystallography and NMR spectroscopy, with both techniques generally yielding highly similar 
structures. The antimicrobial peptide database reports 2900 AMPs, but only 388 peptides have known 
3D structure, of which 87% have been solved by NMR. NMR is the tool most widely employed in 
this area of research, mostly because peptide–lipid complexes cannot be crystallized. NMR is 
therefore the most appropriate tool to tackle the structural characterization of the mode of action of 
AA139. The structural study was performed on AA139 as it is the current lead drug candidate in its 
class. Bacterial and mammalian cells, as well as phospholipid vesicles, are too large for solution NMR 
spectroscopy, thus, alternative model systems have been developed to examine the structure of 
peptides in a membrane mimetic environment.  
Historically, aqueous solution of organic solvents such as trifluoroethanol (TFE) were first employed 
to mimic the cell like lipid environment. However, TFE can induce the formation of α-helical 
secondary structure, which often does not correlate with biological activity.1 Then, detergent micelles 
were introduced, adopting elliptical or rod-like shapes, depending on detergent concentration and 
chain length. Sodium dodecylsulphate (SDS) is negatively charged and dodecylphosphocholine 
(DPC) is zwitterionic, therefore mimicking bacterial and mammalian cell membranes, respectively. 
Discoidal micelles, or bicelles, have also been routinely used. They are formed by long- and short-
chain phospholipids like DMPC or DHPC. Micelles/bicelles better mimic the cell membranes than 
TFE due to the separation of the hydrophobic acyl chains and the hydrophilic head groups. They are 
small enough for conventional proton NMR techniques without significantly broadening the signals 
of the peptide. However, micelles/bicelles do not reflect the true complexity of the bacteria and/or 
mammalian cell membranes due to their monolayer feature, coupled with a really tight curvature 
radius which can cause peptides to adopt non-native conformations or to aggregate. The mode of 
action of arenicin-2 was studied using DPC micelles, suggesting dimeric formation of arenicin-2 upon 
interaction with the micelles and pore formation.2  
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Phospholipid bilayer vesicles are better models of cell membranes. They have been used sporadically 
in solution NMR due to their relatively big size. The smallest possible vesicles DLPC-d64 have been 
used in some cases, giving a better representation of the peptide conformation and potentially the 
same conformation as is found in nature.3 Lipid bilayer vesicles have been extensively used in solid 
state NMR, where size is not a limiting factor. For instance, the mode of action of protegrin was 
studied via solid state NMR (ssNMR) using DLPC or POPC bilayers, using static ssNMR and magic 
angle spinning (MAS) NMR respectively, supporting a toroidal pore mechanism of action.4 
A more recent innovation, since the beginning of the twenty first century, are lipid bilayer nanodiscs, 
and their use is rapidly expanding.5,6 Originally thought to offer advantages for the study of membrane 
proteins, they are now also employed for the structural and functional studies of membrane active 
peptides by solution NMR. Shenkarev et al.7 attempted to study the binding interaction between 
arenicin-2 and nanodiscs constituted of DLPC/DLPG, however the peptide disintegrated the ND 
rendering the experiment impossible to accomplish. 
In this chapter, three approaches have been explored for the structural characterization of AA139’s 
mode of action against bacterial membranes: (i) a computational modelling study, (ii) a solution NMR 
study using lipid bilayer nanodiscs and (iii) a solid-state NMR study using lipid bilayer vesicles. 
 
5.2 Results and discussion 
Computational modelling. To evaluate the binding and insertion/interaction of arenicin peptides 
with the cell membranes, computational analysis was performed. We analyzed the aggregation 
proficiency of arenicin peptide structures by in silico means, in solution (in vitro aggregation) and in 
the presence of bacterial membrane (in vivo aggregation) by using TANGO (http://tango.crg.es/) and 
AGGRESCAN 3D (A3D) algorithms respectively.  TANGO algorithm predicts β-aggregation 
proficiency pattern based on; different energy states, hydrophobicity, solvation energetics, 
electrostatic interactions and hydrogen bonding. The results, as shown in Figure 5-1 – A and B, reveal 
possible aggregation in solution for both arenicin-3 and AA139 taking part in the N-terminal β-sheet 
at physiological pH.  The A3D algorithm assessed the proneness to aggregation of the peptide in in 
vivo conditions. The higher the aggregation score, the more prone is the amino acid for aggregation. 
This algorithm identified 14 amino acids (Gly1-Tyr9 and Val13-Tyr17) for arenicin-3 and 9 amino 
acids (Gly1-Cys7 and Cys16-Tyr17) for AA139 which may facilitate interchain bonding and auto-
aggregation when in the presence of a lipid environment, Figure 5-1 – C and D. The mutations of Val 
to Ala and Tyr to Arg when going from arenicin-3 to AA139 lower the aggregation potential of the 
molecule in vitro and in vivo. 
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Figure 5-1 - Prediction of aggregation propensity of arenicin peptides by TANGO (A and B) and Aggrescan3D (C 
and D).  
 
The orientation and potential interaction of arenicin peptides with a lipid membrane were studied by 
using the Orientation of Proteins in Membrane (OPM) web server8, where the modeled peptide and 
dummy atoms of lipid moieties were viewed through FirstGlance in Jmol, V2.51, Figure 5-2. Note 
that OPM uses a DMPC lipid membrane as a mimic for mammalian cell membranes.  
    
Figure 5-2 – OPM representation of arenicin peptides with DMPC lipid membrane, represented in blue dotted 
lines, (A) arenicin-3 and (B) AA139.  
 
A B 
Chapter 5 – Structural AA139 MoA 
 
 5-93 
The results of OPM are summarized in Table 5-1. Both arenicin peptides possess the same number 
of embedded residues (two), however their orientation toward the membrane differ. Arenicin-3 tends 
to lay almost parallel (82° tilt angle) to the membrane whilst AA139 is predicted to interact with a 
much wider angle (67° tilt angle). Arenicin-3 may interact with an increased depth of penetration into 
the hydrophobic core of the membrane (3.3 ± 1.5 Å) than AA139 (2.1 ± 1.7 Å). The transfer free 
energy of the molecule from water to the lipid bilayer, or ΔGtransfer, is more important for arenicin-3 
(-4.4 kcal/mol) than for AA139 (-3.5 kcal/mol). This trend correlates well with the acrylamide 
quenching study performed in chapter 4. The acrylamide quenching remains quite large for AA139 
as compared to arenicin-3 when exposed to POPC LUVs, still demonstrating exposure of the Trp4 
residue to the aqueous solvent for AA139 and less so for arenicin-3, meaning that the arenicin-3 Trp4 
residue, would be inserted into the hydrophobic core of the liposome. This could explain the 
difference in mammalian toxicity between arenicin peptides.   
Table 5-1 - OPM results describing the depth/hydrophobic thickness, ΔGtransfer and the tilt angle of arenicin 
peptides toward DMPC lipid model membrane. 
Peptide Depth/Hydrophobic Thickness (Å) 
ΔGtransfer 
(kcal/mol) 
Tilt Angle 
(°) 
Membrane 
embedded residue 
arenicin-3 3.3 ± 1.5 -4.4 82 ± 6 2 
AA139 2.1 ± 1.7 -3.5 67 ± 9 2 
 
Nanodisc stability study. Nanodiscs (ND) are the latest lipid bilayer model membranes, sufficiently 
small (about 10 nm) to be analyzed by solution state NMR. ND are a self-assembled lipid bilayer 
stabilized by a scaffold protein, mimicking as closely as possible a cell membrane bilayer. By using 
different compositions of lipids, theoretically any kind of cell membrane could be mimicked. 
However, because of their liquid phase transition or their charge, some lipids are more or less stable 
at any chosen temperature in this constrained environment. Therefore, as the use of ND grows,9 
questions are arising about the stability of this kind of membrane mimicking tool. Here, we evaluated 
the stability of four different ND constructs: (i) two different membrane scaffold proteins were 
designed, MSP1D1ΔH5 (shortened dH5 for the rest of the chapter) and cNW9 (circularized version 
of MSP1D1ΔH5)10 and (ii) two different lipid compositions, POPC (mimicking mammalian cell 
membranes) and POPC/POPG (4:1) (mimicking G-ve bacterial cell membranes). We evaluated 
stability over a range of concentrations of ND, pH, buffer type, temperature and length of storage, 
using size exclusion chromatography (SEC), electron microscopy (EM) and mass spectrometry (MS) 
for characterization.   
The comparison of the size exclusion chromatograms of the different ND compositions revealed 
promising results. The circularized membrane scaffold protein (cNW9) stabilized the ND of any lipid 
composition extremely well. This was true for any chosen buffer, temperature, concentration or 
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storage condition studied. However, the study revealed surprising results for the most commonly used 
membrane scaffold protein for NMR studies, MSP1D1ΔH5. This scaffold tended to be more 
homogeneous and stable when the ND was composed only of zwitterionic lipids rather than 
negatively charged lipids. Moreover, the storage buffer and temperature were found to play an 
extremely important role on its stability. This scaffold only remained stable over 30 days when stored 
in 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM EDTA buffer. For all other conditions, the ND peak 
broadened and shifted over time, pushed to an extreme in the case of 37 °C storage in as little as two 
days. The stability study has been summarized in the Table 5-2. All size exclusion traces can be found 
in the Appendix V, Figures S7.5-1 to S7.5-4.     
 
Table 5-2 – Nanodiscs stability study summary of the number of days the ND remained stable during the length 
of the stability study experiments. The stability was assessed from the SEC chromatograms (Appendix V, page 7-258 
to 7-261). Any shift and/or broadening of the ND peak would be considered as instability.  
Buffer 
(containing 50 mM 
NaCl, 1 mM EDTA) 
Temperature 
(°C) 
Number of days of ND stability/Number of days of experiment 
ND[POPC] ND[(POPC/POPG)(4:1)] 
dH5 cNW9 dH5 cNW9 
20 mM Tris-HCl pH 7.5 4 30/30 30/30 1/30 30/30 
20 mM PO4 pH6.5 4 3/30 30/30 1/30 30/30 
20 mM Bis-Tris pH6.5 
4 3/30 30/30 1/30 30/30 
25 - - 1/2 2/2 
37 - - 0/2 2/2 
freeze - - 2/2 2/2 
 
 
A detailed study was conducted for both scaffold protein constructs of ND constituted with 
POPC/POPG (4:1) to assess degradation in the preferred buffer, 20 mM Bis-Tris pH 6.5, 50 mM 
NaCl, 1 mM EDTA. 
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Figure 5-3 – Stability study of ND constituted with POPC/POPG (4:1) using membrane scaffold protein dH5 (A, 
C, E and G) and cNW9 (B, D, F and H) construct at day 0 (A, B, C and D), time of assembly and day 7 (E, F, G 
and H) after storage at room temperature. A, B, E and F are size exclusion chromatography traces. While C, D, G 
and H are negative staining (1% uranyl acetate) EM images.  
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At time of assembly (day 0), both ND constructs were analyzed by SEC, Figure 5-3 (A and B). 
Electron microscopy of both constructs was imaged at day 0, Figure 5-3 (C and D), showing discs of 
around 8-10 nm diameter. The ND were left at room temperature for seven days and reanalyzed via 
SEC, Figure 5-3 (E and F) and EM, Figure 5-3 (G and H). The SEC were fractionated and each 
fraction was subjected to LC-MS in positive mode, Figure 5-4 and Figure 5-5. Negative mode MS 
was performed for select fractions only to confirm the presence of POPG lipids in the ND peaks, 
Appendix V, Figure S7.5-5. Negative staining, Figure 5-3 (G and H), confirmed the inhomogeneity 
of ND diameter for dH5 construct while the cNW9 construct remained quite homogenous. Negative 
staining was also performed for selected fraction of ND[dH5(POPC/POPG(4:1))], confirming the 
presence of ND of increased diameter after seven days of storage, Appendix V, Figure S7.5-6. The 
degradation of ND[dH5(POPC/POPG(4:1))] demonstrated aggregation of the ND over time, however 
for ND[cNW9(POPC/POPG(4:1))] no degradation was observed.  
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Figure 5-4 – (A) SEC of ND[dH5(POPC/POPG(4:1))] nanodiscs at day 7 stored at room temperature, (B) vertical 
stacking of LC-MS (ESI in positive mode) of the SEC fractions and (C) M/Z TIC trace of selected peaks. MW(dH5) 
= 19486 g/mol, MW(Bis-Tris) = 209.2 g/mol and MW(EDTA-Na2) = 372.2 g/mol. 
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Figure 5-5 - (A) SEC of ND[cNW9(POPC/POPG(4:1))] nanodiscs at day 7 stored at room temperature, (B) vertical 
stacking of LC-MS (ESI in positive mode) of the SEC fractions and (C) M/Z TIC trace of selected peaks. 
MW(cNW9) = 19837 g/mol, MW(Bis-Tris) = 209.2 g/mol and MW(EDTA-Na2) = 372.2 g/mol. 
 
 
Dynamic Light Scattering (DLS) experiments were performed using MSP1D1ΔH5 membrane 
scaffold protein either alone or as scaffold for the ND. In this study, the results of the dH5 taken alone 
demonstrated a mono-disperse particle type with a diameter around 8 nm. This surprising result 
matched almost perfectly with all other ND studied here, giving mono-dispersed particles with a 
diameter about 8 nm. This rendered the use of the DLS technique inadequate for our study to evaluate 
if the ND were correctly assembled. Therefore, it was decided to not pursue the use of the DLS 
technique for all other ND studies and/or assemblies. The DLS measurements could be found in 
Appendix V, Figure S7.5-7.  
 
NMR titration experiment. Nanodiscs are detergent free lipid bilayer model membranes and are 
often an ideal tool to study membrane proteins. However, they can also be used to characterize the 
interaction of peptides with cell membranes.   
A preliminary screen was performed to determine the most suitable buffer for NMR titration 
experiments of 15N-AA139. To perform the 3D solution NMR structure of AA139, presented in 
chapter 4, phosphate buffer pH = 3.3 was chosen in order to reduce the solvent exchange and thereby 
aid the detection of the backbone amides present, leading to 100% of the amide backbone being 
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visible.  However, to evaluate the mode of action of the peptide toward model membranes, a pH 
closer to physiological conditions would be a more genuine representation. In this case, the ideal 
buffer would be as close to physiological pH, around 7, as possible and requires at least 80% of the 
amide backbone to remain visible. 
Due to fast exchange of amide protons with the solvent, the higher the pH used, the lower the number 
of detectable protons. Therefore, a compromise was made in the choice of the buffer, which was 20 
mM Bis-Tris pH 6.5, 50 mM NaCl. This buffer allows the detection of 18 out of 21 amide backbone 
peaks, around 90% of the total amide backbones. Two of the backbone amides are therefore not 
visible using pH 6.5: Phe2 and Asn11, Figure 5-6 and Appendix V, Figure S7.5-8.  
 
Figure 5-6 - 1H-15N-HSQC of 15N-AA139 in 20 mM PO4 buffer at pH 3.3 in red and 20 mM Bis-Tris pH 6.5 in blue. 
Peaks have been assigned with both amides backbones only present at pH 3.3 circled in green. Peaks not assigned 
correspond to side chains.     
 
A titration experiment evaluated the effect of 15N labelled AA139 structure upon titration with ND 
containing POPC/POPG (4:1) (ND[cNW9(POPC/POPG(4:1))]), mimicking the lipid bilayer 
membrane of G-ve bacterial cells, such as E. coli.  This was followed by a series of 15N-HSQC 
experiments, Figure 5-7, where the concentration of 15N-AA139 was kept constant while the 
concentration of the ND would increase toward complete saturation, Table 5-3.  
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Table 5-3 - Experimental design of the solution NMR titration experiment between 15N-AA139 and 
ND[cNW9((POPC/POPG(4:1))] 
Experiment 0 1 2 3 4 5 6 
15N-AA139 (μM) 40 40 40 40 40 40 40 
ND[cNW9(POPC/POPG(4:1))] (μM) 0 5 7.5 10 12.5 15 20 
 
 
 
 
Figure 5-7 – (A) Bar graph of the amide backbone peak intensity change between Peptide/ND ratio (1:0) and (4:1), 
the grey dash bar represent the average value of all the data points, (B) 1H-15N-HSQC of 15N-AA139 titrated with 
ND[cNW9(POPC/POPG(4:1))] with varied Peptide/ND molar ratio, (1:0) in blue, (4:1) in red and (2:1) in green.  
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The addition of ND to the peptide environment could lead to (i) structural modifications upon binding 
(including self-association and changes in local chemical environment) and/or (ii) change the overall 
tumbling of the molecule and/or (iii) change the local motion of residues at the binding interface 
leading to chemical shift movement and/or intensity variation of 15N-AA139 peak signals. Upon 
binding, the portion of free versus bound peptide changes and the signal of amide (HN) protons of 
15N-AA139 residues will be modified depending on the timescale of the binding interaction: (i) fast 
exchange would mean that the peaks would undergo chemical shift modifications, (ii) intermediate 
exchange would mean that the peaks would undergo broadening and (iii) slow exchange would mean 
that two separate set of peaks would be observed. Due to the very large difference in the apparent 
size of the free and bound state, the bound state will not contribute to the observed signals, except for 
residues in highly dynamic regions that are not affected by the global tumbling of the molecule (e.g. 
sidechains of glutamine and asparagine residues and in disordered loops or termini). 
The results showed that the amide backbone peaks of 15N-AA139 are not displaying significant 
changes in chemical shifts along the x (1H) and/or y (15N) axis when titrated with ND, however, 
intensity change (or broadening) of the peaks was observed. The interaction between 15N-AA139 and 
ND[cNW9(POPC/POPG(4:1))] is likely to be in the intermediate timescale of interaction (μs-ms).  
The data were analysed qualitatively by measuring the difference in peak intensity between 
Peptide/ND ratio (1:0) and (4:1), as shown in Figure 5-7 (A). The residues with the largest intensity 
changes (tallest bars), above the average (grey dash bar on the graph), (Cys3, Trp4, Tyr5, Val6, Tyr17, 
Arg18, Arg19 and Asn21) are most significantly affected by the presence of the NDs. Thus, those 
residues are most likely to be located at the peptide/ND interface. At a low concentration of ND 
(peptide/ND ratio of 4:1), ten residues appear unaffected by the presence of the ND (Cys7, Ala8, 
Arg9, Arg10, Gly12, Ala13, Arg14, Val15, Cys16 and Cys20), showing only minimal peak intensity 
difference, below the average threshold. Those residues are least likely to be located at the peptide/ND 
interface.  
If the loss in signal can be attributed directly to binding (i.e. the bound state leads to complete loss of 
signal), it is possible to analyse the data more quantitatively, using the approach proposed by 
Williamson et al.11. Considering the vastly greater size of the bound state, it is reasonable to assume 
that the observed signals are only from free peptides in solution (i.e. not bound to nanodiscs). Under 
these circumstances this approach can be applied to determine rough estimates of the Kd of AA139 
to NDs. This approach is usually applied for slow or fast exchange regimes, nevertheless as noted 
above, the model can be applied with some caution under the conditions described here. Thus, the 
application of this model requires the following assumptions: (i) the ligand is be the ND and the 
receptor is the peptide, (ii) the peak broadening is only dependant on binding interaction, leading to 
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observed signals only representing free (unbound) peptides in solution and (iii) an absence of 
cooperative binding. Moreover, Williamson’s equation had to be modified in our case, due to the 
possibility of a multiple number of equivalent binding sites for the peptide toward the ND, introducing 
thus another variable, N.  
Δδobs = Δδmax*((K+P+x*N)-(((K+P+x*N)2)-4*P*x*N)1/2)/(2*P), where Δδobs is the change in the 
observed intensity from the free state, Δδmax is the maximum intensity change in amplitude, P is the 
concentration of peptide, x is the concentration of ND, K is the Kd and N is the number of equivalent 
binding sites. A script was written to perform fitting and plotting of the data to the equation using 
gnuplot.12  
 
The analysis was first run for each residue individually with variable K and N, Table 5-4. The results 
indicated 7 residues with negative Kd values (Cys7, Ala8, Arg10, Gly12, Ala13, Arg14 and Cys16), 
indicating that the broadening of these residues does not simply involve binding interaction between 
AA139 and the ND (i.e. additional exchange processes are occurring that lead to signal loss). Arg9 
and Val15 are residues located in the same loop end of the peptide, thus, probably involved in the 
same type of interaction. For those residues, the broadening of the peaks is potentially due to 
conformational change. The 9 residues (Cys3, Trp4, Tyr5, Val6, Tyr17, Arg18, Arg19, Cys20 and 
Asn21), located at the N- and C-terminal ends of AA139, in contrast show broadening that fits the 
two-site exchange model used to model the binding interactions. Thus, a second analysis was 
performed fitting all nine residues as a whole molecule to determine AA139’s Kd for NDs. N was 
first left as a variable then fixed to the closest even integer number, 4. N equal 4 would mean that two 
AA139 would interact on each side of the ND, Table 5-5. Figure 5-8 shows the graph fitting the 
intensity of change versus ligand concentration.  
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Table 5-4 - Kd and N values for each AA139 residues taken individually. 
residue Kd (μM) N 
G1 - - 
F2 - - 
C3 1.26 ± 0.95 5.48 ± 0.63 
W4 0.21 ± 0.31 4.68 ± 0.27 
Y5 0.56 ± 0.55 3.74 ± 0.29 
V6 0.37 ± 0.24 5.05 ± 0.21 
C7 -44.15 ± 6.85 4.80 ± 0.87 
A8 -0.05 ± 0.29 2.94 ± 0.32 
R9 0.08 ± 0.31 2.81 ± 0.20 
R10 -1.17 ± 1.67 2.53 ± 0.31 
N11 - - 
G12 -0.30 ± 3.38 2.20 ± 0.51 
A13 -0.41 ± 1.61 2.58 ± 0.24 
R14 -0.39 ± 1.84 2.6 ± 0.27 
V15 0.52 ± 0.35 4.09 ± 0.21 
C16 -0.43 ± 1.07 2.87 ± 0.23 
Y17 0.93 ± 1.10 3.99 ± 0.53 
R18 0.70 ± 0.52 4.73 ± 0.34 
R19 0.34 ± 0.33 3.51 ± 0.19 
C20 0.53 ± 1.02 4.47 ± 0.68 
N21 0.62 ± 0.70 3.84 ± 0.37 
 
Table 5-5 - Kd and N value for AA139 taken as a whole. 
residue Kd (μM) N 
overall 0.76 ± 0.31 4.41 ± 0.18 
overall 0.34 ± 0.14 4 
 
Chapter 5 – Structural AA139 MoA 
 
 5-103 
 
Figure 5-8 - Graph of intensity change versus ligand concentration (μM). 
 
The combination of both data analyses indicated that 8 (qualitatively) and 9 (quantitatively) residues 
were significantly involved in the binding interaction. Both analysis methods correlated quite well, 
indicating the same 8 residues (Cys3, Trp4, Tyr5, Val6, Tyr17, Arg18, Arg19 and Asn21) as being 
involved in the binding interaction. Only one residue, Cys20, does not match between both analysis 
types. For a more visual representation of the residues most affected by the binding event, a 3D 
representation was used to illustrate the interaction results, Figure 5-9. This representation shows that 
the N- and C-termini of the peptide are dominated by residues involved in the binding interaction, 
indicating this part of the peptide as potentially the first point of interaction with the lipid bilayer. 
These results correlate well with the computational modelling examined previously, identifying the 
N-terminus of the peptide as the region to first enter at around 67° tilt angle. 
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Figure 5-9 - 3D structure of AA139 in cyan with H-bond marked as dashed lines and residues interacting with the 
lipid bilayer represented in magenta and the undetermined residues in grey.  
 
In this kind of experiment, the type of binding observed needs to be carefully interpreted. To make 
sure the binding observed corresponds to the interaction between AA139 and the lipid bilayer rather 
than binding between AA139 and cNW9, a titration experiment control was performed between 
ND[15N-cNW9(POPC)] and AA139. The ND in this case were made with 100% POPC, as AA139 
was previously reported, in chapter 4, of having weaker binding toward POPC than POPC/POPG(4:1) 
lipid bilayer. Therefore, the control experiment was designed as followed in Table 5-6. Experiment 1 
should already reach saturation point due to the ratio of saturation observed in the previous titration 
experiment between 15N-AA139 and ND[cNW9(POPC/POPG(4:1))], where the saturation was 
reached at peptide to ND ratio 2:1.  
 
Table 5-6 - Experimental design of the solution NMR titration experiment between AA139 and ND[15N-
cNW9(POPC)] 
Experiment 0 1 2 
AA139 (μM) 0 50 100 
ND[15N-cNW9(POPC)] (μM) 100 100 100 
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Figure 5-10 – 1H-15N TROSY HSQC recorded at 50 °C of ND[15N-cNW9(POPC)] titrated with AA139 with varied 
ND/Peptide molar ratio, (1:0) in blue, (2:1) in red and (1:1) in green.  
 
The results, Figure 5-10, showed well distributed spectra for ND[15N-cNW9(POPC)] at 50 °C. The 
titration was also recorded at 25 °C but the resolution was very poor (data in Appendix V, Figure 
S7.5-9). Interactions between AA139 and cNW9 could occur from two distinct regions of the helices 
belt, the external and the internal region. The internal region of the ND belt would only be accessible 
after previous binding to the lipid bilayer as a secondary interaction. This kind of interaction cannot 
be avoided and controlled. However, the interaction at the external region needs to be monitored. The 
titration with non-labelled AA139 did not modify the distribution of the peaks, however slight 
intensity decrease was observed, when AA139 was titrated. Thirty well defined peaks were picked 
and the heights were recorded. The percentage of intensity decrease between experiment 1 and/or 2 
and experiment 0 was calculated. The percentage of height decrease ranged from 4.6% to 51.4% with 
an average around 36%. It was noted that the peak intensities were relatively similar between 
experiment 1 and experiment 2, which correlates with the previous titration experiment, where the 
saturation point was already reached at a ratio of peptide:ND of 2:1. The intensity decrease in the 
titration experiment between ND[15N-cNW9(POPC)] and AA139 is negligible as compared to the 
intensity decrease during the opposite titration experiment, where the average was around 92%, i.e. 
near complete signal loss. In other words, the interaction between AA139 and cNW9 is significantly 
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weaker when compared to its interaction with the lipid bilayer and therefore does not affect the 
derived AA139 Kd value for the interaction with the lipid bilayer POPC/POPG(4:1). 
 
Solid-state NMR study using lipid bilayer vesicles. The results generated from the titration solution 
state NMR with ND, indicated that AA139 had strong interactions with negatively charged lipid 
model membranes. However, which conformational state does AA139 adopt when integrated in the 
lipid bilayer membrane? To answer this question, the characterization of the AA139 structure needs 
to be monitored while integrated in the lipid bilayer. Solid-state NMR offers adequate tools for this 
study. 
Solid-state NMR spectroscopy (ssNMR) is used for hard to solubilize proteins, membrane proteins 
and amyloids/fibrils, or micro-crystalline powder of soluble proteins: samples with very slow or 
inexistent reorientation. ssNMR offers a great advantage over solution NMR, in that it is not limited 
by the size of the molecule. This is the reason why we have chosen to evaluate the structure of AA139 
in lipid vesicles (LUVs) using ssNMR. The absence of molecular tumbling in ssNMR causes extreme 
line-broadening to render spectra impossible to interpret. However, extremely fast spinning at the 
magic angle (θ = 54.7˚ relative to the magnetic field B0), i.e. MAS, offers the possibility to simulate 
motional averaging. In MAS, the normally broad lines become narrower due to removal of the 
anisotropic interaction terms. This increases the resolution of the spectra and renders them 
interpretable. Unlike solution NMR where most nuclei can be detected, in ssNMR generally only 
low-γ nuclear spins nuclei, i.e. 13C and 15N can be observed, since the spinning rate has to be larger 
than the interaction strength.13  
This work was done collaboratively with the Leibniz-Forschungsinstitut für Molekulare 
Pharmakologie in Berlin with the group of Professor Hartmut Oschkinart, who is an expert in this 
field. 
In solution NMR, a titration with lipid ND was possible because only the freely tumbling, unbound, 
peptides were studied. However, the sample for ssNMR needs to be prepared as such that the peptide 
possesses as few orientations as possible to avoid line broadening. Thus, the sample was prepared as 
concentrated as possible to render the detection of the peptide possible whilst maintaining an 
appropriate peptide to lipids ratio, for the peptide to be fully integrated with the LUVs without 
precipitation. The ideal molar peptide to lipids ratio was found to be 1:80. Figure 5-11 validated the 
choice of the 1:80 ratio by showing the peptide proton signal disappearance, due to the change of 
molecular tumbling, when in presence of LUVs. In order to perform a comparison of the solution 
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NMR to the ssNMR as fairly as possible, the same buffer was chosen, 20 mM Bis-Tris pH 6.5, 50 
mM NaCl. 
 
 
Figure 5-11 – 1H solution NMR of 15N-AA139 at 93 μM free in solution (blue) and in presence of LUVs at 7.5 mM 
(molar ratio peptide:lipids 1:80) (red) in 20 mM Bis-Tris pH6.5, 50 mM NaCl. 
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Figure 5-12 – (A) 1H-15N CP with water suppression ssNMR experiment of 15N-AA139 in presence of LUVs at 
molar ratio 1:80 in 20 mM Bis-Tris pH6.5, 50 mM NaCl. (B) Zoomed 1H-15N superimposed spectra (A) in blue and 
15N-AA139 in free solution (red) in 20 mM Bis-Tris pH6.5, 50 mM NaCl. 
 
 
Figure 5-12 (A) shows the 1H-15N CP with water suppression ssNMR experiment of 15N-AA139 in 
presence of LUVs at molar ratio 1:80 in 20 mM Bis-Tris pH 6.5, 50 mM NaCl. Peaks in the right 
region for a peptide were observed, however the signal to noise ratio was poor and therefore limited 
the spectral interpretation. Figure 5-12 (B) shows 1H-15N superimposed spectra of 15N-AA139 in free 
solution (red) and in presence of LUVs at molar ratio 1:80 (blue) in 20 mM Bis-Tris pH 6.5, 50 mM 
NaCl. Even with the poor signal to noise ratio of the ssNMR spectra, we can clearly see that both set 
of peaks are not superimposing and therefore reflect a different secondary structure of AA139 when 
free in solution compared to in presence of LUVs that are representative of a bacterial membrane. 
The ssNMR spectra displayed peaks in the region of random coil secondary structure, as opposed to 
A 
B 
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the solution NMR free state, which demonstrated a fully structured β-hairpin AA139. These results 
could mean that the peptide loses its well defined 3D structure when inserting in the liposomes.  
DLS was performed to evaluate the size of the LUVs in absence and presence of AA139. The results 
are detailed in Table 5-7 and the volume distribution versus the size of the particle can be found in 
Appendix V, Figure S7.5-10. In both samples, the distribution is very mono-disperse, with one single 
peak observed. The Z-average diameter distribution increased from 118.5 ± 0.8 nm to 135.6 ± 1.2 nm 
when LUVs are put in presence of AA139 at a ratio 80:1. The results support that AA139 interacts 
with the LUVs but does not promote aggregation at a peptide/lipid ratio of 1:80, however they seem 
to increase the size of the LUVs most likely by sitting on the surface or inserting in the particle and 
slightly expanding their diameter. 
 
Table 5-7 - DLS results showing the Z. average and volume mean of LUVs in absence and presence of AA139 (ratio 
80:1) 
Sample Z. Ave (nm) Volume mean (nm) 
LUVs [POPC/POPG (4:1)] 118.5 ± 0.8 111.2 ± 1.0 
LUVs [POPC/POPG (4:1)] + AA139 (ratio 80:1) 135.6 ± 1.2 132.8 ± 8.1 
 
  
Chapter 5 – Structural AA139 MoA 
 
 5-110 
5.3 Materials and methods 
Material. Synthetic lipids palmitoyloleoyl-phosphatidylcholine (POPC) and palmitoyloleoyl-
phosphatidylglycerol (POPG) were purchased from Avanti Polar Lipids (Alabaster, AL). All 
chemicals were used without further purification. 
Recombinant expression of 15N, 13C labelled arenicin-3 and AA139. 
Arenicin peptide expression in Escherichia coli 
Recombinant isotopically single and double labelled (15N and 15N/13C) arenicin-3 or AA139, were 
expressed from a His6-tagged SUMO fusion protein in Escherichia coli shuffle strain cells. The 
plasmid construct for arenicin-3 and AA139 expression was designed by myself and Zhenling Cui, 
respectively. The gene fragment containing optimized codons for His6-SUMO-peptide as well as 5’- 
and 3’- overlap to pOPINE plasmid was synthesized by IDT. Recombinant plasmid pOPINE-His6-
SUMO-peptide was constructed by ligating the NotI/XhoI double digested pOPINE plasmid with the 
synthesized gene fragment. The plasmid contains the T7 promoter, the ribosome-binding site while 
the gene insert encodes the fusion protein with His6-tag at N-term, plasmid vector represented in 
Figure 5-13.  
 
Figure 5-13 - Schematic representation of the expression vector. Schematic representation of the pOPINE-SUMO 
expression vector used for cytoplasmic expression of disulfide-rich peptides in an E. coli shuffle strain. The coding region 
includes a His6 tag for affinity purification, a SUMO fusion tag to aid solubility and a codon-optimized gene encoding 
the target peptide. The location of key elements of the vector are shown, including the T7 promoter and lac operator.  
 
Plasmid purification (QIAGEN Plasmid Purification Kit) and transformation were performed 
according to the standard commercial protocol. After transformation, the clones containing the correct 
gene insert were screened for and confirmed by sequencing. The E. coli shuffle cells (NEB) 
transformed with pOPINE-His6-SUMO-AA139 were grown in 10 mL of LB media with 100 µg/mL 
of ampicillin at 37 °C with shaking at 220 rpm until OD600 reached late exponential phase (OD600 = 
0.8). The culture was then transferred to 50 mL of Minimum Media (MM) with 100 µg/mL of 
ampicillin supplemented with 15NH4Cl and/or 13C-D-glucose and grown at 37 °C with shaking at 250 
rpm overnight. The culture was then transferred in 2 L of MM with 100 µg/mL of ampicillin and 
grown at 37 °C with shaking at 250 rpm until OD600 = 0.8. The culture was then cooled down at 20 
°C, followed by induction by adding 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 20 °C 
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with shaking at 250 rpm overnight. The expression level of His6-SUMO-peptide was monitored using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
Comments:  
- Prior to the design of the pOPINE-His6-SUMO-AA139 construct, a different construct was 
designed, taking example of the design presented by Klint et al.,14 for disulfide rich peptides. 
With the presence of a MalE signal sequence in the coding region, the fusion protein is 
transported to the periplasm via the Sec translocase system. MalE is removed during this 
process releasing the fusion protein into the periplasm where the Dsb machinery (DsbA, 
DsbB, DsbC and DsbD) can assist with disulfide bridge formation. Synthetic genes encoding 
the arenicin peptides with codon optimization for expression in E. coli were cloned into 
variant of the pLic-MalE-His6-MBP-peptide expression vector by Lifescience Technology, 
Geneart AG (Regenburg, Germany). The production of arenicin peptides was attempted using 
various E. coli strains (BL21(DE3), BL21(DE3) gold, BL21(DE3) C43, BL21(DE3) C4115, 
BL21(DE3) RP, BL21(DE3) RIL, BL21(DE3) Star, Rosetta-gami(DE3), Rosetta-gami 
B(DE3), Rosetta 2(DE3), Rosetta blue (DE3) and NEB NiCO21 (Wk6) without success. In 
all attempted experiments, the fusion protein was retained in the insoluble part of the cell, 
trapped in the inclusion bodies. This had previously been observed for the recombinant 
production of arenicin-1 and arenicin-2 by Ovchinnikova et al.16 Thus various attempts were 
trialed to retrieve the protein from the inclusion bodies using detergent, without success.17 
- With pOPINE-His6-SUMO-AA139 made first, it was thought that pOPINE-His6-SUMO-
arenicin3 could be constructed using Direct Mutagenesis with the Q5 kit from NEB using 
deletion/insertion PCR methodology. However, after several repeats, the mutagenesis was 
never fully complete and the construct could not be made. Therefore, pOPINE-His6-SUMO-
arenicin-3 was eventually constructed using the same ligation method previously used for the 
construction of pOPINE-His6-SUMO-AA139.  
- The Minimum Media composition was optimized for better yield, see final composition 
below, Table 5-8 and Table 5-9. Due to the high percentage of D-glucose, the shaking speed 
was increased to 250 rpm to ensure enough available oxygen for optimal cell growth.  
 
Table 5-8 - M9 media recipe 
M9 media (5X) Mass (g) to make 1 L solution 
KH2PO4 15 
Na2HPO4 64 
NaCl 5 
Make up to 1L with H2O and adjust the pH to 7 before autoclave 
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Table 5-9 - Minimum media recipe 
Minimum media Volume (mL) to make 1 L solution 
M9 (1X) 1000 
MEM Vitamin Solution (100×) 10 
Thiamine (40 mg/mL) 2 
MgSO4 (1 M) 1.6 
CaCl2 (1 M) 0.08 
(15N)NH4Cl (0.25 mg/mL) 4 
(13C)D-glucose (0.2 g/mL) 50 
Ampicillin (100 mg/mL) 1 
    
Fusion protein purification and cleavage 
The cells were harvested by centrifugation at 7000 rpm for 30 min at 4 °C and resuspended in buffer 
containing 150 mM sodium phosphate buffer (pH 8), 300 mM NaCl, 20 mM imidazole, EDTA-free 
protease inhibitor cocktail. The cells were then disrupted using a cell disruptor at 27 KPsi for 1 cycle 
and subjected to centrifugation at 20000 rpm for 30 min at 4 °C. The supernatant was applied to two 
attached 5 mL Histrap FF prepacked columns on a FPLC (AKTA instrument). The recombinant 
protein was eluted with 0.5 M imidazole and the fractions corresponding to the fusion protein were 
collected and concentrated using Amicon 3 kDa. Buffer exchange was performed by dialysis using 
6-8 kDa MW cut off membrane for 6 h against 2 L of the cleavage buffer of 50 mM Tris-HCl (pH 8), 
150 mM NaCl. SUMO protease was then used for the cleavage of the fusion protein with a (w/w) 
ratio of 1:50, shaking overnight at 4 °C. 
Comments: 
- Throughout the purification and cleavage process, glassware should be used to handle fusion 
protein and protein alone as arenicin peptides are highly adsorbent on plastic. Thus, the use 
of plastic containers would highly reduce production yield. 
AA139 purification by HPLC 
The solution was loaded onto a Gilson HPLC system using C18 column (Zorbax® C18, 9.4 x 100 
mm, 5 um) equilibrated with solution A (0.1% trifluoroacetic acid). The chromatography was 
performed at a flow rate of 3 mL/min with a linear gradient of solution B (100% acetonitrile, 0.1% 
trifluoroacetic acid): 5% for 6 min, 5–50% for 16 min, 50–100% for 4 min, 100% for 2 min and 5% 
for 3 min. The peaks monitored at 210 nm were collected and lyophilized. The lyophilized product 
was then analyzed by LC-MS using Agilent Technologies 1200 Series Instrument with a G1316A 
variable wavelength detector set at λ= 210 nm, 1200 Series ELSD, 6110 quadrupole ESI-MS, using 
an Agilent Zorbax Eclipse XDB-Phenyl (3 × 100mm, 3.5 μm particle size, flow rate 1 mL/min, the 
mobile phases 0.05% formic acid in water and 0.05% formic acid in acetonitrile). 1H and 1H-15N-
HSQC NMR spectra were assessed for comparison to the synthetic material.  
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Comments: 
- After the cleavage step, it is of common practice to remove the affinity tags before performing 
the HPLC step. This can be achieved by applying the cleaved mixture solution to a Ni-NTA 
column (5 mL Histrap FF prepacked). However, the arenicin peptides were highly retained 
by the Ni-NTA beads and only a tiny percentage of the peptide would be released leading to 
very poor yield. Another method was attempted; the addition of 1% TFA to the cleavage 
mixture solution, however this resulted in co-precipitation of the peptide with the tags and 
therefore the purification could not be pursued. By avoiding that step completely, the yield of 
0.125 mg/L of culture using the reverse purification method by Ni-NTA, increased 
dramatically to 0.75 mg/L of culture, leading to a total of 6-fold increase in the yield.14 
Nanodiscs preparation. MSP1D1Δh5 was cloned by PCR mutagenesis to incorporate the DNA 
encoding for the C-terminal LPGT motif to create the cNW9 construct. MSP1D1Δh5 and cNW9 were 
recombinantly expressed in E. coli BL21(DE3) cells from a pET29 vector as a 6-histidine fusion 
protein and purified on a metal affinity column (Ni-NTA). cNW9 was circularized using sortase A 
inhibition approach.10 cNW9 labelled and non-labelled protein were expressed, purified and 
circularized by Alan Zhang.  
To assemble nanodiscs with different lipid compositions, MSP1D1Δh5 or cNW9 protein and lipids 
were co-dissolved in reconstitution buffer (20 mM Tris.HCl pH 7.4, 100 mM NaCl, 0.5 mM EDTA 
and 100 mM Cholate) and mixed for 1 h at 4 °C. Molar ratio of 1:50 (membrane scaffold protein 
(MSP) / lipids) was taken according to the surface area of such type of lipids used, using the equation: 
NL•S = (0.423•M-9.75)2 with the number of lipids per Nanodisc, NL, the number of amino acids in 
the scaffold protein, M and S, the mean surface area per lipid used to form the Nanodisc, measured 
in Å2.18 POPC and POPG have been estimated with similar mean surface area at around 70 Å2.19 0.6 
mg/(mL of reaction) of Bio-Beads SM-2 (Bio-Rad #152-3920) were added to absorb the cholate 
detergent. The mixture was gently shaken for 4 h at 4 °C. The solution was filtered through a 0.45 
µm filter to remove the Bio-Beads and then concentrated to 5 mg/mL (unless otherwise stated) using 
an Amicon 10 kDa at 4 °C and 3000 g. Size exclusion chromatography was performed to ensure the 
homogeneity of the sample using a Superdex S200 5/150 gel filtration column pre-equilibrated in 20 
mM Tris-HCl pH 7.5, 150 mM NaCl. 
Nanodiscs stability study. ND were assembled in 20 mM Tris.HCl pH 7.4, 100 mM NaCl, 0.5 mM 
EDTA and 100 mM cholate buffer and detergent was removed using Biobeads SM2. The ND 
solutions were filtered and subjected to buffer exchange on a PD10 column in three different buffer 
conditions. The buffers were chosen following the literature7,20 and NMR titration requirements; (i) 
20 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM EDTA reducing the salt composition of the original 
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assembly buffer for ease in NMR experiments, (ii) 20 mM Bis-Tris pH 6.5, 50 mM NaCl, 1 mM 
EDTA reducing the pH of the original buffer in case of exchangeable amide protons in the studied 
protein and (iii) 20 mM PO4 pH 6.5, 50 mM NaCl, 1 mM EDTA reducing the pH the same way as 
the buffer (ii) without having any interfering proton signal due to the presence of the Bis-Tris. SEC 
was then performed to follow the homogeneity of the sample using a Superdex S200 5/150 gel 
filtration column pre-equilibrated in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, over several days. The 
detailed study was performed using Superdex S200 10/300 column pre-equilibrated in 20 mM Tris-
HCl pH 7.5, 150 mM NaCl. 
Solution NMR measurement. Solution NMR titration experiments between 15N-AA139 and 
ND[cNW9(POPC/POPG(4:1))] were performed on a Bruker Avance III spectrometer equipped with 
a cryogenically cooled triple resonance probed operating at a nominal 1H frequency of 700 MHz. 15N-
HSQC were recorded at 25 °C. Solution NMR titration experiments between AA139 and ND[15N-
cNW9(POPC/POPG(4:1))] were performed on a Bruker Avance III spectrometer equipped with a 
cryogenically cooled triple resonance probed operating at a nominal 1H frequency of 900 MHz. 
TROSY were recorded at 50 °C. 
Dynamic light scattering (DLS). Dynamic light scattering experiments were carried out at 20 °C 
with DNYAPRO-99 (Wyatt). Size distribution was calculated with the Wyatt software.  
Electron microscopy (EM). Nanodiscs were diluted to a final concentration of 200 nM in 20 mM 
Tris–HCl, pH 7.5, 50 mM NaCl and adsorbed to glow-discharged, carbon-coated EM grids. Samples 
were prepared by conventional negative staining with 1 % (w/v) uranyl acetate. EM images were 
collected with a Tecnai 12 electron microscope operated at an acceleration voltage of 120 kV. 
Liquid Chromatography – Mass Spectrometry (LC-MS). LC-MS analysis were conducted using 
Agilent Technologies 1200 Series Instrument with a G1316A variable wavelength detector set at λ= 
210 nm, 1200 Series ELSD, 6110 quadrupole ESI-MS, using an Agilent Zorbax Eclipse XDB-Phenyl 
(3 × 100mm, 3.5 μm particle size, flow rate 1 mL/min, the mobile phases 0.05% formic acid in water 
and 0.05% formic acid in acetonitrile).  
Solid-state NMR.  
Lipid bilayer vesicles preparation 
LUVs (100 nm diameter) were used as a membrane model and prepared by extrusion method as 
previously described.21 The synthetic lipids were used to prepare model membranes composed of 
POPC, POPC/POPG (4:1 molar ratio). 
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Solid-state NMR measurement 
All solid-state NMR experiments were performed on a Bruker spectrometer operating at a nominal 
1H frequency of 800MHz. The probe used was a wide bore probe for very fast MAS of 60 KHz and 
a 1.3 mm rotor. Temperature of the sample was 18 °C.  
 
5.4 Conclusion 
The aim of this study was to evaluate the mode of action of AA139 toward G-ve bacterial cell 
membranes. A computational modelling study provided an experimental speculation of the 
orientation of the peptide at the interface with the cell membrane, proposing a slight angle of contact. 
Then, in order to perform solution NMR characterization, recombinant expression was used to 
produce labelled AA139, which was then purified via a novel method to produce correctly-folded 
arenicin peptide in E. coli. At the same time, the stability of two ND types were evaluated, concluding 
that cNW9 ND was the most stable construct over MSP1D1ΔH5, the most commonly construct 
currently used. cNW9 ND remained highly stable under all conditions tested; including different 
buffer conditions, pH, temperature and even over relatively long lengths of time (up to 30 days). This 
cNW9 ND construct was then used to perform a solution NMR titration experiment with 15N-AA139. 
The results identified the N- and C-terminal ends of AA139 as the likely first points of contact with 
the lipid bilayer bacterial model membrane, with a Kd value of around 0.3 µM. The preliminary work 
performed using ssNMR suggested that AA139 loses its well-defined 3D structure upon insertion in 
the hydrophobic core of the membrane. This is consistent with the solution state titration studies that 
also reveal that several residues in the hairpin region undergo broadening due to exchange other than 
binding interactions. The consensus outcome suggests that the peptide termini bind to the bilayer and 
that this causes a change in the conformation of the hairpin region which destabilizes the overall 3D 
structure of the peptide in the membrane. 
The structural mode of action study of AA139 allowed us to refine the model of mechanism of action 
proposed in chapter 4. The refined model, Figure 5-14, includes now the orientation of the peptide 
toward the lipid bilayer upon interacting (determined by solution NMR) and upon insertion 
(preliminary data generated by ssNMR). In summary, 1) AA139 binds to the negatively charged outer 
membrane of G-ve bacteria via electrostatic interactions with a slight angle from its N- and C-terminal 
ends; 2) AA139 inserts into the hydrophobic core of the outer membrane creating partial 
permeabilization most likely losing its well defined 3D structure and 3) AA139 accesses and 
permeabilizes the cytoplasmic membrane.   
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Figure 5-14- Refined proposed model of mechanism of action for AA139 against Gram-negative bacteria cell 
membranes. 1) AA139 binds to the negatively charged outer membrane of G-ve bacteria via electrostatic interactions 
with a slight angle from its N- and C-terminal ends; 2) AA139 inserts into the hydrophobic core of the outer membrane 
creating partial permeabilization, while most likely losing its well defined 3D structure and 3) AA139 accesses and 
permeabilizes the cytoplasmic membrane.   
 
 
This work confirms the great potential of nanodiscs to study the mode of action and the structural 
characterization of membrane active peptides. The first Kd value was determined using a solution 
NMR titration experiment to evaluate the binding interaction between the antimicrobial peptide and 
the lipid bilayer nanodisc. The Kd value could be evaluated using other techniques such as ITC, but 
the structural information would be lost. More experiments need to be performed to determine the 3D 
structure of AA139 whilst interacting with the lipid bilayer model membrane. As mentioned by 
Ramamoorthy22, the study of membrane-active peptides in lipid bilayers can be very challenging for 
NMR measurements. While physiological conditions would seem to be more relevant for this type of 
study to provide meaningful insights into the biological function of these membrane active peptides, 
those conditions may not be suitable for NMR measurements. This has often led to the use of modified 
sample conditions or the use of lipid model membranes that poorly mimic the cell complexity. 
Gramicidin-A was the first antimicrobial peptide whose 3D structure, integrated in oriented 
phospholipid bilayers, was determined by solid state NMR and reported in the protein databank.23 
Since then, the structure of other antimicrobial peptides have been studied with various tools and lipid 
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environment. The most recent high-resolution structure of β-hairpin AMPs was performed for 
thanatin in lipopolysaccharide micelles using solution NMR.24 However, no one to date has achieved 
the structural characterization of AMPs in lipid bilayers by solution NMR. Seeing the tremendous 
potential that nanodiscs offer, the 3D solution NMR structure of AMPs in a lipid bilayer environment 
would be the next step forward. This would allow us to visualize the true structure of AMPs while 
integrated in the cell membrane and allow for the design of therapeutically valuable peptides. 
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Chapter 6    –   Conclusions and 
future directions 
 
6.1 Conclusions 
Antimicrobial resistance is a worldwide concern affecting not only the human population but animal, 
food and the environment. Solutions for new therapies need to be devised and engineered as quickly 
as possible. AMPs have great potential due to their broad spectrum of antimicrobial activity and their 
very limited propensity to induce bacterial resistance observed to date. Although discovered more 
than 80 years ago, very few have reached the market so far (Gramicidin for instance is one of the rare 
one)1, due to their high cost of production and their poor stability in human plasma as well as during 
storage. This thesis offers extensive research on the β-hairpin AMPs as replacement therapies for 
obsolete antibiotics against Gram-negative bacterial pathogens.  
This study started its investigation by evaluating the relationship between physicochemical and 
antimicrobial properties of β-hairpin AMPs. The panel of six β-hairpin AMPs (arenicin-3, 
tachyplesin-1, polyphemusin-1, gomesin, protegrin-1 and thanatin) was selected as a representation 
of the β-hairpin AMP family, due to their sequence length, number of disulfide bridges and their 
general antimicrobial properties. The findings of this investigation revealed a very complex 
equilibrium between all properties of their primary, secondary and tertiary structures and their mode 
of action. Of note, the amphipathic character of the peptides seemed to play an important role on their 
antimicrobial activity; the more amphipathic, the more active the peptide becomes.  
This first study allowed us to gain a general knowledge and background on the β-hairpin AMPs. 
However, the underlying goal of the thesis is to understand the function and mode of action of β-
hairpin AMPs in order to design new and improved therapeutic peptide antimicrobials. To do so, two 
approaches were investigated: (i) the classical mutagenesis approach evaluated with the study of 
tachyplesin-1 and (ii) the comprehensive mode of action characterization of the lead drug candidate, 
AA139.   
Our initial comparative study identified tachyplesin-1 as the most promising lead drug candidate for 
further development due to its 8-fold higher therapeutic index than the other peptides studied. This 
finding led the study of tachyplesin’s structure-function and structure-toxicity relationships with the 
aim of designing novel therapeutically valuable peptides. An alanine scan of tachyplesin-1 was 
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performed along with selective positional modifications to assess the significance of each amino acid. 
The evaluation of the therapeutic properties of each tachyplesin-1 analog in combination with early 
ADME studies and structural characterization revealed two newly designed peptides, TP1[F4A] and 
TP1[I11A] with 40- and 64-fold improved antimicrobial activity / toxicity indexes over tachyplesin-
1, respectively. Their high microbial potency and relatively low mammalian toxicity, render 
TP1[F4A] and TP1[I11A] very attractive as potential drug candidates for the treatment of infections 
caused by bacterial and/or fungal pathogens. Further bioavailability, pharmacokinetics and in vivo 
assays will be required to validate their full potential as novel antibiotics.     
The mode of action study focused on arenicin-3 and its synthetic analog, AA139, which is a lead drug 
candidate developed by Adenium Biotech Ltd, currently in preclinical development for MDR urinary 
tract infection and pneumonia. This study aimed to understand how simple amino acid mutations can 
drive one peptide to be toxic but lead to a closely related analog to be developed as a lead drug 
candidate. Their 3D structures were characterized by solution NMR, identifying two β-hairpin 
peptides with a right-handed twist that were almost completely superimposable. However, the number 
of stabilizing interactions along the β-sheets, identified AA139 as a more flexible structure as 
compared to arenicin-3. Their mode of action was first investigated via label free assays using vesicles 
as a lipid bilayer model. Assays such as binding affinity, aggregation, permeabilization, insertion and 
surface charge potential of vesicles were evaluated. The results demonstrated that both arenicin 
peptides bind, permeabilize and insert into negatively charged lipid vesicles (POPC/POPG). AA139 
promoted less vesicle aggregation than arenicin-3. It inserts its N-terminus or tryptophan deeper into 
the hydrophobic core of the negatively charged lipid bilayer model membrane than zwitterionic ones 
as compared to arenicin-3. These results correlate well with the difference observed for the toxicity 
of arenicin peptides against mammalian cells, with AA139 displaying reduced hemolytic activity as 
compared to arenicin-3. Surface charge potential and permeabilization assays were performed using 
E. coli cells. The results suggested that arenicin peptides act on the membrane of E. coli cells by 
neutralizing the outer membrane and permeabilizing the cytoplasm. However, the AA139 rate of 
permeabilization differed from arenicin-3, suggesting a different mode of action.  
Nonetheless, the question remained, which part of the peptide is specifically involved in the 
membrane interaction and what happens next? This was investigated with assays employing 
isotopically labelled peptides. A novel method was developed for recombinantly expressing and 
purifying 15N labelled arenicin peptides, allowing their use for solution and solid-state NMR. The 
solution NMR titration experiment, using novel nanodisc constructs, evaluated which AA139 amino 
acid was involved in the interaction with this lipid bilayer model. The results identified that the N- 
and C- terminal ends of the peptide were likely the first point of contact with the lipid bilayer, and 
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suggested that the β-hairpin loop of the peptide undergoes a conformational change upon binding. 
Furthermore, preliminary work performed using solid-state NMR and vesicles suggested that AA139 
loses its well-defined 3D structure upon insertion in the hydrophobic core of the membrane.  
The mode of action study of AA139 allowed us to propose a model of mode of action, Figure 5-14. 
In summary, 1) AA139 binds to the negatively charged outer membrane of Gram-negative bacteria 
via electrostatic interactions with a slight angle from its N- and C-terminal ends; 2) AA139 inserts 
into the hydrophobic core of the outer membrane, creating partial permeabilization while most likely 
losing its well defined 3D structure; and 3) AA139 accesses and permeabilizes the cytoplasmic 
membrane.  
This suggested mode of action against Gram-negative bacteria may be enough for AA139 to disrupt 
its membrane target and to promote inactivation of the bacterial cells. However, as seen for numerous 
other antimicrobial peptides, its mode of action may not only be due to membrane disruption, but 
linked with a dual mode of action, as suggested by the slope of the E. coli cytoplasm permeabilization 
assays.        
Natural AMPs offer great potential for the fight against resistant bacteria.  So far, most attempts to 
produce antimicrobial candidate from AMPs have been focused on α-helical AMPs, however, these 
have not yet led to any major clinical success. The redesign of natural β-hairpin AMPs, tachyplesin-
1 and arenicin-3, produced two examples of analog peptides, possessing improved therapeutic 
qualities suitable for further drug development. AA139 has progressed into late stage pre-clinical 
development for urinary tract infection and pneumonia diseases. We could postulate that β-hairpin 
AMPs might provide better selectivity than with α-helical AMPs due to their mode of action, allowing 
for better differentiation from cytotoxic effects.  Similar strategies for peptide reengineering, as 
conducted here for tachyplesin-1 and arenicin-3, should be investigated for other potential 
antimicrobial peptides.       
      
6.2 Future directions 
To further understand the mechanism of action of AA139 and its behavioral difference between 
mammalian and bacterial cell membrane, it would be interesting to extend the solid-state NMR 
experiments attempted with the use of nanodiscs for instance and characterize its 3D structure when 
embedded in the membrane. Reverse solid-state NMR experiments, like 31P and 2H would be also 
valuable to evaluate the effect of the peptide on the lipid membrane.2 Other more futurist experiments 
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could also be considered, like in-cell NMR experiments using live bacteria and mammalian cells, 
which has already been reported for few proteins.3    
The mode of action studies of peptides and proteins against cell membrane targets requires lipid 
bilayer model membranes. However, lipid bilayer model membranes do not have the same size and 
membrane curvature as the target organisms. Indeed, lipid model bilayer membranes, usually range 
from 100 nm (LUVs) to 8 nm (nanodiscs) diameter, and bacteria cells are about 3 µm (E. coli) and 8 
µm (red blood cells) in size. This 10-fold difference in size may affect the AMPs behavior and could 
biased their mode of action results. The membrane curvature is significantly different between cells 
and LUVs/SUVs, purely due to their size and their spherical constraints. However, thanks to the non-
spherical property of the nanodiscs, the latter are better reflecting the curvature of the cell membranes 
and more closely mimic the natural radius of the different cells.       
This thesis explored the great potential that newly developed nanodiscs could have on these type of 
studies. However, not all nanodisc constructs can be used under any condition. The stability studies 
of nanodiscs performed in this thesis demonstrated the risk involved in the length of storage, 
temperature and buffer conditions, on retaining the structure of these intricate lipid bilayer model 
membranes. This study also highlighted the commensurate improvement made with the use of a 
circularized nanodisc construct, using cNW9 membrane scaffold protein. This construct remained 
stable under all tested conditions, including length of time and buffer storage conditions, pH and 
temperature. The circularized nanodisc construct was tested here using two different compositions of 
phospholipids, POPC and POPC/POPG (4:1), mimicking mammalian and bacterial cell membranes, 
respectively. Nanodiscs are one of the most advanced model membrane systems used today, 
mimicking as closely as possible the cell membranes. However, this mimic replacement provides 
only a very simplistic model of the true membrane composition complexity. Thus, one could imagine 
building a nanodisc composed not only of the cNW9 MSP, offering tremendous stability, but also 
with directly extracted cell membrane, constituting the lipid bilayer. Preliminary work has explored 
the possibility of such nanodisc constructs. Material and methods can be found in Appendix V, page 
7-265.  
Results. The lipid membranes of both E. coli ATCC 25922 and red blood cells were extracted and 
characterized to evaluate the lipid type as well as the amount of proteins extracted. The mass 
spectrometry, Figure 6-1, Figure 6-2 and Figure 6-3, demonstrated the success of the lipid extraction 
for both cell types. In E. coli, the presence of POPG, POPE and cardiolipins were identified. In red 
blood cells, POPC and sphingomyelin were identified. Cholesterol could not be observed under these 
conditions due to the ionization mode used, cholesterol only ionizes in positive mode.  
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Figure 6-1 - E. coli lipid extract of phospholipids characterized by MS-TOF in negative mode ionization. 
MW(POPG 32:1) = 720.5 Da, MW(POPG) = 734.5 Da, MW(POPG 34:1) = 748.5 Da and MW(POPG 36:2) = 774.5.  
 
 
Figure 6-2 - E. coli lipid extract of cardiolipins characterized by MS-TOF in negative mode ionization.  
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Figure 6-3 – Red blood cells lipid extract of phospholipids characterized by MS-TOF in negative mode ionization. 
MW(sphingomyelin) = 688.5 Da and MW(POPC) = from 716 to 796 Da.  
  
To quantitate the protein concentration extracted alongside the lipids in both E.coli and RBC 
solutions, a bicinchoninic acid (BCA) assay was performed, Figure 6-4. The substantial amount of 
proteins extracted alongside the lipids confirm the extraction of a full complex lipid bilayer of both 
cell membranes.  
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Figure 6-4 - BCA protein assay. For E. coli and RBC the concentration of proteins in their respective solutions were 
175 and 254 μg/mL, respectively.    
 
The membrane extraction produced solution mixtures of lipids, which were hard to quantitate, and 
proteins, which were hard to qualitatively identify. The bottleneck of such membrane extractions 
reside in the fact that the extract cannot be well quantified. Thus, nanodisc production with membrane 
extracts will be difficult to achieve due to the crucial ratio lipid to MSP required for the auto-
formation of the nanodisc. However, one could imagine that the lipid to MSP ratio was only essential 
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when the MSP was linear. Now using the circularized MSP (cNW9 for example), the circle is already 
formed and only the lipid bilayer needs to get integrated. The use of the circular MSP reduces the 
auto-formation steps of the nanodisc. Using an excess amount of lipids, or membrane extract, will 
probably not affect the formation of the nanodisc but only the propensity of the nanodisc to aggregate. 
Further experiments and quality control tests would validate or revoke the idea of novel nanodiscs 
formed by membrane extracts. The latter could revolutionize the mode of action study of peptides, as 
direct membrane would be used instead of a model mimicking only partially the original. 
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Figure S7.2-1 - Amino acid frequency of β-hairpin AMPs. The amino acid frequency graph has been done using 
Seq2logo 2.0 server, using P-Weighted Kullback-Leibler logo type and Hobohm 1 clustering method with 0.63 
threshold and pseudo counts of 200. 
 
Amino acid frequency graph was performed using Seq2logo 2.0 server online tool. It is a graphical 
representation of the sequence conservation of amino acids, showing how well residues are 
conserved at each position within the β-hairpin AMP family. The relative size of the letters 
indicates their frequency in the compared sequences. As already observed in the standard 
alignment, the most prominent amino acid represented in the frequency graph is the last cysteine 
of the peptide sequences, which is the most conversed residue in all β-hairpin AMPs studied here. 
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Figure S7.2-2 - Hemolysis activity (%) of β-hairpin compounds tested from 0.1 to 300 μg/mL. 
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Detailed Methodologies 
Antibacterial assay (Minimum Inhibitory Concentration [MIC]). MIC assay was performed 
by a broth microdilution plate based method as per CLSI guidelines for antimicrobial susceptibility 
testing of aerobic bacteria.1 Compounds were prepared at 1.28 mg/mL solution in water. The tested 
strains, Table S1, were cultured in Luria broth (LB) (In Vitro Technologies, USB75852), at 37 °C 
overnight. A sample of culture was then diluted 40-fold in fresh Muller Hinton broth (MHB) 
(Bacto laboratories, 211443) and incubated at 37 °C for 1.5-2 h. The compounds were serially 
diluted two-fold across the wells, with compound concentrations ranging from 0.015 μg/mL to 512 
μg/mL, plated in duplicate. The resultant mid-log phase cultures were diluted to the final 
concentration of 1×106 CFU/mL, then 50 µL was added to each well of the compound-containing 
96-well plates (Corning 3641, Non-binding Surface [NBS]), giving a final compound 
concentration range of 0.008 μg/mL to 256 μg/mL and 5x105 CFU/mL. All the plates were covered 
and incubated at 37 °C for 18 h. MICs were determined visually, being defined as the lowest 
concentration showing no visible growth. Resazurin was added at 0.001% final concentration to 
each well and incubated for 2 h before MICs were re-read for confirmation using the colour change 
from blue to pink to indicate wells containing viable cells. The resazurin assay was added in some 
wells where some form of precipitate was present in otherwise clear wells, making it difficult to 
ascertain which wells had visible growth.  
Antifungal assay (Minimum Inhibitory Concentration [MIC]). MIC assay was performed by 
a broth microdilution plate based method as per CLSI guidelines for antimicrobial susceptibility 
testing.2 Fungi strains, Table S1, were cultured for 3 days on Yeast Extract-Peptone Dextrose 
(YPD) (Sigma-Aldrich, Y1500) agar at 30 °C. A yeast suspension of 1x106 to 5x106 CFU/mL was 
prepared from five colonies. These stock suspensions were diluted with Yeast Nitrogen Base 
(YNB) (Becton Dickinson, 233520) broth to a final concentration of 2.5 ×103 CFU/mL. All 
samples, compounds and standards were plated in 96-well plates (Corning 3641, Non-binding 
Surface [NBS]), by adding 10 μL of 1.28 mg/mL stock solution to each well and 90 μL of media. 
Then, the samples were serial diluted (1:2) in 12 concentrations across the plate. The standard 
antifungal ranged from 256 μg/mL to 0.12 μg/mL and compounds from 128 μg/mL to 0.06 μg/mL 
with final volumes of 50 μL per well, plated in duplicate. Then, 50 μL of the fungi suspension that 
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was previously prepared in YNB broth to the final concentration of 2.5×103 CFU/mL, was added 
to each well of the compound-containing plates, giving a final standard compound concentration 
range of 128 μg/mL to 0.06 μg/mL and tested compound from 64 μg/mL to 0.03 μg/mL. Plates 
were covered and incubated at 35 °C for 24 h. Candida albicans MICs were determined by 
measuring the absorbance at OD530. For Cryptococcus neoformans 10 μL of 0.06 % resazurin were 
added to the 24 h incubated plates. Then, these plates were incubated for another 3 h. Cryptococcus 
neoformans MICs were determined by measuring the absorbance at OD570-600. 
 
Table S7.2-1 – Microbial strains and cell line used for the antimicrobial assay. 
Organism Strains Comment 
Escherichia coli ATCC 25922 FDA control, CLSI QC Strain 
Escherichia coli MB 4902 ∆lpxC mutant 
Escherichia coli ATCC 700926 MG 1655; K12 substr 
Klebsiella pneumoniae ATCC 700603 Multi-drug Resistant (MDR) 
Klebsiella pneumoniae ATCC 13883 Type strain 
Klebsiella pneumoniae ATCC BAA-2146 New Delhi Metallo-beta-
lactamase-1 (NDM-1) positive 
Acinetobacter baumannii ATCC 19606 Type strain 
Pseudomonas aeruginosa ATCC 27053 Quality Control strain 
Bacillus subtilis ATCC 6051 Type strain 
Staphylococcus aureus ATCC 43300 Methicillin Resistant 
Staphylococcus aureus (MRSA) 
Candida albicans ATCC 90028 CLSI reference strain 
Cryptococcus neoformans 
var grubii 
ATCC 208821 H99, Type strain 
HepG2 ATCC HB-8065 Hepatocellular carcinoma liver 
cells  
HEK293 ATCC CRL-1573  Embryonic kidney cells  
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Cytotoxicity. Cytotoxicity to HEK293 and HepG2 cells was determined using the Alamar Blue 
(resazurin) assay,3, 4 For the assays supplemented with 1 % FBS as final concentration the cells 
were seeded one day prior to the assay (3,000 per 20 µL for HEK293 and 4,000 per 20 µL for 
HepG2) with DMEM + 2 % FBS. The compounds were prepared as described below, using 
DMEM with no FBS instead to give the final FBS concentration of 1 %. 
The highest concentration the compounds were tested was 300 µg/mL. A dilution series of 1:3 fold 
steps in DMEM (GIBCO-Invitrogen, cat. no. 11995-073) + 10 % FBS was created (concentration 
range of 600 µg/mL – 0.28 µg/mL), and 20 µL of these 2x concentrated compound dilutions were 
added in duplicates to wells of a black wall, clear bottom 384-wells cell culture plate. For the 
assays with 1 % FBS the compounds in 0 % FBS were added to the existing cell plates in 2 % 
FBS. 200 µM Tamoxifen (Sigma T5648) served as negative control and in addition a serial dilution 
of tamoxifen, starting at 200 µM (74 µg/mL), was included as a dose response control (1 in 2 
dilution series for tamoxifen). For the assay with 10 % FBS, HepG2 cells were seeded at 5000 
cells per well, in a volume of 20 µL in DMEM medium + 10 % of FBS and added to the 20 µL of 
compound solution (total volume of 40 µL), resulting in a final compound concentration range of 
300 µg/mL to 0.14 µg/mL. Cells were incubated together with the compounds for 20 h at 37 oC, 5 
% CO2. 
After the incubation, 5 µL of 100 µM (25 µg/mL) resazurin dissolved in PBS (final concentration 
was approximately 11 µM) was added to each well. The plates were then incubated for 3 h at 37 
oC, 5 % CO2. The fluorescence intensity was read using the TECAN Infinite M1000 PRO with 
excitation/emission 560/590. The data was analysed by Graph Pad Prism software. The data were 
plotted as the average percentage of control ± SD for each set of duplicate wells using the following 
equation: Cell survival % = (FISAMPLE – FINegative/FIUNTREATED –FINegative)*100. (100 µg/mL 
tamoxifen was set as 0 % survival, media control as 100 %). From those graphs, the CC50, the 
Cytotoxic Concentration of the peptide to cause death to 50% of viable cells in the host, were 
calculated and reported.   
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Hemolysis assay. Hemolytic activity was performed as previously descripted in the literature with 
slight modifications.5 In brief, human erythrocytes were isolated from anonymous fresh human 
blood and adjusted to 1x109 blood cells/mL in PBS buffer. Control compounds and peptides were 
prepared to 3 mg/mL solutions in PBS. Then up to 300 µg/mL of peptide were added and incubated 
for 3 h at 37 °C. Following incubation, samples were centrifuged at 3,000 rpm for 20 min, and the 
supernatants, 100 μL, were carefully collected for measurement. The degree of hemolysis in the 
samples was determined by measurement of the absorption of the supernatants at 540 nm using 
the Polarstar-Omega plate reader. 1 % Triton-X100 was used as positive control for inducing 100 
% hemolysis. Full graph results available in Figure S2.  
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Inner membrane permeability measured by SYTOX green fluorescence emission. E. coli 
ATCC 25922 cells were grown to exponential phase (OD~0.6), centrifuged at 2,500 RCF for 10 
min, the pellet washed with PBS buffer (x3) to remove any trace of nucleic acids and residual 
growth media, and then a cell suspension prepared at 1x107 cells/mL. Bacterial cell suspensions 
were then incubated with compounds at different concentrations (five-fold dilutions starting from 
20 μg/mL) for 1 h at 37 °C, repeated in triplicate. SYTOX green (Life Technologies S7020), a 
DNA-binding dye that becomes fluorescent when bound to nucleic acids and only enters cells with 
comprised plasma membranes,6 was added to the peptide–treated cells at a final concentration of 
2 μM, and incubated for 5 min at room temperature. The fluorescence emission intensity of the 
bacterial suspensions were scanned using λex = 488 nm and λem = 530 nm with 30 nm bandpass by 
flow cytometry performed with a BD FACSCanto II (BD biosciences).7 For each sample 100,000 
events were recorded and the fluorescence signals were expressed as a percentage of cell 
permeability as compared to in-tact (un-treated) and damaged (treated with isopropanol) cell 
controls. Polymyxin B was included as a positive inner membrane permeating compound control 
and meropenem as negative inner membrane permeating compound control (antimicrobial 
compound that enters cells without compromising the bacterial cell membrane). 
Based on forward and side scattering measurements of the in-tact versus damaged cell controls 
two distinct populations were identified; i) healthy or in-tact cells, ii) dead/unhealthy or 
completely/partially permeabilised cells. Healthy cells were deemed as 101 to 103 range of 
detection, at 530 nm, and dead or unhealthy cells were deemed as 103 to 105 range of detection at 
530 nm. 
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Figure S7.2-3 – Inner bacterial membrane permeability in E. coli ATCC 25922 evaluated from SYTOX green 
fluorescence emission intensity. Average ± SD of three replicates. 
 
The SYTOX green data suggests that arenicin-3, tachyplesin-1, polyphemusin-1, gomesin and 
protegrin-1 permeabilise the cytoplasmic membrane of E. coli cells at lethal concentrations (50% 
cell damage 0.1-1 μg/mL). However, thanatin does not permeabilise E. coli cells at lethal 
concentrations. The ability of each β-hairpin peptide to permeabilise or not permeabilise the E. 
coli cytoplasmic bacterial membrane is in agreement with previous studies in the literature. For 
example, Hong et al.,8 demonstrate that tachyplesin-1 compromises the integrity of the E. coli cell 
membrane via flow cytometric analysis of cells following single- or double-staining with 
carboxyfluorescein diacetate or propidium iodide; Powers et al.,9 found the mechanism of action 
of polyphemusin-1 to be a lipid flip-flop mechanism; Domingues et al.,10 display lipid leakage 
induced by gomesin in the presence of a lipid mimicking environment; Drin et al.,11 showed that 
protegrin-1 translocates into the membrane via tryptophan fluorescence assay data; Robert et al.,12 
suggests that the cytoplasmic membrane is not the target for thanatin but instead the peptide 
agglutinates the cells in order to cause cell death.     
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Plasma protein binding assay. Plasma protein binding was performed using an Ultrafiltration 
method.13 Fresh frozen human plasma was pooled from O Negative (Product number 1274512) 
blood from the R & D division of the Australian Red Cross Blood Services (Brisbane). Stock 
solutions (20 mg/mL) of the test compounds were prepared in H2O. Test compounds (40 µg/mL) 
were incubated in 100 % human plasma at 37 °C for 30 min (1 mL volume). For unfiltered samples, 
an aliquot (50 µL) was removed, diluted with PBS (50 µL) and quenched with ice-cold 
precipitating solution comprising 0.5 µM carbutamide MS internal standard in acetonitrile : 
methanol : formic acid (1: 1 : 0.001). Samples were incubated at 4 °C for 30 min then centrifuged 
at 14000 × g for 8 min, with the clear supernatant transferred to a vial for LC-MS-MS analysis. 
For filtered samples, the plasma sample (250 µL) was filtered using Amicon Ultra-0.5 Centrifugal 
Filter Devices 30K NMWL at 14000 × g for 7 min and then an aliquot (50 µL) was processed as 
described for unfiltered samples. The fraction of unbound compound was calculated by 
determining the concentration of the filtered sample and the concentration of unfiltered sample. 
All samples were performed in triplicate with sulfamethoxazole as a control.  
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Peptide Characterisation 
Final purity of more than 95 % for all compounds was confirmed by LC-MS analysis using both 
ELSD and UV (210 nm) detection. LC-MS analysis were conducted using Agilent Technologies 
1200 Series Instrument with a G1316A variable wavelength detector set at λ= 210 nm, 1200 Series 
ELSD, 6110 quadrupole ESI-MS, using an Agilent Zorbax Eclipse XDB-Phenyl (3 × 100mm, 3.5 
μm particle size, flow rate 1 mL/min, the mobile phases 0.05% formic acid in water and 0.05% 
formic acid in acetonitrile). Identities of final products were confirmed by high resolution mass 
spectrometry (HRMS), performed on a Bruker Micro TOF mass spectrometer using (+)-ESI 
calibrated to sodium formate. 
 
 
Figure S7.2-4 – HRMS of tachyplesin-1 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C99H151N35O19S4 + 5H)/5, 453.4162; found 453.4234. 
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Figure S7.2-5 – LC-MS of tachyplesin-1 
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Figure S7.2-6 – HRMS of polyphemusin-1 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C108H161N39O20S4 + 5H)/5, 491.4333; found 491.4405. 
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Figure S7.2-7 – LC-MS of polyphemusin-1 
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Figure S7.2-8 – HRMS of gomesin 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C93H152N36O23S4 + 5H)/5, 454.8143; found 454.8216. 
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Figure S7.2-9 – LC-MS of gomesin 
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Figure S7.2-10 – HRMS of protegrin-1 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C88H147N37O19S4 + 5H)/5, 431.8111; found 431.8184. 
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Figure S7.2-11 – LC-MS of protegrin-1 
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Figure S7.2-12 – HRMS of thanatin 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C103H178N36O26S3 + 5H)/5, 487.2575; found 487.2648. 
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Figure S7.2-13 – LC-MS of thanatin 
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Figure S7.2-14 – LC-MS of arenicin-3 
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7.3    Appendix III - Supplementary information Chapter 3 
 
Table S7.3-1 – Microbial strains and cell line used for the antimicrobial assay and cytotoxicity assays 
Organism Strains Description 
Escherichia coli ATCC 25922 FDA control strain 
Klebsiella quasipneumoniae 
subsp. similipneumoniae 
ATCC 700603 Multi-drug Resistant (MDR) 
Klebsiella pneumoniae ATCC 13883 Type strain (polymyxin hetero-
resistant) 
Klebsiella pneumoniae ATCC BAA-2146 New Delhi Metallo-beta-
lactamase-1 (NDM-1) positive 
Klebsiella pneumoniae CI 100650661:1 Extensively-drug Resistant (XDR) 
Acinetobacter baumannii ATCC 19606 Type strain 
Acinetobacter baumannii CI 100734512:2 Extensively-drug Resistant (XDR) 
Pseudomonas aeruginosa ATCC27053 Quality control strain 
Pseudomonas aeruginosa FADDI-PA070 Polymyxin resistant 
Bacillus subtilis ATCC 6051 Type strain 
Staphylococcus aureus ATCC 43300 Methicillin Resistant 
Staphylococcus aureus (MRSA) 
Candida albicans ATCC 90028 CLSI reference strain 
Cryptococcus neoformans 
var grubii 
ATCC 208821 H99, Type strain 
HEK293 ATCC CRL-1573  Human Embryonic kidney cells  
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Peptide Characterisation 
Final purity of more than 90 % for all compounds was confirmed by HPLC analysis using UV 
(214 nm) detection. HPLC analysis were conducted using Agilent Technologies 1200 Series 
Instrument with a G1316A variable wavelength detector set at λ= 214 nm, using an Agilent Zorbax 
Eclipse XDB-Phenyl (3 × 100mm, 3.5 μm particle size, flow rate 1 mL/min). Two different solvent 
systems were used, 0.1% trifluoroacetic acid in water / 0.1% trifluoroacetic acid in acetonitrile and 
0.1% trifluoroacetic acid in water / 0.1% trifluoroacetic acid in methanol). Identities of final 
products were confirmed by high resolution mass spectrometry (HRMS), performed on a Bruker 
Micro TOF mass spectrometer using (+)-ESI calibrated to sodium formate. 1H and 2D TOCSY 
NMR were acquired on Bruker Avance III spectrometer equipped with a cryogenically cooled 
triple resonance probed operating at a normal 1H frequency of 600 MHz at 298 K. Water 
suppression was done via excitation sculpting unless otherwise stated.  
 
 
 
Figure S7.3-1 – HRMS of 1 (TP1) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C99H151N35O19S4 + 5H)/5, 453.4234; found 453.4231. 
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Figure S7.3-2 – HPLC of 1 (TP1). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-3 – 1H NMR of 1 (TP1) 
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Figure S7.3-4 – 2D TOCSY NMR of 1 (TP1), MLEV17 spin-lock mixing pulses = 80 ms, water suppression was performed using Watergate sequence.  
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Figure S7.3-5 – HRMS of 2 (TP1[K1A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C96H144N34O19S4 + 5H)/5, 442.0119; found 442.0111. 
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Figure S7.3-6 – HPLC of 2 (TP1[K1A]). A – In Acetonitrile solvent system. B – In Methanol solvent system. 
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Figure S7.3-7 – 1H NMR of 2 (TP1[K1A]) 
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Figure S7.3-8 – HRMS of 3 (TP1[W2A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C91H146N34O19S4 + 5H)/5, 430.4150; found 430.4166. 
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Figure S7.3-9 – HPLC of 3 (TP1[W2A]) – A – In Acetonitrile solvent system. B – In Methanol solvent system. 
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Figure S7.3-10 – 1H NMR of 3 (TP1[W2A]). The quadruplet at 3.65 and the triplet at 1.17 ppm are residual ethanol.  
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Figure S7.3-11 – HRMS of 4 (TP1[C3A,C16S]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C99H153N35O20S2 + 5H)/5, 444.2367; found 444.2373. 
 
  
Chapter 7 – Appendix 
 
7-160 
A 
 
 
B 
 
 
Figure S7.3-12 – HPLC of 4 (TP1[C3A,C16S]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.
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Figure S7.3-13 – 1H NMR of 4 (TP1[C3A,C16S]). The quadruplet at 3.65 and the triplet at 1.17 ppm are residual ethanol.   
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Figure S7.3-14 – HRMS of 5 (TP1[F4A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C93H147N35O19S4 + 5H)/5, 438.2172; found 438.2189. 
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Figure S7.3-15 – HPLC of 5 (TP1[F4A]). A – In Acetonitrile solvent system. B – In Methanol solvent system. 
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Figure S7.3-16 – 1H NMR of 5 (TP1[F4A]). The quadruplet at 3.65 and the triplet at 1.17 ppm are residual ethanol.   
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Figure S7.3-17 – 2D TOCSY NMR of 5 (TP1[F4A]), MLEV17 spin-lock mixing pulses = 80 ms, water suppression was performed using Watergate 
sequence.  
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Figure S7.3-18 – HRMS of 6 (TP1[R5A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C96H144N32O19S4 + 5H)/5, 436.4106; found 436.4103. 
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Figure S7.3-19 – HPLC of 6 (TP1[R5A]). A – In Acetonitrile solvent system. B – In Methanol solvent system. 
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Figure S7.3-20 – 1H NMR of 6 (TP1[R5A]) 
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Figure S7.3-21 – HRMS of 7 (TP1[V6A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C97H147N35O19S4 + 5H)/5, 447.8172; found 447.8166. 
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Figure S7.3-22 – HPLC of 7 (TP1[V6A]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
 
NMR could not be carried out for TP1 V6A as this analog was not soluble in 100% H2O.  
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Figure S7.3-23 – HRMS of 8 (TP1[C7A,C12S]) 
HRMS-ESI (m/z): [M + 3H]3+ calculated for (C99H153N35O20S2 + 3H)/3, 739.7230; found 739.7226. 
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Figure S7.3-24 – HPLC of 8 (TP1[C7A,C12S]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.  
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Figure S7.3-25 – 1H NMR of 8 (TP1[C7A,C12S]). The quadruplet at 3.65 and the triplet at 1.17 ppm are residual ethanol.   
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Figure S7.3-26 – HRMS of 9 (TP1[Y8A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C93H147N35O18S4 + 5H)/5, 435.0182; found 435.0185. 
 
  
Chapter 7 – Appendix 
 
7-175 
A 
 
 
B 
 
 
Figure S7.3-27 – HPLC of 9 (TP1[Y8A]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-28 – 1H NMR of 9 (TP1[Y8A]) 
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Figure S7.3-29 – HRMS of 10 (TP1[R9A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C96H144N32O19S4 + 5H)/5, 436.4106; found 436.4123. 
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Figure S7.3-30 – HPLC of 10 (TP1[R9A]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-31 – 1H NMR of 10 (TP1[R9A]) 
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Figure S7.3-32 – HRMS of 11 (TP1[G10A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C100H153N35O19S4 + 5H)/5, 456.2266; found 456.2288. 
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Figure S7.3-33 – HPLC of 11 (TP1[G10A]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-34 – 1H NMR of 11 (TP1[G10A]) 
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Figure S7.3-35 – HRMS of 12 (TP1[I11A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C96H145N35O19S4 + 5H)/5, 445.0141; found 445.0160. 
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Figure S7.3-36 – HPLC of 12 (TP1[I11A]). A – In Acetonitrile solvent system. B – In Methanol solvent system. 
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Figure S7.3-37 – 1H NMR of 12 (TP1[I11A]) 
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Figure S7.3-38 – 2D TOCSY NMR of 12 (TP1[I11A]), MLEV17 spin-lock mixing pulses = 80 ms, water suppression was performed using Watergate 
sequence. 
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Figure S7.3-39 – HRMS of 13 (TP1[C7S,C12A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C99H153N35O20S2 + 5H)/5, 444.2367; found 444.2388. 
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Figure S7.3-40 – HPLC of 13 (TP1[C7S,C12A]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system. 
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Figure S7.3-41 – 1H NMR of 13 (TP1[C7S,C12A]) 
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Figure S7.3-42 – HRMS of 14 (TP1[Y13A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C93H147N35O18S4 + 5H)/5, 435.0182; found 435.0187. 
 
 
  
Chapter 7 – Appendix 
 
7-191 
A 
 
 
B 
 
 
Figure S7.3-43 – HPLC of 14 (TP1[Y13A]). A – In Acetonitrile solvent system. B – In Methanol solvent system. 
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Figure S7.3-44 – 1H NMR of 14 (TP1[Y13A]) 
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Figure S7.3-45 – HRMS of 15 (TP1[R14A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C96H144N32O19S4 + 4H)/4, 545.2615; found 545.2639. 
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Figure S7.3-46 – HPLC of 15 (TP1[R14A]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-47 – 1H NMR of 15 (TP1[R14A]). The quadruplet at 3.65 and the triplet at 1.17 ppm are residual ethanol.  
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Figure S7.3-48 – HRMS of 16 (TP1[R15A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C96H144N32O19S4 + 5H)/5, 436.4106; found 436.4124. 
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Figure S7.3-49 – HPLC of 16 (TP1[R15A]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-50 – 1H NMR of 16 (TP1[R15A]) 
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Figure S7.3-51 – HRMS of 17 (TP1[C3S,C16A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C99H153N35O20S2 + 5H)/5, 444.2367; found 444.2377. 
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Figure S7.3-52 – HPLC of 17 (TP1[C3S,C16A]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.
Chapter 7 – Appendix 
 
7-201 
 
 
 
Figure S7.3-53 – 1H NMR of 17 (TP1[C3S,C16A]) 
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Figure S7.3-54 – HRMS of 18 (TP1[R17A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C96H144N32O19S4 + 5H)/5, 436.4106; found 436.4124. 
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Figure S7.3-55 – HPLC of 18 (TP1[R17A]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-56 – 1H NMR of 18 (TP1[R17A]) 
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Figure S7.3-57 – HRMS of 19 (TP1[C3A,C16A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C99H153N35O19S2 + 5H)/5, 441.0377; found 441.0389. 
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Figure S7.3-58 – HPLC of 19 (TP1[C3A,C16A]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.
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Figure S7.3-59 – 1H NMR of 19 (TP1[C3A,C16A]) 
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Figure S7.3-60 – 2D TOCSY NMR of 19 (TP1[C3A,C16A]), MLEV17 spin-lock mixing pulses = 80 ms, water suppression was performed using Watergate 
sequence.  
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Figure S7.3-61 – HRMS of 20 (TP1[C7A,C12A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C99H153N35O19S2 + 5H)/5, 441.0377; found 441.0385. 
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Figure S7.3-62 – HPLC of 20 (TP1[C7A,C12A]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.  
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Figure S7.3-63 – 1H NMR of 20 (TP1[C7A,C12A]) 
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Figure S7.3-64 – HRMS of 21 (TP1[C3A,C7A,C12A,C16A]) 
HRMS-ESI (m/z): [M + 4H]4+ calculated for (C99H155N35O19 + 4H)/4, 535.5632; found 535.5650. 
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Figure S7.3-65 – HPLC of 21 (TP1[C3A,C7A,C12A,C16A]). A – In Acetonitrile solvent system. B – In Methanol 
solvent system.  
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Figure S7.3-66 – 1H NMR of 21 (TP1[C3A,C7A,C12A,C16A]) 
 
 
Chapter 7 – Appendix 
 
7-215 
 
 
 
Figure S7.3-67 – HRMS of 22 (TP1[V6R,R9A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C97H147N35O19S4 + 5H)/5, 447.8172; found 447.8189. 
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Figure S7.3-68 – HPLC of 22 (TP1[V6R,R9A]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.  
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Figure S7.3-69 – 1H NMR of 22 (TP1[V6R,R9A]) 
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Figure S7.3-70 – HRMS of 23 (TP1[K1R]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C99H151N37O19S4 + 5H)/5, 459.0247; found 459.0250. 
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Figure S7.3-71 – HPLC of 23 (TP1[K1R]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-72 – 1H NMR of 23 (TP1[K1R]). The quadruplet at 3.65 and the triplet at 1.17 ppm are residual ethanol.   
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Figure S7.3-73 – HRMS of 24 (TP1[F4G]) 
HRMS-ESI (m/z): [M + 4H]4+ calculated for (C92H145N35O19S4 + 4H)/4, 544.0157; found 544.0165. 
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Figure S7.3-74 – HPLC of 24 (TP1[F4G]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
Chapter 7 – Appendix 
 
7-223 
 
 
 
 
Figure S7.3-75 – 1H NMR of 24 (TP1[F4G]) 
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Figure S7.3-76 – HRMS of 25 (TP1[F4S]) 
HRMS-ESI (m/z): [M + 4H]4+ calculated for (C93H147N35O20S4 + 4H)/5, 551.5184; found 551.5187. 
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Figure S7.3-77 – HPLC of 25 (TP1[F4S]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-78 – 1H NMR of 25 (TP1[F4S]) 
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Figure S7.3-79 – HRMS of 26 (TP1[Y8G]) 
HRMS-ESI (m/z): [M + 4H]4+ calculated for (C92H145N35O18S4 + 4H)/4, 540.0170; found 540.0172. 
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Figure S7.3-80 – HPLC of 26 (TP1[Y8G]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-81 – 1H NMR of 26 (TP1[Y8G]) 
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Figure S7.3-82 – HRMS of 27 (TP1[I11G]) 
HRMS-ESI (m/z): [M + 4H]4+ calculated for (C95H143N35O19S4 + 4H)/4, 552.5118; found 552.5143. 
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Figure S7.3-83 – HPLC of 27 (TP1[I11G]). A – In Acetonitrile solvent system. B – In Methanol solvent system.  
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Figure S7.3-84 – 1H NMR of 27 (TP1[I11G]) 
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Figure S7.3-85 – HRMS of 28 (TP1[F4A,Y8A,I11A]) 
HRMS-ESI (m/z): [M + 4H]4+ calculated for (C84H137N35O18S4 + 4H)/4, 514.0022; found 514.0014. 
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Figure S7.3-86 – HPLC of 28 (TP1[F4A,Y8A,I11A]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.  
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Figure S7.3-87 – 1H NMR of 28 (TP1[F4A,Y8A,I11A]) 
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Figure S7.3-88 – HRMS of 29 (TP1[–R5,R17G]) 
HRMS-ESI (m/z): [M + 3H]3+ calculated for (C89H130N28O18S4 + 3H)/3, 669.9740; found 669.9758. 
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Figure S7.3-89 – HPLC of 29 (TP1[–R5,R17G]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system. 
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Figure S7.3-90 – 1H NMR of 29 (TP1[–R5,R17G]) 
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Figure S7.3-91 – HRMS of 30 (TP1[K1A,F4A]) 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C90H140N34O19S4 + 5H)/5, 426.8056; found 426.8052. 
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Figure S7.3-92 – HPLC of 30 (TP1[K1A,F4A]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.  
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Figure S7.3-93 -1H NMR of 30 (TP1[K1A,F4A]). The quadruplet at 3.65 and the triplet at 1.17 ppm are residual ethanol.   
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Figure S7.3-94 – HRMS of 31 (TP1[K1A,Y8A]) 
HRMS-ESI (m/z): [M + 4H]4+ calculated for (C90H140N34O18S4 + 4H)/4, 529.2565; found 529.2584. 
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Figure S7.3-95 – HPLC of 31 (TP1[K1A,Y8A]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.  
Chapter 7 – Appendix 
 
7-244 
 
 
 
Figure S7.3-96 – 1H NMR of 31 (TP1[K1A,Y8A]) 
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Figure S7.3-97 – HRMS of 32 (TP1[K1A,I11A]) 
HRMS-ESI (m/z): [M + 4H]4+ calculated for (C93H138N34O19S4 + 4H)/4, 541.7513; found 541.7525. 
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Figure S7.3-98 – HPLC of 32 (TP1[K1A,I11A]). A – In Acetonitrile solvent system. B – In Methanol solvent 
system.  
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Figure S7.3-99 – 1H NMR of 32 (TP1[K1A,I11A]) 
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Figure S7.3-100 – HRMS of 33 (TP1[R9A,R17A]) 
HRMS-ESI (m/z): [M + 3H]3+ calculated for (C93H137N29O19S4 + 3H)/3, 698.3249; found 698.3278. 
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Figure S7.3-101 – HPLC of 33 (TP1[R9A,R17A]). A – In Acetonitrile solvent system. B – In Methanol 
solvent system.  
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Figure S7.3-102 – 1H NMR of 33 (TP1[R9A,R17A]) 
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Figure S7.3-103 – HPLC of blank solution. A – In Acetonitrile solvent system. B – In Methanol solvent system.   
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Table S7.3-104 – Analytical data of TP1 and analogs. 
Peptide 
HPLC 
k'a k'b 
1 15.0 27.3 
2 15.4 27.8 
3 13.5 23.9 
4 15.3 26.8 
5 13.5 24.8 
6 16.3 29.6 
7 14.8 27.0 
8 14.9 25.6 
9 14.4 26.0 
10 16.2 28.6 
11 15.4 28.0 
12 14.2 25.4 
13 16.0 29.2 
14 14.8 27.1 
15 16.1 28.2 
16 16.7 30.2 
17 15.1 27.2 
18 17.0 30.9 
19 15.1 27.2 
20 15.0 26.8 
21 15.2 27.2 
22 14.8 25.6 
23 14.8 26.1 
24 12.8 23.2 
25 13.0 23.3 
26 14.6 26.1 
27 14.0 24.6 
28 11.5 20.7 
29 15.6 28.0 
30 13.5 24.0 
31 15.0 26.6 
32 14.6 26.1 
33 18.2 32.3 
k’ = [(peptide retention time – solvent retention time)/solvent retention time]. 
in 0.1% TFA in H2O / 0.1% TFA in AcN at 214 nm 
in 0.1% TFA in H2O / 0.1% TFA in MeOH at 214 nm 
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7.4    Appendix IV - Supplementary information Chapter 4 
 
Table S7.4-1 – Microbial strains and cell line used for the antimicrobial assay. 
Organism Strains Comment 
Escherichia coli ATCC 25922 FDA control 
Escherichia coli CGSC 7139 DC2 
Escherichia coli MB 4902 lpxC mutant 
Escherichia coli MB 5747 tolC mutant 
Escherichia coli MB 5746 lpxC and tolC mutant 
Escherichia coli ATCC 700926 MG 1655; K12 substr 
Escherichia coli CGSC 5167 D31; Ampicillin resistant 
Klebsiella pneumoniae ATCC 700603 Multi-drug Resistant (MDR) 
Klebsiella pneumoniae ATCC 13883 Type strain 
Klebsiella pneumoniae ATCC BAA-2146 New Delhi Metallo-beta-
lactamase-1 (NDM-1) positive 
Acinetobacter baumannii ATCC 19606 Type strain 
Pseudomonas aeruginosa ATCC27053 Type strain 
Bacillus subtilis ATCC 6051 Type strain 
Staphylococcus aureus ATCC 43300 Methicillin Resistant 
Staphylococcus aureus (MRSA) 
Candida albicans ATCC 90028 CLSI reference strain 
Cryptococcus neoformans 
var grubii 
ATCC 208821 H99, Type strain 
HepG2 ATCC HB-8065 Hepatocellular carcinoma liver 
cells  
HEK293 ATCC CRL-1573  Embryonic kidney cells  
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Peptide Characterisation 
Final purity of more than 95 % for all compounds was confirmed by LC-MS analysis using both 
ELSD and UV (210 nm) detection. LC-MS analysis were conducted using Agilent Technologies 
1200 Series Instrument with a G1316A variable wavelength detector set at λ= 210 nm, 1200 Series 
ELSD, 6110 quadrupole ESI-MS, using an Agilent Zorbax Eclipse XDB-Phenyl (3 × 100mm, 3.5 
μm particle size, flow rate 1 mL/min, the mobile phases 0.05% formic acid in water and 0.05% 
formic acid in acetonitrile). Identities of final products were confirmed by high resolution mass 
spectrometry (HRMS), performed on a Bruker Micro TOF mass spectrometer using (+)-ESI 
calibrated to sodium formate. 
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Figure S7.4-1 – LC-MS of arenicin-3. MW(arenicin-3) = 2611.1 Da 
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Figure S7.4-2 – HRMS of arenicin-3 
HRMS-ESI (m/z): [M + 4H]4+ calculated for (C115H166N36O27S4 + 4H)/4, 653.7974; found 
653.7947. 
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Figure S7.4-3 – LC-MS of AA139. MW(AA139) = 2548.1 Da 
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Figure S7.4-4 – HRMS of AA139 
HRMS-ESI (m/z): [M + 5H]5+ calculated for (C108H161N39O26S4 + 5H)/5, 510.6344; found 
510.6366. 
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Figure S7.4-5 – NMR data of arenicin-3 in PO4 buffer pH3.3.  
  
Residue N NH Cα Hα Cβ Hβ Cγ Cδ Hγ Hδ Hε Hζ Hη Nε Nδ2
Gly1 43.43 3.96 3.96
Phe2 120.59 8.60 57.27 4.99 40.98 3.25, 7.36 7.24 7.21
Cys3 119.00 8.19 55.81 5.57 48.27 2.50, 2.85
Trp4 122.85 9.24 4.86 31.80 3.33, 6.96 9.98, 7.11 7.29, 6.82 6.98 128.69
Tyr5 8.70 57.69 5.14 2.71, 2.84 6.88 6.76
Val6 123.94 8.92 60.90 4.36 33.82 1.66 20.99 0.94
Cys7 123.60 8.77 55.14 5.77 47.53 2.44, 3.00
Val8 119.47 9.17 59.38 4.64 35.80 2.27 21.42 0.93, 1.01
Tyr9 8.69 57.56 5.11 2.72, 2.84 6.90 6.78
Arg10 124.48 9.09 54.85 4.63 32.29 1.65, 1.78 26.93 43.49 1.54, 1.65 3.21 7.22 124.81
Asn11 125.63 9.64 54.31 4.40 37.55 2.80, 3.10 7.64, 6.95 112.77
Gly12 102.63 8.58 45.33 3.68, 4.25
Val13 120.36 7.72 61.09 4.38 34.55 2.11 18.88 0.95
Arg14 123.26 8.63 55.30 4.15 30.68 1.31, 1.69 27.82 43.57 0.92, 1.22 3.03 7.09 124.48
Val15 129.72 9.16 61.49 4.24 34.32 1.91 20.77 0.81, 0.92
Cys16 122.93 8.59 54.88 5.79 48.49 2.60, 2.98
Tyr17 121.35 9.16 4.89 2.91, 3.00 6.97 6.65
Arg18 123.26 8.71 55.30 4.20 31.76 1.36, 1.63 27.79 43.55 0.88, 1.13 2.95 6.97
Arg19 128.63 8.67 54.08 4.29 32.60 0.55, 0.94 26.71 43.21 1.21, 1.34 3.12 7.14 124.94
Cys20 116.84 8.09 55.07 5.20 48.78 2.82, 2.97
Asn21 121.55 8.75 51.86 4.91 39.30 3.28, 2.97 6.66, 7.71 110.79
aChemical shift are relative to DSS (0 ppm)
Chemical Shift (ppm)a
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Figure S7.4-6 - NMR data of AA139 in PO4 buffer pH3.3. 
Residue N NH Cα Hα Cβ Hβ Cγ Cδ Cε Cζ Cη Hγ Hδ Hε Hζ Hη Nε Nδ2
Gly1 43.54 3.95
Phe2 121.25 8.80 55.97 4.94 40.89 3.23 132.25 131.55 129.80 7.33 7.26 7.22
Cys3 119.28 8.19 55.82 5.60 48.18 2.49, 2.86
Trp4 122.88 9.26 4.85 31.88 3.31 127.34 122.81 113.91, 121.83 123.86 6.98 9.98, 7.16 7.28, 6.89 7.00 128.71
Tyr5 123.12 8.69 57.57 5.09 43.56 2.94 132.66 118.01 6.90 6.76
Val6 123.97 8.87 61.30 4.31 1.55 21 0.88
Cys7 123.68 8.84 55.23 5.71 48.21 2.63, 3.05
Ala8 125.82 9.11 50.97 4.65 22.35 1.47
Arg9 120.58 8.62 55.17 5.02 27.44 1.39, 1.69 27.36 1.52 3.12 6.78
Arg10 125.30 9.00 55.23 4.59 32.47 1.71, 1.79 33.48 43.4 1.54 3.21 7.22
Asn11 125.26 9.58 54.23 4.42 37.51 2.80, 3.09 7.65, 6.96 112.68
Gly12 104.30 8.66 45.56 3.61, 4.21
Ala13 123.74 7.78 50.66 4.68 21.30 1.40
Arg14 122.34 8.66 56.28 4.64 30.90 1.80 28.1 43.42 1.46, 1.62 3.14
Val15 127.77 8.94 61.22 4.43 34.46 2.00 20.85 0.94
Cys16 123.81 8.77 55.14 5.80 48.82 2.63, 3.04
Tyr17 120.80 9.04 57.38 4.93 40.45 2.93, 3.01 133.67 117.71 6.96 6.66
Arg18 117.68 8.69 55.24 4.22 27.77 0.86, 1.12 31.93 40.7 1.33, 1.63 2.70, 2.83
Arg19 128.47 8.69 54.23 4.30 32.62 0.62, 0.92 26.85 43.23 1.19, 1.52 3.11
Cys20 117.74 8.12 55.20 5.24 48.46 2.81, 3.06
Asn21 126.34 8.64 54.08 4.61 3.04, 2.92 6.59, 7.55 110.31
aChemical shift are relative to DSS (0 ppm)
Chemical Shift (ppm)a
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Table S7.4-2 – Hydrogen-deuterium exchange of arenicin peptides 
Peptides 
residues with slowly exchanging amides 
Hydrogen bonds 
1 h (weak) 3-4 h (medium) >24 h (strong) 
arenicin-3 C3, C7, N11, G12, C16, C20, N21 F2, Y5, R14, R18 W4, V6, V8, V13, V15, Y17, R19 
W4-R19 (HN=O) 
V6-Y17 (HN=O) 
V8-V15 (HN=O) 
V13-R10 (HN-O) 
AA139 C3, C7, R9, R10, N11, G12, R14, C16, C20, N21 A8, A13, R18 W4, V6, V15, Y17 
W4-R19 (HN-O) 
V6-Y17 (HN=O) 
V15-V8 (HN-O) 
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Table S7.4-3 – Amide temperature coefficient of arenicin peptides 
arenicin-3 slope (ppb/K) AA139 
slope 
(ppb/K) 
Phe2 -3.4 Phe2 -3.6 
Cys3 -6.4 Cys3 -6 
Trp4 -3.2 Trp4 -4 
Tyr5 -6.8 Tyr5 -6.2 
Val6 -4 Val6 -7.6 
Cys7 -8.2 Cys7 -9.2 
Val8 -2.4 Ala8 -2.4 
Tyr9 -6.8 Arg9 -7.6 
Arg10 -4.2 Arg10 -6.4 
Asn11 -9.8 Asn11 -10 
Gly12 -10 Gly12 -7.6 
Val13 -3 Ala13 -1.4 
Arg14 -7.8 Arg14 -6 
Val15 -4.4 Val15 -6 
Cys16 -8 Cys16 -9 
Tyr17 -2.4 Tyr17 -2.2 
Arg18 -6 Arg18 -5 
Arg19 -6.2 Arg19 -5 
Cys20 -2.2 Cys20 -3 
Asn21 -4 Asn21 -5 
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7.5    Supplementary information Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7.5-1 – Nanodiscs, composed of POPC, stability over 30 days at 4 °C storage. (A), (C) and (E) use dH5 
construct while (B), (D) and (F) use cNW9 construct. From top to bottom; (A) and (B) Tris buffer pH7.5 (blue), (C) 
and (D) Bis-Tris buffer pH 6.5 (red), (E) and (F) PO4 buffer pH 6.5 (green).  
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Figure S7.5-2 – Nanodiscs, composed of POPC/POPG (4:1), stability over 30 days at 4 °C storage. (A), (C) and 
(E) use dH5 construct while (B), (D) and (F) use cNW9 construct. From top to bottom; (A) and (B) Tris buffer pH7.5 
(blue), (C) and (D) Bis-Tris buffer pH 6.5 (red), (E) and (F) PO4 buffer pH 6.5 (green). 
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Figure S7.5-3 - Nanodiscs, composed of POPC/POPG (4:1) in Bis-Tris buffer pH 6.5, stability over 2-3 days. 
(A) and (B) 25 °C, (C) and (D) 37 °C, (E) and (F) after freeze-thawing. (A), (C) and (E) use dH5 construct while (B), 
(D) and (F) use cNW9 construct.   
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Figure S7.5-4 - Nanodiscs, composed of POPC/POPG (4:1) in Bis-Tris buffer pH 6.5, stability over 2 days. (A) 
and (B) stored at 1 mg/mL, (C) and (D) stored at 10 mg/mL. (A) and (C) use dH5 construct while (B) and (D) use 
cNW9 construct. 
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Figure S7.5-5 - LC-MS in negative mode of the SEC of ND[dH5(POPC/POPG(4:1))], shown Figure 5-10 (A), of 
fractions 10 to 19, fraction corresponding to the ND region, red arrow in Figure 5-10. MW(POPG) = 749.2 g/mol 
 
  
Figure S7.5-6 - Negative staining electron microscopy of (A) fraction 10 showing ND aggregates and (B) fraction 
16 showing homogeneous ND, of ND[dH5(POPC/POPG(4:1))] at day 7 after storage at room temperature, Figure 5-
10(A). 
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Figure S7.5-7 - DLS experiments of dH5 either alone or as a scaffold for the ND formation showing the mass 
distribution of the particles. 
 
Figure S7.5-8 - 1H-15N-HSQC of 15N-AA139 in (A) 20 mM HEPES buffer pH 7.5 containing 50 mM NaCl and 
(B) 20 mM Bis-Tris buffer pH6.5 containing 50 mM NaCl.  
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Figure S7.5-9 - Solution NMR titration experiment of AA139 with ND[15N-cNW9(POPC)]. Ratio ND/peptide 
were 1:0 in blue, 2:1 in red and 1:1 in green.  
 
 
Figure S7.5-10 - DLS of LUVs [POPC/POPG(4:1)] in absence (blue) and presence (orange) of AA139 (ratio 
80:1). 
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7.6    Supplementary information Chapter 6 
Materials and methods.  
Membrane extraction was perform from E. coli ATCC 25922 and from red blood cells. For 
E. coli cells, the cells were grown in 500 mL of LB media at 37 °C with shaking at 220 rpm until 
OD600 reached late exponential phase (OD600 = 0.8). The cells were pelleted by centrifugation at 
10000 rpm, for 15 mins at 4 °C. The pellets were washed once with PBS. The pellets were 
transferred to Teflon tubes and dissolved and incubated for one hour in solvent mixture 
chloroform/MeOH/H2O (1:2:0.8) with occasional shaking. The cells were washed three times with 
this solvent mixture, collecting each time the solvent as it is where the lipids are located. Lipid 
membranes were finally extracted using solvent ratio chloroform/MeOH/H2O (2:2:1.8). The 
solution was placed in a separatory funnel for decantation. The chloroform phase was removed, 
evaporated and left under nitrogen flow overnight for complete drying. The lipid extract was then 
weighted out and characterized.  
For red blood cells (RBC), 200 mL of blood taken from the Red Cross were centrifuged at 4000 
rpm for 20 min to separate the plasma from the red blood cells. The plasma was removed and the 
pelleted RBC were washed three times with PBS or until the supernatant becomes clear. Deionized 
water was added to the RBC to lyse the cells. Cells were pelleted by centrifugation at 4000 rpm 
for 20 mins and the hemoglobin was removed. The “ghost” membrane of the RBC transferred to 
Teflon tubes and solubilized in solvent mixture chloroform/MeOH/H2O (1:2:0.8) and incubated 
for one hour with occasional shaking. The cells were washed three times with this solvent mixture, 
collecting each time the solvent as it is where the lipids are located. Lipid membranes were finally 
extracted using solvent ratio chloroform/MeOH/H2O (2:2:1.8). The solution was placed in a 
separatory funnel for decantation. The chloroform phase was removed, evaporated and left under 
nitrogen flow overnight for complete drying. The lipid extract was then weighted out and 
characterized. 
Both E. coli and RBC lipid membrane extracts were dissolved in 500 μL MeOH. Samples we 
injected into a QSTAR Elite (Applied Biosystems) hybrid quadrupole Time-of-Flight (TOF) mass 
spectrometer. Direct infusion on negative mode was performed.  
 
BCA assay. 25 μL of the MeOH solution used for MS was dried up under nitrogen flow and 
reconstituted in 80 and 160 μL of PBS for E. coli and RBC, respectively. The BCA assay was 
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performed as per provider instruction and the 96 wells plates cooled to room temperature before 
absorption at 562 nm were measured using Tecan M1000 Pro plate reader.  
 
 
